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The emergence of antibiotic resistance is a notorious problem worldwide. In the 
United States alone, antibiotic-resistant bacteria infect at least two million people and kill 
around 23,000 patients each year. Half of these infections are attributed to the bacterial 
pathogen, methicillin resistant Staphylococcus aureus (MRSA) according to a report 
published in 2013 by the Centers for Disease Control and Prevention (CDC). Similarly, S. 
pseudintermedius is a leading cause of opportunistic infections in pet animals and has 
zoonotic potential. Furthermore, the marked increase in the incidence of infections due to 
extensively drug-resistant and pandrug-resistant isolates of Pseudomonas aeruginosa and 
Acinetobacter baumannii presents an alarming challenge that necessitates the development 
of novel therapeutic alternatives to traditional antibiotics in order to address this scourge. 
Currently, there is significant interest in antimicrobial peptides (AMPs) as novel 
therapeutic alternatives to conventional antibiotics. AMPs are major constituents of the 
host innate defense system for most organisms. AMPs are composed of a short sequence 
of amino acids (less than 50 residues), with a cationic charge and amphipathic character. 
AMPs possess several unique features that support their utility as antibacterial agents 
including possessing rapid bactericidal activity against a wide spectrum of pathogenic 
bacteria. Additionally, AMPs are typically not susceptible to the same mechanisms that 
confer resistance to traditional antibiotics. However, naturally-derived AMPs do possess 
limitations that have hindered their translation as clinically useful agents including, 
moderate antimicrobial activity, toxicity to host tissues, intolerance to physiological 
conditions, sensitivity to enzymatic degradation, and high manufacturing costs due to their 
complex design and long length of amino acids. Thus, there is a critical need for finding 
small peptides with strong antibacterial activity, salt tolerance and low toxicity. To address 
these issues, we screened a library of short synthetic peptides that were developed for 
xvii 
 
alternative therapeutic applications and identified four peptides, namely RR, RRIKA, 
WR12 and D-IK8, with potent antimicrobial activity against a panel of drug-resistant 
staphylococci including MRSA. In contrast to many natural AMPs; these peptides retained 
their activity in the presence of high salt concentrations. WR12 and D-IK8 were able to 
eradicate persister cells, MRSA in stationary growth phase, and showed significant 
clearance of intracellular MRSA in comparison to antibiotics of choice (vancomycin and 
linezolid). In addition to their antibacterial activity against MRSA, these peptides were 
found to possess more potent activity against clinical isolates of methicillin-resistant S. 
pseudintermedius (MRSP) isolated from infected dogs. Topical application of investigated 
peptides effectively reduced both the bacterial load and inflammatory cytokines in a murine 
model of MRSA skin lesions. 
Next, we designed modified derivatives of the RR peptide to enhance the peptide’s 
potency and spectrum of antimicrobial activity against Gram-negative pathogens (P. 
aeruginosa and A. baumannii). From the peptides designed in this study, RR4 and its D-
enantiomer, D-RR4, were the most potent analogues with at least 32-fold improvement in 
antimicrobial activity observed. Interestingly, D-RR4 demonstrated potent activity against 
colistin-resistant, cystic fibrosis strains of P. aeruginosa indicating a potential therapeutic 
advantage of this peptide over several AMPs. Of note, D-RR4 was able to bind to LPS to 
reduce the endotoxin-induced proinflammatory cytokine response in macrophages. 
Furthermore, D-RR4 protected Caenorhabditis elegans worms from lethal infections of P. 
aeruginosa and A. baumannii and enhanced the activity of colistin in vivo against colistin-
resistant P. aeruginosa. 
The ability of bacterial pathogens to form biofilms that are highly tolerant to 
antibiotics further aggravates the situation and can lead to recurring infections. To address 
this significant problem, we conjugated the antibiotic kanamycin with a novel 
antimicrobial peptide (P14LRR) to develop a kanamycin peptide conjugate (P14KanS). 
P14KanS was superior in disrupting adherent bacterial biofilms when compared to 
conventional antibiotics. Furthermore, P14KanS protected C. elegans from lethal 
infections of biofilm-forming Gram-positive and Gram-negative pathogens. 
In conclusion, this study supports the potential of investigated peptides and the kanamycin 
peptide conjugate for the treatment of multi-drug resistant bacterial infections.
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CHAPTER 1. LITERATURE REVIEW 
1.1 Introduction 
The rapid development and spread of bacterial resistance to conventional antibiotics has 
become a serious global concern (1-4). Currently, members of ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species), represent one of the 
biggest threats to health as a result of their multidrug resistance (5). In the United States 
alone, antibiotic-resistant bacteria infect at least two million people and kill around 23,000 
patients each year (6). Half of these infections are attributed to the bacterial pathogen, 
methicillin resistant Staphylococcus aureus (MRSA) (6). Furthermore, the marked 
increase in the incidence of infections due to extensively drug-resistant and pandrug-
resistant isolates of Pseudomonas aeruginosa and Acinetobacter baumannii (7-9) presents 
an alarming challenge that necessitates the development of novel therapeutic alternatives 
to traditional antibiotics in order to address this scourge. Antimicrobial peptides (AMPs) 
have shown significant promise in recent years as novel therapeutic alternative to treat 
infections caused by multidrug-resistant pathogens (10-16). AMPs are short sequences of 
amino acids (less than 50 residues), with a cationic charge and amphipathic character (15, 
17). AMPs constitute the first line of innate immunity against infections (15, 16). 
Decreased production of AMPs in the host is associated with increased susceptibility to 
various infections (18-20). For example, decreased production of AMPs in the dermis is 
associated with increased susceptibility to various skin infection involving S. aureus in 
humans (21). Moreover, reduced expression of β-defensins (hBD-2) in premature infants 
increases their susceptibility to pneumonia (19). In addition, mice deficient in the 
cathelicidin-related antimicrobial peptide (CRAMP) were susceptible to elevated 
persistence of P. aeruginosa in the lungs (18). AMPs possess several unique features that 
support their utility as antibacterial agents including possessing rapid bactericidal activity 
against a wide spectrum of pathogenic bacteria. Additionally, AMPs are typically not 
susceptible to the same mechanisms that confer resistance to traditional antibiotics. 
However, AMPs do possess limitations that have hindered their translation as clinically 
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useful agents including, toxicity to host tissues, intolerance to physiological conditions, 
sensitivity to enzymatic degradation, and high manufacturing costs due to their complex 
design and long length of amino acids. Here we discuss the different mechanisms of action 
of AMPs and their advantages over conventional antibiotics. Moreover, we discuss 
challenges to using AMPs as therapeutic agents and proposed solutions to overcome these 
limitations. We conclude by discussing AMPs that successfully reached clinical trials 
1.2 Mechanism of action of antimicrobial peptides  
The exact mechanism of action of AMPs has been controversial, until now (17, 22). 
Initially, it was believed that AMPs produce effects on bacterial function only by 
permeabilizing and destabilizing cell membranes (22). However, later studies 
demonstrated that some peptides penetrate the bacterial membrane without damaging it, 
and accumulate intracellularly to inhibit multiple internal targets including nucleic acid 
synthesis, protein synthesis, cell division and cell wall synthesis (22, 23). Below, we 
discuss the different modes of action of peptide antibiotics. 
1.2.1 Cell membrane lysis 
Most antimicrobial peptides belong to the class of membrane-lytic agents (22). Initially, 
these peptides interact with the negatively charged lipid group exposed on bacterial 
surfaces (lipopolysaccharides in Gram negative and lipo-teichoic acids in case of Gram 
positive) via electrostatic forces (17). This leads to destabilization of the anionic 
phospholipids groups to form pores and consequently killing of the microorganism due to 
leakage of intracellular contents (17, 22, 24). 
The most widely accepted models of membrane lysis by AMPs are the barrel-stave model, 
carpet model, and toroidal model for killing organisms (figure 1.1). In barrel-stave model, 
peptides position themselves for binding on the cell membranes, this leads to peptide 
aggregation and conversion to a bilayer membrane. So in this way the hydrophobic 
peptides align with the lipid core and hydrophilic peptides form an access pore in the 
interior part of membrane (figure 1.1A). The carpet model is described as a disruption of 
the membrane like "detergent action” by the binding of peptides to the outer surface 
(phospholipids) of cell membrane and forming a prolonged layer or carpet (figure 1.1B). 
3 
 
In the toroidal model, attached peptides start aggregation and force the lipid monolayer to 
bend incessantly through the pores. In this way the core is lined by both the inserted 
peptides and the lipid head groups (figure 1.1C) (17, 22, 24). 
1.2.2 Non-permeabilizing mechanism (targeting intracellular components) 
Recent studies suggest that membrane disruption is not the only mechanism of bacterial 
killing by AMPs. Otherwise, as presented in (figure 1.2), some peptides can penetrate 
membranes and induce killing by acting on one or more intracellular targets; such as 
inhibiting nucleic acids and protein synthesis or  inhibition of cell wall synthesis and cell 
division (17, 22, 23).  
1.2.2.1 Inhibition of cell wall synthesis 
The cell wall is a vital bacterial component that preserves cell structure and protects the 
bacteria from osmotic lysis (25). As the cell wall is absent in mammalian cells and present 
only in prokaryotic cells, this structure was the target of many successful antibiotics such 
as penicillins and cephalosporins (25). Recent studies revealed that some antimicrobial 
peptides such as the fungal defensin, plectasin, do not permeabilize the cytoplasmic 
membrane nor cause leakage of intracellular ions (K+) or ATP (26). Instead, the study 
found that plectasin kills bacteria by inhibiting the biosynthesis of cell wall by binding to 
a precursor of peptidoglycan synthesis (lipid II) (26). This mechanism was found in other 
peptide antibiotics such as some bacteriocins (Lcn972), lantibiotics (mersacidin), and 
lipo-peptides (daptomycin) (25, 27). Moreover, nisin, an antibacterial peptide commonly 
used as a food preservative, has several mechanisms; initially it binds to lipid II and then 
induces pore formation, leakage of cell contents, and death (28-30). Another study showed 
that nisin binds to lipids III and IV, inhibiting the biosynthesis of teichoic and lipoteichoic 
acids (31). Additionally, nisin and another AMP (Pep5) activate the function of an 
autolysin (N-acetylmuramoyl-L-alanine amidase) which triggers bacterial lysis, as 
demonstrated in Staphylococcus simulans (32). 
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1.2.2.2 Inhibition of nucleic acid and protein synthesis: 
Some peptides translocate the bacterial cell membrane to reach intracellular 
macromolecules such as DNA, RNA and proteins and inhibit their synthesis (22, 23). For 
example, buforin II, a short linear peptide consisting of 21 residues, is able to penetrate 
the bacterial membrane and accumulate in the cell without causing damage to the cell 
membrane (33). The proline hinge (Pro11) of the buforin peptide was responsible for this 
type of translocation as evidenced by its ability to translocate another non-cell permeable 
peptide inside cells (34). After internalization inside bacterial cells, buforin II showed high 
affinity for binding to DNA, RNA and interfering with their functions leading to cell death 
(33). This potent ability for binding nucleic acids could be interpreted that buforin II has 
sequence similarity to the N-terminal region of histone H2A (34).  
Other peptides from different families (such as dermaseptin, human neutrophil platelet -1 
defensin and pleurocidin) inhibit nucleic acid and protein synthesis in bacteria as 
evidenced by blocking the uptake of radioactive precursors (thymidine, uridine and 
leucine) in the macro-molecular biosynthesis technique (22, 35, 36).   
Another group of peptides called proline-rich antimicrobial peptides (such as 
pyrrhocoricin, drosocin and apidaecin) have been discovered in insects. These peptides 
kill bacteria without a membrane lytic mechanism of action. Instead, they translocate 
inside bacterial cells by binding to a specific bacterial transporter (SbmA) and accumulate 
inside cells to bind the target molecule (37-42). Initially, it was shown that proline rich 
peptides bind with high affinity to a heat shock protein (DnaK) in bacterial lysates at low 
micromolar concentration (23). However, recent studies showed that DnaK is not the main 
target of these peptides as evidenced by the observation that the DnaK null mutant bacteria 
were more susceptible to proline peptides compared to wild-type strains, which excludes 
DnaK as the target (42). Moreover, the investigators found that proline-rich peptides are 
capable of binding strongly to the 70S ribosomal subunit in nanomolar concentrations thus 
inhibiting protein biosynthesis very efficiently (42). The mechanism of translation 
inhibition of the oncocin derivative (Onc 112) in complex with the 70S ribosomal subunit 
has been resolved recently by crystallography (38, 39). The authors showed that the 
peptide interacts with the exit tunnel of the ribosome and interferes with the binding of 
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aminoacyl-tRNA. This leads to destabilization of the initiation complex and inhibition of 
translation (38, 39). 
Indolicidin, a very short cationic peptide isolated from bovine neutrophils has been shown 
to inhibit DNA and RNA synthesis at lower concentrations (43-45). However, protein 
synthesis inhibition was achieved only at higher concentrations. Moreover, bacterial 
elongation and filamentation was observed in E. coli treated with indolicidin (43). Similar 
filamentation was seen in Salmonella Typhimurium treated with PR-39 (a proline–
arginine-rich peptide) which also inhibited nucleic acid and protein synthesis (46, 47). 
Bacterial filamentation arises from defects in septum formation which could be result of 
inhibition of nucleic acid replication or inhibition of membrane proteins responsible for 
septum formation and cell division (22). 
A recent study showed that a hexapeptide ,WRWYCR, could induce filamentation and 
killing of S. Typhimurium in vitro and inside macrophages by inhibiting enzymes 
responsible for DNA repair leading to double-stranded DNA breaks and defects in 
chromosomal segregation (48). 
Microcins, a group of peptides isolated from bacteria, don’t cause membrane lysis, for 
example. Microcin C penetrate bacterial membranes and blocks translation by interfering 
with aminoacyl-tRNA synthetase function (49, 50). Another modified derivative, 
(Microcidin B17) inhibits the replication of DNA by targeting DNA gyrase (51). 
In conclusion, antimicrobial peptides have different mechanisms of action which mainly 
depend on the structure of the peptide and the amino acids incorporated in the structure. 
Moreover, some peptides have multiple mechanisms of bacterial killing which could 
explain why it is difficult for bacteria to develop resistance to antimicrobial peptides. 
1.3 Advantages of Antimicrobial peptides  
1.3.1 Broad spectrum, rapid killing and synergism with antibiotics. 
Most antimicrobial peptides discovered to date have demonstrated potent activity against 
many Gram-positive and Gram-negative bacteria (15, 16, 22); some antimicrobial 
peptides also have antifungal (52, 53), antiviral (54, 55) (56) and antiparasitic activity 
(57). This broad-spectrum activity is very useful when treating poly-microbial infections, 
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especially in immunocompromised patients (such as HIV patients), where many 
infections are prevalent (58, 59). 
Moreover, in contrast to conventional antibiotics, antimicrobial peptides kill bacteria 
very rapidly, within minutes to a few hours, and they have potent bactericidal activity at 
concentrations similar to or above their MIC (15, 22). AMPs with fast bactericidal 
activity have several advantages including limiting spread of infection, improving 
treatment prognosis, limiting the emergence of resistance, and reducing duration of 
treatment (52). 
Furthermore, several peptides have been successful in combination with current 
antibiotics (60-63),  as peptides cause weakening of the cell membrane to increase the 
access of antibiotics into bacterial cells to bind to their targets (63). The synergistic effect 
of this combination has several advantages. These advantages include minimizing the 
likelihood of emergence of bacterial drug-resistance to either agent, lowering the dose 
required for each antibacterial agent thus mitigating drug toxicity, and expanding the 
spectrum of pathogens that can be targeted (64). For example, the amphibian 
antimicrobial peptide, esculentin-1b (1–18) was also reported to cause permeabilization 
of bacterial membranes at subinhibitory concentrations leading to synergism with 
conventional antibiotics against Escherichia coli (65). The peptidomimetic OAK (oligo-
acyl-lysyl), was able to resensitize erythromycin-resistant E. coli to erythromycin both 
in vitro and in an animal model of infection. The authors explained the mechanism of 
resensitization to be transient depolarization of the membrane potential at subinhibitory 
concentrations (66).  
1.3.2 Active against drug resistant pathogens and low emergence of bacterial resistance to 
antimicrobial peptides  
Due to their unique mechanism of killing (22), antimicrobial peptides are not cross-
resistant with traditional antibiotics (15). Additionally, most antimicrobial peptides are 
effective against multi-drug and pan-drug resistant strains (10, 63, 67, 68). Furthermore, 
bacteria are less prone to develop resistance to antimicrobial peptides compared to 
conventional antibiotics (11, 67, 69, 70). This most likely is due to the fact that peptides 
target the cell membrane or essential processes in the bacterial cell (i.e. are “dirty” drugs) 
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(22). Thus, mutations that confer resistance to peptides are less likely to occur as this 
would require alterations in the lipid profile of the bacterial cell membrane or multiple 
mutations in many essential targets which would affect the fitness of the microorganism. 
Previous reports indicated that after 7 passages at a subinhibitory concentration with 
pexiganan, bacteria failed to develop resistance (7). These data were confirmed in clinical 
trials as no significant resistance to pexiganan emerged among patients who received 
pexiganan. However, in the same study, bacterial resistance to ofloxacin emerged in 
some patients who received ofloxacin (2). Furthermore, several studies with different 
antimicrobial peptides that have conducted resistance studies for longer duration of time 
than pexiganan (20-30 passages), demonstrated either complete lack of resistance to the 
AMPs (8) (9, 10) or their AMPs displayed a lower propensity to select for resistant 
bacteria compared to conventional antibiotics (11). 
1.3.3 Anti-endotoxic activity 
A key virulence factor unique to Gram-negative bacterial pathogens is the presence of 
lipopolysaccharide (LPS). LPS is a principal structure of the outer membrane of Gram-
negative bacteria. During bacterial death, cell replication, or exposure to certain 
antibiotics, LPS is released from bacteria leading to stimulation of proinflammatory 
cytokine release such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) from 
mononuclear phagocytes. Excessive LPS exposure leads to overproduction of these 
cytokines which can result in septic shock and death. Annually there are 18 million cases 
of septic shock globally with a mortality rate of ~30% (71, 72).  
Various antimicrobial peptides are able to bind to LPS and interfere with its binding to 
lipopolysaccharide binding protein (LBP) and consequently block the activation of toll-
like receptor 4. This leads to inhibition of proinflammatory cytokine release and other 
mediators involved in septic shock (13, 73-76). For example, the human cathelicidin (LL-
37) inhibited the binding of LPS to CD14 on mononuclear phagocytes preventing the 
expression of TNF-α. In the murine model of endotoxin shock, LL-37 demonstrated potent 
inhibition of proinflammatory cytokines (77-80). Moreover, LL-37 prevents the LPS-
induced apoptosis of endothelial cells by interfering with the assembly of the LPS receptor 
complex, consisting of CD14 and Toll like receptor 4 (TLR4) and phosphorylation of c-
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Jun N-terminal kinase (JNK) (81).Therefore, by neutralizing the effect of LPS, AMPs 
prevent severe reactions such as sepsis and endotoxaemia which are responsible for many 
deaths worldwide (71, 72). This is particularly advantageous in the treatment of infections 
caused by Gram-negative bacteria, as most traditional antibiotics (particularly cell wall 
synthesis inhibitors) cause lysis and more release of LPS during treatment (82-84). 
1.3.4  Immune-modulatory properties 
Besides their potent antimicrobial activity, various AMPs have direct immune-
modulatory effects that play a role in clearance of a bacterial infections (13, 76, 77, 85-
90). For example, LL-37 was found to play a role in activation of chemotaxis, modulation 
of cytokine release, regulation of immune cell differentiation and stimulation of dendritic 
cells functions (13, 76, 77, 85-90). LL-37, also, was found to be involved is the formation 
of the neutrophil extracellular traps (NETs). NETs are extracellular fibers primarily 
consisting of neutrophil DNA which bind pathogens. Human cathelicidin appears to be 
an initiator of NET formation as well as its defender, protecting from bacterial nucleases 
(80, 91). Biochemical features facilitating these activities are hydrophobicity and the 
cationicity, respectively. LL-37 have a chemotactic property as it induced migration of 
highly purified human neutrophils and CD4 T cells and human monocytes (79, 80, 92). 
Moreover, the innate defense regulator peptide-1 (IDR-1) has no direct antimicrobial 
activity in vitro, but it has been shown to protect mice from bacterial infection (93).IDR-
1 selectively increases the production of the anti-inflammatory cytokine (IL-10) in the 
blood and suppresses pro-inflammatory cytokines (TNF- and IL-6) at the site of infection, 
(93). Moreover, IDR-1 act as chemotactic by recruiting both monocytes and 
macrophages to the site of infection by increasing the production of two important 
chemokines (MCP-1 and RANTES) that play a role in protection against infection (93). 
Given the potent immunomodulatory properties of IDR-1, this agent has a therapeutic 
potential to be used to clear bacterial infections. Thus, the overall net result of the 
immunomodulatory functions of AMPs leads to the control of inflammatory responses 
in the affected host without altering or compromising the immune responses that are 
essential for the clearance of the bacterial infection. 
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1.3.5 Wound healing properties 
Wound treatment is an economic burden globally (94, 95). Some antimicrobial peptides 
in addition to their immune-modulatory effect, have been shown to accelerate wound 
healing by promoting neovascularization and angiogenesis (96-99). Moreover, peptides 
stimulate the migration and proliferation of epithelial cells and keratinocytes into 
damaged tissues (97). Furthermore, peptides have been shown to stimulate the deposition 
of extracellular matrix to accelerate wound repair (12, 100, 101).   
1.3.6 Efficacy of peptides on established biofilms 
Biofilms are aggregated bacterial communities covered by polysaccharide matrix that 
protects bacteria from host immune defenses and hinders antibiotics from targeting deep-
seated bacteria encased within the biofilm (104). Biofilm development has been linked 
to serious infections including pneumonia in cystic fibrosis patients and colonization of 
medical devices (105). Biofilms of A. baumannii permit this pathogen to survive on 
abiotic equipment in hospital settings. This facilitates contact with susceptible patients 
and has led to outbreaks of ventilator-associated pneumonia (106). Biofilms pose a 
serious medical challenge that are difficult to control. There is a critical need to find novel 
approaches to address this problem. Recently, several reports have presented AMPs that 
possess potent antibiofilm activity compared to conventional antibiotics. For example, 
de la Fuente-Nunez et al. reported a potent broad-spectrum antibiofilm peptide (peptide 
1018), despite its weak antimicrobial activity against planktonic bacteria (107). The 
mechanism of antibiofilm activity of peptide 1018 was found to occur through binding 
and degradation of the stress related second messenger nucleotide, guanosine 
pentaphosphate (pppGpp) (107). The same group designed a series of more potent 
antibiofilm peptides that work by the same mechanism. The most potent antibiofilm 
peptides in the series were two D enantiomeric peptides (DJK-5 and DJK-6). These 
peptides were resistant to proteolysis and protected invertebrates from lethal P. 
aeruginosa infections (108). The synthetic peptides IDR-1018, DJK5, and DJK6 acted 
synergistically against several Gram-negative pathogens with one or more of the major 
conventional antibiotics ceftazidime, ciprofloxacin, imipenem and tobramycin, lowering 
their effective concentrations up to 64-fold (109). IDR-1018 also showed synergy with 
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the antiseptic agent chlorhexidine against multispecies oral biofilm (110)and DJK-6 
enhanced the activity of the carbapenem imipenem against plasmid-mediated 
carbapenems-producing Klebsiella pneumoniae (111), highlighting how peptides can be 
used to repurpose antibiotics. 
Another group of researchers reported a de novo engineered cationic antimicrobial 
peptide (WLBU2) that reduced P. aeruginosa biofilm growth on CF airway epithelial 
cells and protected mice from lethal P. aeruginosa infections A specifically targeted 
AMPs, C16G2 can specifically recognize S. mutans and disrupt its biofilms (115). 
Therefore, this peptide selectively eliminates the plaque bacterium, S. mutans from the 
normal microflora in humans (115). Currently, C16G2 is under clinical trial phase II as 
mouthwash for the treatment of dental caries caused by S. mutans by C3 Jian, Inc. 
(ClinicalTrials.gov registration number NCT02254993). 
1.4 Limitations of antimicrobial peptides  
Despite the great potential of AMPs including their broad spectrum and rapid bactericidal 
activity, and low resistance mechanism, they still have several problems with application 
to clinical cases such as host toxicity, liability to proteases, impaired activity in the 
presence of biological fluids (serum, plasma, high concentration of salts and acidic pH); 
and high cost of synthesis (15, 16, 22, 116). Below, we discuss these challenges and 
proposed solutions to overcome these limitations.   
1.4.1 Potential for host toxicity 
Since the mechanism of action of most antimicrobial peptides is complex and involves  
damaging the cell membrane, there is concern pertaining to toxicity to host cells/tissues 
(15, 16, 22). Indeed, peptides tested at relatively high concentrations required for bacterial 
killing tend to be non-selective and have high potential for blood cell hemolysis, 
mitochondrial toxicity and eukaryotic cell necrosis. Thus, all clinical trials up to date are 
limited to topical application for surface infections rather than parenteral and oral 
administration (116). However, it should be possible to develop synthetic AMPs which 
can overcome the above obstacles by designing improved short peptides and modifying 
the physicochemical features of AMPs (117-119). As for the toxicity of AMPs, high 
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hydrophobicity is related to increased hemolytic activity (119). Control of hydrophobicity 
and charge can reduce the toxicity of AMPs and closely link the improved selectivity to 
bacteria (119). For example, several analogs from brevinin-1EMa, a frog AMP, were 
designed by amino-acid substitution to monitor the effect of hydrophobicity. An analog 
peptide in which Leu was substituted with Ala in the hydrophobic side of the amphipathic 
helix showed decreased hydrophobicity, showing lower hemolytic activity against human 
blood cells and a higher therapeutic index than the parent molecule (120). A more recent 
study designed a series of analogues of the modified melittin derivative, AR-23, by 
substitution of Ile with positively charged residues (Arg or Lys) (121). Substitution of Ile 
on the nonpolar face with positively charged Lys dramatically altered the hydrophobicity, 
amphipathicity, helicity and the hemolytic activity of the modified peptides. Of all the 
analogues, A(A1R, A8R, I17K), a peptide with Ala1-Arg, Ala8-Arg and Ile17-Lys 
substitutions, exhibited similar bactericidal activity and anti-biofilm activity to AR-23 but 
had much lower hemolytic activity and cytotoxicity against mammalian cells compared 
with AR-23 (121) . Likewise, the improvement of selectivity by design of molecular 
targeted AMPs, such as bacterium-selective AMPs, specifically targeted AMPs and 
environment-sensing AMPs, can be a solution for reducing toxicity (115, 122, 123).An 
example of specifically targeted AMPs is a fusion peptide, C16G2. Generally, a fusion 
peptide has two domains: one is a domain for selectively targeting bacteria and the other 
is a domain for bactericidal action. The two domains are connected with a short linker. 
The targeting domain consists of species-specific monoclonal antibodies or target 
bacterial-specific pheromones and delivers the AMP domain by binding to the bacterial 
surface (115, 122).The C16G2 peptide is conjugated to the targeting domain, which can 
specifically recognize Streptococcus mutans because it was made from a pheromone 
produced by S. mutans. Therefore, this peptide selectively eliminates the plaque bacterium 
S. mutans from the normal microflora in humans. Currently, C16G2 is under clinical trial 
phase II as mouthwash for the treatment of dental caries caused by S. mutans by C3 Jian, 
Inc. (ClinicalTrials.gov registration number NCT02254993) (123). Environment-sensing 
AMPs use the changes in the surrounding induced by pathogenic organisms. For example, 
the AAP2 peptide was designed to be activated at acidic pH but not at physiological pH 
7.5. Under low pH conditions triggered by highly populated bacterium such as S. mutans, 
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this AMP can show maximum activity and successfully remove infected microorganisms 
(124). Recently, other techniques such as polymeric nanoencapsulation of peptides and 
liposomal formulations have been applied to solve stability and toxicity problems (125). 
Encapsulation of AMPs using nanoparticles such as nanospheres and nanovesicles could 
improve therapeutic activity and stability at the same time, which was demonstrated in  
the  study  of  the P34  peptide  encapsulated  in  phosphatidylcholine  nanovesicles (126). 
In addition, as shown in several examples such as indolicidin and polymyxin E, their 
liposomal formulations reduced peptide toxicity and increased plasma half-life 
maintaining their original activity (127). Moreover, PEGylating peptides and usage of  
drug  delivery  systems  have  been  newly introduced  in  this  field  (128). The PEGylated 
M33 peptide showed its increased resistance to peptidase and decreased toxicity, resulting 
in improving peptide activity (128).  
1.4.2 Susceptibility to proteolytic digestion  
Susceptibility of peptides to digestion by proteases serves as major impediment to the 
clinical application of AMPs (15). The linear structure of AMPs can be easily attacked 
by host proteases and peptidases (15, 129). The short half-lives of AMPs that may be 
caused by proteolysis make repetitive administration of AMPs quite problematic with 
high cost (15). Moreover, proteolytic activity of serum is strong, which can provide 
unfavorable circumstances to the administered AMPs into blood (15). That is why AMPs 
are usually used as topical treatment for skin infections associated with burns, diabetic 
wounds, the eyes and gum infections in practice. Thus, to overcome the limitation of 
application, the escaping strategy for protease degradation of AMPs is required. 
Moreover, peptides have high affinity to bind serum proteins leaving small unbound 
fraction in the circulation. Furthermore, peptides are rapidly cleared from circulation 
which results in short half-life in plasma and failure to access pathogens inside tissues to 
clear infections (130). These issues hindered the development of antimicrobial peptides 
in systemic applications (both oral and parenteral), and explain why antimicrobial 
peptides that reach the clinical phases are designed for topical applications (16) (54). 
(130). However, several strategies have been investigated to overcome these issues. The 
strategies employed include, 1) substitution of amino acids with their D isoform, 
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rendering the peptide resistant to the action of proteases (69, 108); 2) creation of chemical 
compounds that mimic the structure of antimicrobial peptides (peptoids (131-133) and 
peptidomimetics (134, 135)) which are more stable to proteolysis; and 3) packaging of 
peptides inside a carrier such as liposomes and nanoparticle results in increasing the 
peptide half-life in circulation (136-139). 
 
1.4.3 Impaired antibacterial activity in the presence of physiologically relevant 
conditions (e.g., salts, acidic pH, plasma, and serum) 
A significant drawback of many antimicrobial peptides is their antibacterial activity is 
impaired in the presence of high concentration of salts; this severely limits their clinical 
utility (140, 141). For example, in the epithelial cell secretions of a CF patients, the NaCl 
concentration is approximately 120 mM (142); at this concentration β-defensins, lost its 
antibacterial activity. Recently, several studies reported that abnormally reduced pH in the 
airway surface liquid of CF patients (pH 6.8) inhibits the antimicrobial activity of host 
defense peptides and may impair the host’s defense against pathogens (143, 144). In 
addition to salts and acidity, serum and plasma can also impair the antibacterial activity 
of conventional antibiotics and peptides either via proteolytic digestion or binding to 
protein or lipid fractions (145). Several strategies have been investigated to overcome 
these issues, for example, De novo designing of tryptophan and arginine rich AMPs can 
improve antimicrobial activity under physiological conditions (e.g., salts, plasma, and 
serum) without negatively impacting host toxicity (24, 146, 147). In addition, substitution 
of tryptophan- and histidine-rich peptides with the bulky amino acid, naphthylalanine 
have shown to increase the serum stability and boost salt resistant of a short Trp-rich 
antimicrobial peptide, S1 (141).  
1.4.4 Cost to manufacture  
The cost of synthesizing antimicrobial peptides in bulk are very expensive compared to 
conventional antibiotics (15). A single gram of peptide (sufficient for an average daily 
dose orally or via intravenous injection) may cost $100- $600 to manufacture (15).  This 
is considered one of the major hurdles for development of peptides for large scale 
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productions and testing in different clinical applications (15). Various strategies have been 
developed to decrease the cost of AMPs production. The strategies employed include, A) 
Size reduction and/or de novo synthesis of AMPs. For example, Won et al. tried to 
synthesize the shortest AMP analogs from Gaegurin 5, which showed good antimicrobial 
activity in their studies. They found that 11 residues are the marginal length showing good 
activity (148). B) Development of a suitable expression system is another strategy to 
decrease the cost, as seen in the example of plectasin, of which the fungal expression 
system was helpful to obtain a high yield of peptides (149). The recombinant human 
lactoferrin also has been expressed in transgenic cattle to provide the large-scale 
production of lactoferrin for pharmaceutical use (150). In addition, the improved solubility 
of AMPs using a fusion expression system that contains a solubility-enhancing moiety 
could increase efficiency in producing AMPs, leading to a reduction in cost Recent studies 
have shown that thioredoxin and small ubiquitin-related modifiers can be used for 
improving the solubility of peptides and finally producing high yields of peptides (151, 
152).  
1.5 Antimicrobial peptides in clinical trials 
AMPs in current and past clinical trials have been reviewed here (Table 1.1). 
One of the AMPs that has advanced furthest in clinical trials is pexiganan for the 
treatment of diabetic foot ulcers (153). Pexiganan (22 amino acids peptide) is an analog 
of magainin 2. Magainin was first discovered from the skin of the African clawed frog 
Xenopus laevis in 1987. Pexiganan showed excellent in vitro broad-spectrum bactericidal 
activity against large panel of clinically isolated bacteria. Topical application of 2% 
pexiganan cream showed therapeutic resolution equivalent to oral ofloxacin for treatment 
of mild infections of diabetic foot ulcers (153). Interestingly, no significant resistance to 
pexiganan emerged among patients who received pexiganan. However, bacterial 
resistance to ofloxacin emerged in some patients who received ofloxacin (153). Currently, 
pexiganan is undergoing phase 3 development as a topical agent for treatment of mild 
infections of diabetic foot ulcers (ClinicalTrials.gov registration numbers NCT01594762 
and NCT01590758). Another compound that showed success in clinical trials is the 
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peptidomimetic, brilacidin. Brilacidin is a defensin-mimetic that targets the bacterial 
membrane, similar to AMPs. Brilacidin was capable of inhibiting growth of a collection 
of multidrug-resistant S. aureus isolates at a concentration of 2 μg/ml. Brilacidin also 
demonstrated clinical efficacy and safety in two phase II clinical trials for the treatment 
of acute bacterial skin and skin structure infections (ABSSSI). The FDA approved 
brilacidin to advance into Phase III clinical trials (123, 156, 157). Omiganan (MBI-226) 
is a synthetic analog (12 amino acid residue) of bovine indolicidin. It has several benefits 
such as it can be applied topically up to 5% concentration without toxicity and resistance 
(123, 158). Unfortunately, Phase III clinical trials for the prevention of infectious 
complications after blood vessel catheterization failed. This is because the study 
involving more than 1400 patients did not show statistically significant evidence of 
higher efficacy compared to standard treatment. Omiganan 1% gel, named Omigard, is 
now under another Phase III clinical trial for the prevention of catheter-related infections 
as topical treatment by Carrus Capital Corporation (123). In addition, Cutanea Life 
Sciences Inc. has developed a Phase II clinical trial for the treatment of rosacea (123). 
Iseganan (IB-367) is a synthetic derivative (18 amino acids) of pig protegrin. Iseganan 
forming a b-hairpin structure stabilized by two disulfide bonds. Iseganan demonstrated 
potent and broad-spectrum antibacterial and antifungal activity (159, 160). A Phase I 
clinical study demonstrated its safety and provided the first evidence of efficacy by the 
reduction of microorganisms by mouth treatment over ten days (159). Phase II clinical 
trials involving 134 patients indicated that IB-367 decreased the population of bacteria 
in infected lungs and helped in recovering pulmonary function in cystic fibrosis patients 
(160). Iseganan was intended to be developed as a local mouthwash to inhibit ulcerative 
oral mucositis for patients who are susceptible to infection with high risk. The company, 
IntraBiotics Pharmaceuticals, tried a Phase III clinical study with 502 patients receiving 
stomatotoxic chemotherapy. Unfortunately, this trial was not successful because of a 
dispensing error of a portion or the clinical supplies during the trial, resulting in 
consequent reduction of statistical power (161). In addition, another Phase III trial with 
545 patients receiving radiotherapy for head-and-neck malignancies did not show any 
clinical improvement in ulcerative oral mucositis (162). As a result, the development of 
IB-367 was stopped for this particular indication (163). 
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A number of LL-37 related peptides have also shown the potential for therapeutic 
development], such as OP-145, which was developed by OctoPlus, and when the peptide 
was included in cream formulations for nasal application, these preparations were found 
to be efficacious in the eradication of MRSA carriage (164, 165).The completion of phase 
I/II clinical trials by OP-145 also showed that the peptide was safe and efficacious as a 
treatment for chronic otitis media (Table 1.1). This disease affects millions of people 
worldwide and is highly recalcitrant to treatment by conventional antibiotics, which is 
now known to be primarily due to bacterial biofilms (166). Derivatives of human 
lactoferrin have shown the potential for therapeutic development such as hLF(1-11), 
which was developed by AM Pharma, and in clinical trials the peptide was safely injected 
into neutropenic stem cell transplantation patients (167).Currently, hLF(1-11) in clinical 
trial II for the prevention of bacteremia and fungal infections in immunocompromised 
individuals (Table 1.1). Lytixar (LTX-109) is a synthetic, membrane-degrading peptide 
that has been developed by Lytix Biopharma (Oslo); this peptide has completed a Phase 
I/IIa clinical trial for nasally colonized MRSA. The anterior nares are the main reservoir 
for colonization by S. aureus and the nasal carriage of MRSA is an important risk factor 
for subsequent infection and transmission of this pathogen, which has led to intensive 
efforts to identify agents able to efficiently reduce MRSA colonization (168, 169).A 
significant effect on nasal decolonization of MRSA and MSSA was observed after only 
two days of LTX-109 treatment in subjects treated with 2% or 5% LTX-109, compared 
to the vehicle (168, 169). The success of pexiganin, brilacidin, hLF(1-11), OP-145 and 
LTX-109 demonstrates the promise that antimicrobial peptides have as potential topical 
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Table 1.1. Antimicrobial peptides (AMPs) in past and current clinical trials. 
Antimicrobial 
Peptides 
Description Indication Phase Clinical trial ID Company 
Pexiganan 
(MSI-78) 
An analogue of 
magainin. 
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the treatment of 
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fungal infections. 
2 NCT00509938 AM Pharma. 
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(NP213), 
A synthetic cyclic 
AMP. 
Treatment for 
fungal infections of 
the toenail. 





An analogue of 
indolicidin. 
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Life Sciences, Inc. 
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Ear drops for the 
treatment of chronic 
otitis 










the treatment of 
acute bacterial skin 
and skin structure 













Mouthwash for the 
treatment of dental 
caries caused by 
Streptococcus 
mutans. 









Figure 1.1. Various models of membranolytic mechanism of action of antimicrobial 
peptides (AMPs). 
AMPs associating with the bacterial membrane (top left). The red and blue parts of the 
peptide represents a hydrophilic and a hydrophobic surfaces, respectively. A) The barrel-
stave model, B) The carpet model and C) The toroidal pore model. Reproduced with 
















Figure 1.2. Intracellular mechanism of action of antimicrobial peptides. 
Several peptides can penetrate membranes and induce killing by acting on one or more 
intracellular targets; such as inhibiting nucleic acids and protein synthesis, inhibition of 
cell wall synthesis and cell division. Reproduced with permission from Nature Reviews 












CHAPTER 2. TARGETING METHICILLIN-RESISTANT 
STAPHYLOCOCCUS AUREUS WITH SHORT SALT-
RESISTANT SYNTHETIC PEPTIDES 
(Mohamed, M.F., Hamed, M.I., Panitch, A., Seleem, M.N (2014) Targeting methicillin-
resistant Staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrobial 
agents and chemotherapy doi:10.1128/AAC.02578-14) 
2.1 Abstract 
The seriousness of microbial resistance combined with the lack of new antimicrobials 
have increased the interest in the development of antimicrobial peptides (AMPs) as novel 
therapeutics. In this study, we evaluated the antimicrobial activity of two short synthetic 
peptides, namely RRIKA and RR. These peptides exhibited potent antimicrobial activity 
against Staphylococcus aureus and their antimicrobial effects were significantly enhanced 
by addition of three amino acids in the C terminus, which consequently increased the 
amphipathicity, hydrophobicity and net charge. Moreover, RRIKA and RR demonstrated 
a significant and rapid bactericidal effect against clinical and drug-resistant 
Staphylococcus isolates including methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA), 
linezolid-resistant S. aureus and methicillin-resistant S. epidermidis. In contrast to many 
natural AMPs; RRIKA and RR retained their activity in the presence of physiological 
concentrations of NaCl and MgCl2. Both RRIKA and RR enhanced the killing of 
lysostaphin over 1000-fold and eradicated MRSA and VRSA isolates within 20 minutes. 
Furthermore, the peptides presented were superior in reducing adherent biofilms of S. 
aureus and S. epidermidis when compared to conventional antibiotics. Our findings 
indicate that the staphylocidal effects of our peptides were through permeabilization of 
the bacterial membrane, leading to leakage of cytoplasmic contents and cell death. 
Furthermore, peptides were not toxic to HeLa cells at 4 to 8 fold their antimicrobial 
concentrations. The potent and salt-insensitive antimicrobial activities of these peptides 
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present an attractive therapeutic candidate for treatment of multidrug-resistant S. aureus 
infections.  
2.2 Introduction 
Methicillin-resistant Staphylococcus aureus (MRSA) infections have become a major 
public health concern in both hospital and community settings (1, 2). Since the late 1990s, 
community-associated MRSA (CA-MRSA) emerged as a principal cause of skin and soft-
tissue epidemics throughout the world (3). It has been estimated that mortality rates from 
MRSA infections in US hospitals are higher than infections caused by HIV/AIDS and 
tuberculosis combined (4). Furthermore, there is a considerable medical challenge for 
treating MRSA infections due to the remarkable ability of S. aureus to develop resistance 
to multiple antibiotics, thus limiting the number of viable therapeutic options (2, 5). 
Therefore, there is an urgent need to develop novel antimicrobials with unique 
mechanisms of action to combat MRSA. 
Antimicrobial peptides (AMPs) are key components of the host innate defense against 
infections in most creatures (6, 7). The potential therapeutic applications of AMPs are 
significant (8). They have rapid and broad spectrum antibacterial activity.  In addition, it 
is extremely difficult for bacteria to evolve resistance against AMPs that disrupt the 
microbial membrane, as it would necessitate fundamental alterations in the lipid 
composition of the bacterial membranes. Though AMPs have many important 
antibacterial properties, several studies have exposed their potential limitations as 
therapeutic agents. 
A significant number of natural AMPs are large in size with high host cytotoxicity and 
moderate antimicrobial activity. Moreover, their production cost is high (8, 9). In addition, 
many natural AMPs lose their antimicrobial activity in physiological salt concentrations 
(10, 11). These characteristics have substantially hindered their pharmaceutical 
development as new therapeutic agents. Thus, successful development of novel AMPs as 
future therapeutics requires identification of short AMPs demonstrating strong 
antimicrobial activity, salt tolerance and minimal toxicity to host tissues. 
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Previously, our group has developed short synthetic peptide templates for therapeutic 
applications against hyperplasia and inflammation (12-14). However, their antimicrobial 
activity was never explored. In the present study, we screened four synthetic peptides and 
identified two peptides, namely RRIKA and RR, with potent antimicrobial activity against 
a panel of clinical and drug resistant Staphylococci strains. In addition, we investigated 
the synergistic activity of these peptides in combination with clinically relevant 
antimicrobials and examined the peptides’ ability to disrupt staphylococcal biofilms. 
Moreover, we performed a series of experiments to explore the antibacterial mechanism 
of action of RRIKA and RR and examined the toxicity of these peptides toward 
mammalian cells. 
2.3 Materials and methods  
Bacterial strains and media  
All Staphylococcus strains tested in this study are presented in (Table 2.1). Mueller-
Hinton broth (MHB) and Mueller-Hinton agar (MHA) were purchased from Sigma-
Aldrich, while trypticase soy broth (TSB) and trypticase soy agar (TSA) were purchased 
from Becton-Dickinson, Cockeysville, Md.  
Reagents, peptides and antibiotics  
Nisin (Sigma, N5764), melittin from honey bee venom (Sigma, M2272), magainin I 
(Sigma, M7152), vancomycin hydrochloride (Gold Biotechnology), linezolid (Selleck 
Chemicals), ampicillin sodium salt (IBI Scientific), recombinant lysostaphin (3000 U/ mg) 
from Staphylococcus simulans (Sigma, L9043) and calcein AM (Molecular Probes, Life 
Technologies) were all purchased from commercial vendors. 
Peptide synthesis 
Peptides RRIKA, RR, KAF, and FAK were synthesized on Knorr-amide resin (Synbiosci 
Corp.) using standard FMOC chemistry. Two different chemistries were used to couple 
each amino acid. The first coupling reagents were N-hydroxybenzotriazole (HoBt)/N, N’-
diisopropylcarbodiimide (DIC) and the second coupling reagents were 2-
(1Hbenzotriazole-1-yl)-1, 1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 
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lutidine. For FITC labeled YARA, an aminohexanoic acid spacer was added to the N-
terminus to serve as a spacer for the addition of FITC isomer 1 (Molecular Probes). The 
FITC isomer was solubilized in 12:7:5 pyridine/DMF/DCM and incubated with the 
deprotected peptide overnight. A ninhydrin test was used to check complete coupling of 
FITC to the peptide. Following synthesis, the peptide was cleaved from the resin with a 
trifluoroacetic acid-based cocktail, precipitated in ether, and recovered by centrifugation. 
The recovered peptide was dried in vacuo, resuspended in MilliQ purified water, and 
purified using an FPLC (ÄKTA Explorer, GE Healthcare) equipped with a 22/250 C18 
prep-scale column (Grace Davidson). An acetonitrile gradient with a constant 
concentration of 0.1% trifluoroacetic acid was used to achieve purification. Desired 
molecular weight was confirmed by time-of-flight MALDI mass spectrometry using a 
4800 Plus MALDI TOF/TOF™ Analyzer (Applied Biosystems). 
Antibacterial assays 
Minimum inhibitory concentrations (MIC) of peptides and antibiotics were evaluated with 
the broth microdilution technique in MHB with an initial inoculum of 5×105 cells non-
treated Polystyrene microtiter plates (CytoOne, CC7672-7596) in accordance with the 
Clinical and Laboratory Standards Institute (CLSI) (15). The MIC was interpreted as the 
lowest concentration of peptide or antibiotic that completely inhibited the visible growth 
of bacteria after 16 hr incubation of the plates at 37°C. Each agent was tested in triplicate 
in at least two independent experiments. The highest MIC value was reported. 
 Antimicrobial activity in the presence of salts 
To investigate the activity of peptides in the presence of high salt concentrations, the MIC 
was again identified as described above except, fixed concentrations of NaCl or MgCl2 
were added to each well of the microtiter plate. For further analysis of the effect of salinity 
on killing ability of peptides; logarithmic phase of MRSA USA300 and VRSA VRS13 at 
5×105 colony forming units/ml (CFU/ml) were incubated with 2 × MIC of RRIKA and 
RR, in MHB, with different concentrations of NaCl (0, 50, 100, 150 mM) or MgCl2 (0, 1, 
2, 3 mM) for 4 hr. Bacteria were serially diluted and plated, in triplicate, on TSA plates. 
CFUs were counted after incubation of plates for 24 hr at 37°C.  
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Time-kill assay  
An overnight culture of MRSA USA300 was diluted in fresh MHB and incubated until 
optical density (OD600) ≈1, was reached, then washed twice with phosphate buffered saline 
(PBS) diluted to ~5×105 CFU/ml in MHB. Peptides, vancomycin and linezolid were added 
at concentrations equivalent to 5 × MIC. Peptide diluent (sterile water) served as a 
negative control. Bacterial cell viability was monitored up to 24 hr. Samples were 
removed at specific intervals, serially diluted in PBS, and plated, in triplicate, on TSA 
plates. CFUs were counted after 24 hr incubation of plates at 37°C. To study the effect of 
serum and salinity on the killing kinetics of the peptides, a time-kill assay was performed 
as described above with the exception that bacteria and peptides at 5 × MIC were 
incubated in MHB alone or with 10% fetal bovine serum (FBS) or incubated in PBS 
(containing 137 mM NaCl). 
Synergy with antimicrobials 
The fractional inhibitory concentration (FIC) index was utilized to determine the 
relationship between antimicrobial agents. Peptide MICs against test microorganisms 
were determined in triplicate samples. Two-fold serial dilutions of antimicrobials 
(lysostaphin, vancomycin, linezolid and nisin) were tested in the presence of a fixed 
concentration of peptide, equals to ¼ × peptide MIC. It is worthy to note that none of the 
peptides killed the test microorganisms at their quarter MICs. The FIC index was 
calculated as follows: FIC = 0.25 + MIC (antibiotic in combination)/MIC (antibiotic 
alone); 0.25 is equal to MIC (peptide in combination)/MIC (peptide alone). An FIC index 
of ≤ 0.5 is considered to demonstrate synergy. Additive effect was defined as an FIC index 
of 1. Antagonism was defined as an FIC index of > 4(16).  
To further investigate the synergism of peptides with lysostaphin, the time-kill method of 
determining synergy was utilized as described elsewhere (17). MRSA USA300 and 
VRSA VRS13 were incubated with ½ × MIC of RRIKA or ½ × MIC of RR alone; or in 
combination with ¼ × MIC of lysostaphin (MIC of lysostaphin against MRSA USA300 
and VRSA VRS13 were 0.04 and 0.08 µM, respectively). Samples were obtained at 
different time points, then diluted and plated on TSA plates.  The plates were incubated 
for 24 hr at 37°C before CFU were determined. Synergy was defined as a 100-fold or 2-
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log10 decrease in colony count by the combination of two agents together as compared to 
each agent tested alone. Additivity or indifference was defined as a 10-fold change in CFU 
and antagonism was defined as a 100-fold increase in CFU by the combined peptide 
treatment in comparison to the single treatment. 
Bacterial membrane disruption activity (Bacteriolysis) 
Cell lysis, as indicated by a decrease in OD595, was determined as described before (18). 
Briefly, MHB was inoculated with an overnight culture of MRSA USA300 and incubated 
aerobically at 37°C until an OD595≈0.6 was reached and then diluted to OD595≈0.2 in MHB 
(equivalent to ≈108 CFU/mL). 200 µL of diluted bacteria was added to all wells of a 96-
well plate. RRIKA and RR were added in concentrations equivalent to 4 × MIC. Nisin at 
4 × MIC was used as a positive control and untreated bacteria served as a negative control. 
MHB with the same concentrations of drugs served as blanks. Turbidity was monitored at 
defined intervals up to 10 hr in a Molecular Devices Vmax microplate reader at 595 nm 
absorption. The assay was carried out in triplicate samples for each treatment regimen. 
Calcein leakage assay 
Membrane permeabilization of S. aureus by peptides was monitored and quantified by the 
leakage of the preloaded fluorescent dye, calcein, as described before (19). MRSA 
USA300 was grown in MHB to logarithmic phase at 37°C. Cells were then harvested by 
centrifugation, washed twice with PBS, and then adjusted spectrophotometrically to an 
OD600 of 1.0 (≈10
9 CFU/ml) in PBS containing 10% (vol/vol) MHB. Then MRSA cells 
were incubated with 3 µM calcein AM for 1 hr at 37°C. Calcein-loaded cells were 
harvested by centrifugation (3,000 × g, 10 min), suspended in PBS, and diluted to achieve 
a final inoculum of 107 CFU/ml. Aliquots of 100 µL were then added into a sterile black-
wall 96-well plate. RRIKA and RR were added in concentrations equivalent to 5 × and 10 
× MIC. Bacteria treated with peptide diluent (sterile water) and nisin (10 µg/mL) served 
as negative and positive controls, respectively. Calcein leakage was measured for 120 min 
using a fluorescence plate reader (FLx800 model BioTek® Instruments, Inc. Winooski, 
Vermont). Membrane permeabilization (%) was calculated as the absolute percent calcein 
leakage by peptides with respect to calcein-loaded with no-peptide treated cells. 
Experiments were done in triplicate and repeated independently twice.  
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DNA binding assay  
The ability of RRIKA and RR to bind DNA was investigated by the electrophoretic 
mobility shift assay as has been previously described (20). In brief, increasing 
concentrations of RRIKA, RR and magainin were incubated with 250 ng of plasmid DNA 
(pUC19) in 30 µL binding buffer (10 mM Tris-HCl, 1 mM EDTA buffer, pH 8.0) at room 
temperature for 30 min. After incubation, the DNA was analyzed by 1% gel 
electrophoresis. DNA migration was visualized by ethidium bromide staining. 
Quantification of activity against biofilms  
Biofilm-forming clinical isolates of S. aureus (ATCC 6538) and S. epidermidis (ATCC 
35984) were grown overnight in TSB. After incubation, cultures were diluted 1:100 in 
TSB supplemented with 1% glucose. Diluted bacteria were inoculated in either 24- or 96-
well flat bottom cell culture plates (polystyrene) and incubated at 37°C for 24 hr. The 
culture medium was subsequently removed and wells were carefully washed with PBS 
three times to remove planktonic bacteria before re-filling wells with fresh MHB. Peptides 
and antibiotics were added at different concentrations and plates were incubated at 37°C 
for 24 hr. After the removal of medium at the end of incubation, wells were rinsed by 
submerging the entire plate in a tub containing tap water. Biofilms were stained with 0.1% 
(w/v) crystal violet for 30 min. After staining, the dye was removed and the wells washed 
with water. The plates were dried for at least 1 hr, prior to addition of ethanol (95%) to 
solubilize the dye bound to the biofilm. The optical densities (OD) of biofilms were 
measured at 595 nm absorbance by using a microplate reader (Bio-Tek Instruments Inc.). 
An inverted microscope (Vista Vision, VWR), with attached camera and 25X objective 
was used to photograph the biofilm in 24-well plates. 
Hemolysis assay  
Human red blood cells (RBCs) (Innovative Research “Novi, MI”) were pelleted by 
centrifugation at 2000 rpm for 5 min followed by washing three times with PBS. An 8% 
suspension (v/v) of RBCs was prepared in PBS and 50 L of the solution was transferred 
to a 96-well plate. Then, 50 L of different concentration of peptides in PBS were added 
to give a final suspension of 4% (v/v) of RBCs. PBS served as a negative control. 0.1 % 
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triton X-100 as well as 5 µM melittin served as a positive control.  The plate was incubated 
at 37°C for 1 hr.  The plate was subsequently centrifuged at 1000 rpm for 5 min at 4°C. 
75 L aliquots of the supernatants in each well were carefully transferred to a new sterile 
96-well plate. Finally, the hemolytic activity was evaluated by measuring the optical 
absorbance at OD405 with a microplate reader (Vmax, Molecular Devices). The hemolysis 
percentage was calculated based on the 100% release with 0.1 % triton X-100 or 5 µM 
melittin. Experiments were done in triplicates. 
Cytotoxicity assay  
The toxicity of RRIKA, RR and melittin against HeLa cells was carried out using the 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit from Promega (21). 
Briefly, ~ 2 × 10
4 HeLa cells suspended in 200 µL of DMEM supplemented with 10% 
FBS, were seeded in 96-well plates and incubated at 37°C in a 5% CO2 atmosphere for 24 
hr. The HeLa cells were further incubated with different concentration of peptides for 24 
hr. At the end of the incubation period, the culture media was discarded and the cells in 
each well were washed with PBS. 100 µL of cell culture media and 20 µL CellTiter 96® 
AQueous assay reagent were added next (solution reagent contains a tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] ). The plate was returned to the incubator for 2 hr to allow 
color development. The intensity of color was quantified at 490 nm using a 96-well 
microplate reader (Vmax, Molecular Devices). Results were expressed as the percentage 
mean absorbance by cells upon incubation with peptide with respect to incubation with 
the control (untreated wells). 
Statistical analyses 
The mean absorbance of crystal violet in the biofilm reduction was compared between the 
groups using the two-tailed Student t test (p ˂ 0.05). All statistical analyses were performed 






The amino acid sequences and characteristics of the synthetic peptides used in this study 
are shown in Table 2.2. We screened the synthetic peptides against a panel of clinical and 
drug-resistant Staphylococcal strains (Table 2.1). RRIKA inhibited the growth of 
methicillin-sensitive S. aureus (MSSA), MRSA, VISA, VRSA, linezolid-resistant S. 
aureus, methicillin-resistant S. epidermidis and multidrug-resistant strains from 
concentrations ranging from 2 to 4 µM. RR inhibited the same isolates with MICs ranging 
from 8 to 32 µM. In contrast, KAF and FAK peptides were inactive against all strains 
tested up to 64 µM (data not shown). 
Bacterial killing kinetics 
Figure 2.1 presents the rate of microbial killing by RR, RRIKA, vancomycin and linezolid 
when MRSA USA300 was exposed to 5 × MIC of each treatment over a 24 hr incubation 
period at 37 ºC. Both RRIKA and RR exhibited a rapid bactericidal effect with 3-log10 
reduction (99.9 % clearance) within 60 and 90 min, respectively. In addition, both peptides 
completely eliminated the inoculum (5×105 CFU/mL) within 120 and 180 min, 
respectively. In comparison, vancomycin achieved a 3-log10 bacterial reduction only after 
24 hr; while linezolid (a protein synthesis inhibitor) exhibited a bacteriostatic effect 
producing only a single log bacterial reduction over the 24 hr incubation. The killing 
kinetics of RRIKA and RR in PBS (containing 137 mM NaCl) did not significantly change 
when compared to MHB (figure 2.2). In the presence of 10% FBS, RRIKA retained its 
bactericidal activity, though it required longer to kill the bacteria completely (6h), while 
RR lost its antibacterial activity at the same condition. 
Antimicrobial activity in the presence of salts 
The MIC of RRIKA and RR for MRSA USA300 was determined in the presence of NaCl 
or MgCl2. There was no increase in the MICs of RRIKA and only a one-fold increase in 
case of RR was observed in the presence of 100 mM NaCl. Moreover, the antimicrobial 
activity of RRIKA and RR was not impeded in the presence of MgCl2 at a concentration 
equivalent to reported physiological conditions (2 mM). To study the effect of salinity on 
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the killing ability of the peptides, CFU were counted after incubation of MRSA USA300 
and VRSA VRS13 strains with RRIKA and RR (2 × MIC) in increasing concentrations 
of NaCl or MgCl2. There was no significant difference in the bactericidal activity of 
RRIKA in the presence of NaCl up to 150 mM. Similar patterns were observed for RR 
with the exception of one log10 increase in CFU observed at 150 mM NaCl; however, this 
peptide retained its bactericidal activity at this concentration (producing a 3-log10 
reduction). Furthermore, physiological concentrations of MgCl2 (1, 2 and 3 mM) had no 
effect on the killing ability of both RRIKA and RR.  
Synergy with antimicrobial agents 
Both RRIKA and RR acted synergistically with lysostaphin against MSSA, MRSA and 
VRSA strains with a FIC index equal to 0.26 (Table 2.3). When both peptides were 
combined together, only one-fold decrease in each peptide’s MIC was observed (FIC 
index = 0.75). However, an additive effect was observed when each peptide was combined 
with vancomycin, linezolid or nisin against tested strains (data not shown). There were no 
antagonistic effects observed between the peptides and antimicrobials against all strains 
tested.  
Time-kill synergy studies revealed RRIKA and RR, at only ½ × MIC enhanced the killing 
of lysostaphin (at ¼ × MIC) more than 1000-fold and completely eradicated MRSA and 
VRSA isolates within 20 minutes (figure 2.3). 
Bacterial membrane disruption activity (Bacteriolysis) 
Since evidence of rapid cell lysis of treated cultures is indicative of membrane damaging 
activity of antimicrobial peptides (22, 23), we assessed whether the bactericidal activity 
of our peptides was associated with lysis of bacterial cells by measuring culture turbidity 
over time after treatment. We monitored the turbidity of MRSA cultures treated with 4 × 
MIC of peptides over a 10 hr period at OD595 via a microplate reader. As shown in figure 
2.4 both RRIKA and RR caused a rapid decrease in OD595 even with a high inoculum 
concentration of 108 CFU/ml.  Peptide RRIKA produced greater than 50% and 86% 
reduction in turbidity after 2.5 and 6 hr, respectively. RR produced a similar percentage 
of turbidity as RRIKA albeit at a slower rate (after 4.5 and 10 hr).  Nisin at 4 × MIC, a 
polycyclic antibacterial peptide which is known as a membrane perturbing agent (24), 
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lysed cells at a slightly higher rate than RRIKA with more than 70% reduction in turbidity 
observed after 2.5 h. In contrast, wells treated with 4 × MIC of vancomycin (a cell wall 
biosynthesis inhibitor) had no effect on culture turbidity within the same time frame. 
Permeabilization of S. aureus membrane (calcein leakage assay) 
We monitored the effect of the peptides on MRSA membrane integrity by using the 
calcein leakage assay as described previously (19, 25). Damage of membrane integrity is 
indicated by calcein leakage from bacterial cells, leading to a reduction in fluorescence 
intensity. Figure 2.5 demonstrates that both peptides perturb the S. aureus cell membrane 
leading to leakage of preloaded calcein in both a concentration- and time-dependent 
manner. RRIKA was faster and more potent in comparison to RR in membrane 
perturbation. At 5 × MIC, RRIKA and RR caused more than 60% and 30% leakage 
respectively within 60 minutes. When the concentration of peptide was increased to 10 × 
MIC, a significant change in membrane damage was observed for both peptides. There 
was a more than 75% and 60% reduction in fluorescence intensity measured for RRIKA 
and RR respectively in the same time frame. Nisin at 5 × MIC resulted in more than 70% 
calcein leakage from cells, which is comparable to RRIKA at 10 × MIC. Vancomycin, as 
expected, had no effect on the bacterial cell membrane integrity even at high concentration 
(10 × MIC).  
DNA binding properties 
Since there was no obvious evidence that the antibacterial effect of AMPs was restricted 
to perforation of membranes, we explored the feasibility of other intracellular targets, such 
as DNA by assessing the DNA-binding properties of peptides (26, 27). As shown in figure 
2.6, both peptides were able to bind the plasmid DNA and delay its electrophoretic 
migration into agarose gel, in a dose-dependent manner. At 8 µM concentration, of 
RRIKA peptide, a fraction of the plasmid DNA was still able to migrate into the gel as 
non-complexed DNA; however, at 16 µM, the majority of DNA remained in the gel’s 
wells. At higher concentrations, complete retardation of DNA migration was exhibited, 
implying that the DNA was aggregated by peptide. Similar patterns of migration were 
observed with the RR peptide except that free DNA was still seen at 16 µM concentration. 
44 
 
In contrast, magainin, a cationic antimicrobial peptide of amphibian skin, lacks this ability 
to bind DNA even at concentrations up to 80 µM. 
Quantification of activity against biofilms  
In order to evaluate the efficacy of RR and RRIKA against established biofilms, we 
measured the biofilm mass post-treatment by crystal violet staining biofilms formed by 
clinical isolates of S. aureus and S. epidermidis. As observed in figure 2.7A, both peptides 
significantly reduced S. aureus biofilms as compared to the antibiotics of choice. RRIKA 
and RR, at only 2 × MIC, dispersed more than 65% of mature biofilms (p < 0.01), while 
vancomycin and linezolid, at 16 × MIC, was only capable of reducing 40% of biofilm 
mass (p < 0.01). There was significant difference between peptide and antibiotics treated 
biofilms (p < 0.01). 
With regards to S. epidermidis, both RR and RRIKA, at 32 and 64 × MIC, were able to 
reduce more than 50% of biofilm mass respectively (p < 0.01) (figure 2.7B). Vancomycin 
and linezolid, on the other hand, reduced only 9.5 and 10.7% of biofilm mass, respectively 
(p < 0.01) at concentrations equivalent to 256 × MIC. Also, we found statistical 
significance between peptide and antibiotics treated biofilms (p < 0.01). 
Hemolysis assay and cell toxicity 
We assessed the release of hemoglobin from human erythrocytes exposed to different 
concentrations of peptides. As depicted in figure 2.8, even at concentrations as high as 
300 µΜ, RRIKA and RR exhibited minimal hemolysis against RBCs (maximum of 10% 
hemolysis observed). In contrast, melittin completely lysed RBCs (100% hemolysis) at a 
significantly lower concentration of 5 µM.  
The cytotoxic effect of the peptides on HeLa cells was evaluated by the MTS assay. As 
depicted in figure 2.9, neither RRIKA nor RR was toxic to the mammalian cells tested up 
to concentrations of 32 µM and 64 µM, respectively. These values correlate to 8 and 4 × 
MIC for RRIKA and RR, respectively. The half maximal effective concentration (EC50) 
of RRIKA and RR against macrophage cell lines was 64 and 128 µM respectively. On the 
other hand, melittin showed high toxicity even at bacteriostatic concentration with EC50 
less than 5 µM. 
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Discussion In this study, we evaluated the antimicrobial activity of two short synthetic 
peptides, and revealed their potential mechanisms of action. We observed that RRIKA 
and RR exhibited potent antibacterial activity against all tested S. aureus isolates. 
Moreover, our peptides demonstrated activity against multiple clinical isolates of MRSA, 
particularly MRSA USA300, a community-associated strain which is responsible for 
outbreaks of staphylococcal skin and soft-tissue infections (SSTI) in the United States 
(28). Similarly, the potent bactericidal activity was observed in other clinical MRSA 
isolates (USA100, USA200 and USA500) that are resistant to various antibiotic classes 
including macrolides, aminoglycosides, lincosamides, and fluoroquinolones. Additionally, 
we found that these peptides retained their activity against strains of S. aureus which have 
resistance to drugs of choice in treating MRSA infections, namely linezolid (MRSA 
NRS119) and vancomycin (VRSA strains). It is worthy to note that, the C terminus of the 
RR peptide was modified to contain three additional amino acids (isoleucine, lysine and 
alanine) which made the RRIKA peptide more amphipathic and hydrophobic and also 
increased its positive net charge.  These modifications augmented the antibacterial activity 
of RRIKA which exhibited MICs two to eight folds lower than those of RR. The enhanced 
efficacy of RRIKA may reveal a functional structure activity relationship and provide a 
template for future peptide synthesis. 
Time-kill kinetics revealed a major advantage of the synthetic peptides over tested 
antibiotics. While RRIKA and RR eliminated MRSA within 1-2 hr after treatment, 
vancomycin required 24 hr to reduce the bacterial CFU by 3-log10. Linezolid, on the other 
hand, exhibited only a bacteriostatic effect. 
Growth kinetic measurements of MRSA exposed to peptides clearly demonstrated that 
RRIKA and RR peptides exhibited kinetic behavior similar to membrane lytic peptides 
such as the lantibiotic nisin (24) and amphibian magainin (23) but different from non-lytic 
peptides such as fungal plectasin (29) and amphibian buforin II (23). These data suggest 
that our peptides act by disrupting the integrity of the bacterial membrane. To validate this 
hypothesis, we studied the effect of peptides on MRSA membranes using a calcein leakage 
assay.  Similar to the well-known membrane damaging peptide, nisin, both RRIKA and 
RR permeabilized S. aureus cells in a concentration and time-dependent manner. These 
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observations clearly validate that the mechanism of bacterial killing by our peptides is 
mediated by pore formation and disruption of the bacterial cell membrane, leading to 
leakage of cytoplasmic contents and ultimately cell lysis. However, recent evidence 
suggests that lysis of bacterial cells by pore formation is not the only mechanism of 
microbial killing of some AMPs and there are other possible intracellular targets, such as 
aggregation of DNA (26). To further explore this possibility, we examined the bacterial 
DNA-binding ability of the peptides by electrophoretic gel retardation. Our data indicated 
that both RRIKA and RR bind with bacterial DNA and alter its electrophoretic mobility 
in agarose gels. Although a detailed study on the interaction between peptides and nucleic 
acids in vivo is needed, the current results lead us to suggest that RRIKA and RR might 
inhibit the bacterial functions by binding to bacterial DNA after perturbing the cell 
membranes, resulting in an augmented effect by two different mechanisms. While RRIKA 
and RR are not toxic to mammalian cells at the levels used here, possible crossing of the 
peptides to the nuclear membrane and binding to eukaryotic DNA must be examined 
further. 
Major limitations with the use of AMPs for systemic applications are their possible 
inactivation by serum or physiological concentrations of salts. Serum inactivate peptides 
either through cleavage by proteases or through binding with proteins or lipids (30) We 
observed that RRIKA but not RR retained its bactericidal activity, although at a slower 
rate, in the presence of 10% FBS. Furthermore, both RRIKA and RR retain their 
antibacterial activity when tested in increasing concentration of NaCl and MgCl2; in 
contrast to many well studied AMPs (such as LL-37, human β-defensin-1, gramicidins, 
bactenecins, and magainins) which showed substantially reduced antibacterial activities 
under the same conditions (11).  Previously,  Turner et al. reported that LL-37 and HNP-
1 demonstrated a 12-fold and 100-fold increase in the MIC of MRSA, respectively when 
100 mM NaCl was added to the test medium (10). The ability to resist the effects of salt 
and serum provide a selective advantage for our peptides for potential therapeutics in 
physiological solutions. 
After identifying that our peptides were capable of inhibiting bacterial growth alone, we 
wanted to explore their ability to be used in combination with other antimicrobials such 
47 
 
as lysostaphin. Lysostaphin is a zinc metalloenzyme that specifically cleaves the abundant 
pentaglycine cross-bridges of the staphylococcal cell wall.  Several studies have reported 
the potential applications of lysostaphin in the treatment of staphylococcal infections, 
however, S. aureus has developed resistance against lysostaphin via different mechanisms 
(31). When we tested both RR and RRIKA in combination with lysostaphin, we observed 
a synergistic relationship demonstrated by complete eradication of MRSA and VRSA 
within 20 minutes (at very low concentrations). The observed synergistic effect may be 
due the cleaving of the cell wall peptidoglycan by lysostaphin, which allows more access 
of peptides to the bacterial membrane. The synergistic relationship observed between our 
peptides and lysostaphin is important as it has the advantage of reducing the emergence 
of bacterial resistance to both agents while also minimizing drug-associated toxicity (by 
lowering the therapeutic dose needed for each antimicrobial agent to effectively treat 
MRSA infection).     
One of the difficult challenges facing current antibiotics is bacterial biofilms, which are 
vital in the pathogenesis of staphylococcal infections.  Biofilms hinder the penetration of 
antimicrobials to access bacteria, leading to failure of treatments (32). Our data showed 
that both RR and RRIKA are capable of disrupting S. aureus and S. epidermidis biofilms 
more efficiently than drugs of choice (vancomycin and linezolid). Most bacteria living in 
biofilms are either slow-growing or non-growing dormant cells that are difficult to treat 
with antibiotics that normally inhibit macromolecular synthesis in growing cells (33). 
However our peptides target mainly the microbial cell membrane, a characteristic that is 
not only in dividing organisms, but also in quiescent cells or stationary phase bacteria (34).  
Cell toxicity is one of the major limitations in the development of antibacterials, 
particularly if the target of action is the cell membrane (7).  We observed minimal 
hemolysis (less than 10%) with our peptides even with high concentrations (300 µΜ). On 
the other hand, 5 µM of melittin completely lysed human RBCs (100% hemolysis). 
Furthermore, RRIKA and RR were not toxic to HeLa cells at 8 and 4 × MIC, respectively.  
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2.5 Discussion  
In this study, we evaluated the antimicrobial activity of two short synthetic peptides, and 
revealed their potential mechanisms of action. We observed that RRIKA and RR exhibited 
potent antibacterial activity against all tested S. aureus isolates. Moreover, our peptides 
demonstrated activity against multiple clinical isolates of MRSA, particularly MRSA 
USA300, a community-associated strain which is responsible for outbreaks of 
staphylococcal skin and soft-tissue infections (SSTI) in the United States (28). Similarly, 
the potent bactericidal activity was observed in other clinical MRSA isolates (USA100, 
USA200 and USA500) that are resistant to various antibiotic classes including macrolides, 
aminoglycosides, lincosamides, and fluoroquinolones. Additionally, we found that these 
peptides retained their activity against strains of S. aureus which have resistance to drugs 
of choice in treating MRSA infections, namely linezolid (MRSA NRS119) and 
vancomycin (VRSA strains). It is worthy to note that, the C terminus of the RR peptide 
was modified to contain three additional amino acids (isoleucine, lysine and alanine) 
which made the RRIKA peptide more amphipathic and hydrophobic and also increased 
its positive net charge. These modifications augmented the antibacterial activity of 
RRIKA which exhibited MICs two to eight folds lower than those of RR. The enhanced 
efficacy of RRIKA may reveal a functional structure activity relationship and provide a 
template for future peptide synthesis. 
Time-kill kinetics revealed a major advantage of the synthetic peptides over tested 
antibiotics. While RRIKA and RR eliminated MRSA within 1-2 hr after treatment, 
vancomycin required 24 hr to reduce the bacterial CFU by 3-log10. Linezolid, on the other 
hand, exhibited only a bacteriostatic effect. 
Growth kinetic measurements of MRSA exposed to peptides clearly demonstrated that 
RRIKA and RR peptides exhibited kinetic behavior similar to membrane lytic peptides 
such as the lantibiotic nisin (24) and amphibian magainin (23) but different from non-lytic 
peptides such as fungal plectasin (29) and amphibian buforin II (23). These data suggest 
that our peptides act by disrupting the integrity of the bacterial membrane. To validate this 
hypothesis, we studied the effect of peptides on MRSA membranes using a calcein leakage 
assay.  Similar to the well-known membrane damaging peptide, nisin, both RRIKA and 
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RR permeabilized S. aureus cells in a concentration and time-dependent manner. These 
observations clearly validate that the mechanism of bacterial killing by our peptides is 
mediated by pore formation and disruption of the bacterial cell membrane, leading to 
leakage of cytoplasmic contents and ultimately cell lysis. However, recent evidence 
suggests that lysis of bacterial cells by pore formation is not the only mechanism of 
microbial killing of some AMPs and there are other possible intracellular targets, such as 
aggregation of DNA (26). To further explore this possibility, we examined the bacterial 
DNA-binding ability of the peptides by electrophoretic gel retardation. Our data indicated 
that both RRIKA and RR bind with bacterial DNA and alter its electrophoretic mobility 
in agarose gels. Although a detailed study on the interaction between peptides and nucleic 
acids in vivo is needed, the current results lead us to suggest that RRIKA and RR might 
inhibit the bacterial functions by binding to bacterial DNA after perturbing the cell 
membranes, resulting in an augmented effect by two different mechanisms. While RRIKA 
and RR are not toxic to mammalian cells at the levels used here, possible crossing of the 
peptides to the nuclear membrane and binding to eukaryotic DNA must be examined 
further. 
Major limitations with the use of AMPs for systemic applications are their possible 
inactivation by serum or physiological concentrations of salts. Serum inactivate peptides 
either through cleavage by proteases or through binding with proteins or lipids (30) We 
observed that RRIKA but not RR retained its bactericidal activity, although at a slower 
rate, in the presence of 10% FBS. Furthermore, both RRIKA and RR retain their 
antibacterial activity when tested in increasing concentration of NaCl and MgCl2; in 
contrast to many well studied AMPs (such as LL-37, human β-defensin-1, gramicidins, 
bactenecins, and magainins) which showed substantially reduced antibacterial activities 
under the same conditions (11).  Previously,  Turner et al. reported that LL-37 and HNP-
1 demonstrated a 12-fold and 100-fold increase in the MIC of MRSA, respectively when 
100 mM NaCl was added to the test medium (10). The ability to resist the effects of salt 




After identifying that our peptides were capable of inhibiting bacterial growth alone, we 
wanted to explore their ability to be used in combination with other antimicrobials such 
as lysostaphin. Lysostaphin is a zinc metalloenzyme that specifically cleaves the abundant 
pentaglycine cross-bridges of the staphylococcal cell wall.  Several studies have reported 
the potential applications of lysostaphin in the treatment of staphylococcal infections, 
however, S. aureus has developed resistance against lysostaphin via different mechanisms 
(31). When we tested both RR and RRIKA in combination with lysostaphin, we observed 
a synergistic relationship demonstrated by complete eradication of MRSA and VRSA 
within 20 minutes (at very low concentrations). The observed synergistic effect may be 
due the cleaving of the cell wall peptidoglycan by lysostaphin, which allows more access 
of peptides to the bacterial membrane. The synergistic relationship observed between our 
peptides and lysostaphin is important as it has the advantage of reducing the emergence 
of bacterial resistance to both agents while also minimizing drug-associated toxicity (by 
lowering the therapeutic dose needed for each antimicrobial agent to effectively treat 
MRSA infection).     
One of the difficult challenges facing current antibiotics is bacterial biofilms, which are 
vital in the pathogenesis of staphylococcal infections.  Biofilms hinder the penetration of 
antimicrobials to access bacteria, leading to failure of treatments (32). Our data showed 
that both RR and RRIKA are capable of disrupting S. aureus and S. epidermidis biofilms 
more efficiently than drugs of choice (vancomycin and linezolid). Most bacteria living in 
biofilms are either slow-growing or non-growing dormant cells that are difficult to treat 
with antibiotics that normally inhibit macromolecular synthesis in growing cells (33). 
However our peptides target mainly the microbial cell membrane, a characteristic that is 
not only in dividing organisms, but also in quiescent cells or stationary phase bacteria (34).  
Cell toxicity is one of the major limitations in the development of antibacterials, 
particularly if the target of action is the cell membrane (7). We observed minimal 
hemolysis (less than 10%) with our peptides even with high concentrations (300 µΜ). On 
the other hand, 5 µM of melittin completely lysed human RBCs (100% hemolysis). 
Furthermore, RRIKA and RR were not toxic to HeLa cells at 8 and 4 × MIC, respectively. 
In conclusion, our findings reveal the potent bactericidal action of peptides RRIKA and 
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RR against MRSA. The mechanism of action of the peptides is mainly due to bacterial 
lysis as a consequence of bacterial membrane disruption and possibly by binding of the 
peptides to bacterial DNA, which interferes with necessary cellular functions vital for 
microbial survival. Such effects are extremely challenging for pathogens to overcome by 
developing resistance; unlike current antibiotics, which usually inhibit metabolic 
pathways that can lead to bacterial resistance (8). To date, issues such as poor 
pharmacokinetics have limited the potential systemic applications of therapeutic AMPs 
(7, 8, 30). Therefore, AMPs which have advanced into preclinical or clinical trials, are 
indicated for topical treatment of bacterial skin infections (7, 8, 30) such as Pexiganan 
(Access Pharmaceuticals, Inc.) for curing diabetic foot ulcers (35). S. aureus is the most 
frequently isolated microorganism in diabetic foot infections, and those caused by MRSA 
are associated with the worse outcomes and more frequent amputations (36-41). 
Additionally, bacterial biofilms appear to play an important role in increasing the 
difficulty of treating these ulcers (40). Furthermore, it has been proven recently that the 
clinical severity of S. aureus skin infection is driven by the inflammatory response to the 
bacteria, rather than bacterial burden (42-44). Taken together, the characteristics of the 
presented peptides with combined bactericidal, anti-biofilm and anti-inflammatory effect 
may offer an effective way for treating Staphylococcal skin infection. Therefore, these 
results support the potential for further study and development of RRIKA and RR as 
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Table 2.1. Minimum inhibitory concentration (MIC) of peptides and antibiotics 
































2 16 2 0.5 1 ≤0.25 
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VRS1 United States 
Resistant to 
vancomycin 








VRS5 United States 
Resistant to 
vancomycin 
4 32 2 128 nd >32 
VRS6 United States 
Resistant to 
vancomycin 




VRS7 United States 
Resistant to 
vancomycin 
4 16 2 128 nd >32 
VRS8 United States 
Resistant to 
vancomycin 




VRS9 United States 
Resistant to 
vancomycin 




VRS10 United States 
Resistant to 
vancomycin 




VRS11b United States 
Resistant to 
vancomycin 




VRS12 United States 
Resistant to 
vancomycin 




VRS13 United States 
Resistant to 
vancomycin 








Resistant to  
methicillin and 
gentamicin 
2 8 2 0.5 nd >32 
L: linezolid, V: vancomycin, N: nisin, A: ampicillin, nd: not determined 
 
Table 2.4. Amino acid sequence and physicochemical properties of peptides used in 
this study 




% of amino 
acids that are 
hydrophobic 
RR WLRRIKAWLRR 11 1553.9 + 5 54 % 
RRIKA WLRRIKAWLRRIKA 14 1866.3 + 6 57 % 
KAF KAFAKLAARKA 11 1174.4 + 4 63 % 
FAK FAKLAARLYRKA 12 1407.7 + 4 58 % 
 
VRS2 United States 
Resistant to 
vancomycin 
4 16 1 16 1 >32 
VRS3a United States 
Resistant to 
vancomycin 
4 16 1 128 2 >32 
VRS4 United States 
Resistant to 
vancomycin 







Table 2.5. Fractional inhibitory concentration (FIC) index for the combination of 











RRIKA RR RRIKA RR RRIKA RR 
RRIKA - 0.75 - 0.75 - 0.75 
RR 0.75 - 0.75 - 0.75 - 
Lysostaphin 0.26 0.26 0.26 0.26 0.26 0.26 
a  The FIC index was determined in the presence of a fixed concentration of 




Figure 2.1. Bacterial killing kinetics of peptides. 
 
RRIKA, RR, vancomycin and linezolid at 5X MIC against MRSA USA300 in MHB 
(Mueller Hinton broth). Samples treated with peptide diluent (sterile water) were used as 
a control. The results are given as means ± SD (n = 3; data without error bars indicate that 
the SD is too small to be seen) 
 
Figure 2.2. Effect of culture conditions on killing kinetics of peptides. 
 
RRIKA (A), RR (B) at 5X MIC against MRSA USA300. Abbreviations, MHB “Mueller 
Hinton broth”, PBS “phosphate buffered saline” or MHB+10% FBS “fetal bovine serum”. 
Untreated samples were used as a control was. The killing curves were identical 
(overlapping in the figure) for RRIKA in MHB and in PBS. 
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Figure 2.3. Synergistic killing of peptides with lysostaphin by time kill assay. 
 
MRSA USA300 (A) and VRSA VRS13 (B) were incubated with 0.5X MIC of RRIKA or 
RR alone or in combination with 0.25X MIC of lysostaphin. Samples were obtained at 
different time points, then plated and counted. Control was untreated samples. The killing 
curves were identical (overlapping in the figure) for RRIKA and RR in combination with 
lysostaphin. The results are given as means ± SD (n = 3; data without error bars indicate 
that the SD is too small to be seen). 
 
Figure 2.4. Killing kinetics of MRSA USA300 exposed to peptides by measuring 
optical density. 
 
4X MIC of RRIKA, RR, nisin, vancomycin and sterile water (control) as observed by 
measuring OD595 by microplate reader over time. Results are representative of two 
separate experiments, each was done in triplicate. Error bars represent standard deviation 
values (data without error bars indicate that the SD is too small to be seen). 
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Figure 2.5. Permeabilization of the cytoplasmic membrane of MRSA USA300 as a 
function of peptide concentration. 
 
Permeabilization indicated by percent of calcein leakage for 60 min exposure. The results 
are given as means ± SD (n = 3; data without error bars indicate that the SD is too small 






Figure 2.6. Interaction of peptides with plasmid DNA.  
 
Binding was assayed by measuring inhibition of migration by plasmid DNA. Different 
concentrations of peptides were incubated with 250 ng for 1 hr at room temperature prior 
to electrophoresis on a 1.0% agarose gel. The numbers above the lanes represent the 






Figure 2.7. The effect of peptides and antibiotics on established biofilms of S. 
aureus (A) and S. epidermidis (B). 
 
Bacteria were incubated at 37°C in glucose supplemented TSB medium for 24 h to allow 
biofilm formation.  Then wells were rinsed with PBS and the medium was switched to 
MHB containing different concentrations of peptides and antibiotics. Following 
incubation for 24 h, wells were washed again and left for air dry. Surface associated 
biofilm was visualized either unstained by inverted microscope 25X objectives and an 
attached camera (middle) or the adherent biofilm stained by crystal violet and the wells 
imaged with digital camera (above), then the dye was extracted with ethanol, measured at 
595 nm absorbance and presented as percentage of biofilm reduction compared to 
untreated wells “control” (below). All experiments were done in triplicate for statistical 
significance. ”. One asterisk (*) indicates statistically different than the positive control (p 
< 0.01). Two asterisks (**) indicates statistically different than the antibiotic treated wells 
(p < 0.01).  
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Figure 2.8. The release of hemoglobin in the supernatant of human erythrocytes 
after treatment peptides. 
 
 Increasing amounts of RRIKA and RR was incubated with human erythrocytes for one 
hour and OD was measured at 415 nm. Melittin (5 µM) and 0.1 % of triton X-100 served 




Figure 2.9. Cytotoxicity of peptides to HeLa cells. 
 
Cytotoxicity assay showing the percent mean absorbance at 490 nm after incubating HeLa 
cells with RRIKA and RR and melittin at different concentrations. Diluent was used as a 
control. Cell viability was measured by MTS assay. Results are expressed as means from 
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CHAPTER 3. EFFICACY OF SHORT NOVEL ANTIMICROBIAL AND ANTI-
INFLAMMATORY PEPTIDES IN A MOUSE MODEL OF METHICILLIN-
RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) SKIN INFECTION 
(Mohamed, M.F., Seleem, M.N (2014) Efficacy of short novel antimicrobial and anti-
inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus 
(MRSA) skin infection. Drug Design, Development and Therapy 2014:8; 1979–1983.) 
3.1 Abstract  
The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory peptides 
(RR and RRIKA) was evaluated in a mouse-model of staphylococcal skin infection. RR 
(2%) and RRIKA (2%) significantly reduced the bacterial counts and the levels of pro-
inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), in 
methicillin-resistant Staphylococcus aureus (MRSA) USA300-0114 skin lesions. 
Furthermore, the combined therapy of RRIKA (1%) and lysostaphin (0.5%) had 
significantly higher antistaphylococcal and anti-inflammatory activity compared to 
monotherapy. This study supports the potential use of these peptides for topical treatment 
of MRSA skin infections. 
3.2 Introduction 
Bacterial infections, especially those caused by Staphylococcus aureus, are the most 
significant complication encountered in the management of wounds. (1) Furthermore, 
multidrug resistant S. aureus strains and their secreted toxins are responsible for 
interfering with the wound healing process and creating portals of entry for systemic 
complications in affected patients. (2) With the increasing incidence of staphylococcal 
resistance to topical antimicrobials such as mupirocin and fusidic acid, (3-5) there is a 
pressing need to develop novel antimicrobials and new approaches to circumvent this 
burgeoning problem. Recently, there has been increased interest in the development of 
antimicrobial peptides (AMPs) as novel therapeutics due to their high potency, broad 
spectrum of activity, and reduced potential for resistance development. (6, 7) In addition 
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to the potent bactericidal activity of AMPs, the recognized anti-inflammatory response of 
certain AMPs should be an advantage in the treatment of S. aureus skin infections. (8) 
In a recent study, we described two novel short peptides, RR (WLRRIKAWLRR) and 
RRIKA (WLRRIKAWLRRIKA), with potent bactericidal activity in vitro against 
multiple clinical isolates of MRSA (6). In particular, the peptides were active against the 
highly virulent MRSA USA300, a community-associated strain responsible for outbreaks 
of staphylococcal skin and soft-tissue infections (SSTIs) in the United States. (9) 
Moreover, RR and RRIKA were superior in reducing adherent biofilms of both S. aureus 
and S. epidermidis when compared to conventional antibiotics. Furthermore, both RR and 
RRIKA enhanced the antistaphylococcal activity of lysostaphin in vitro more than 1,000-
fold. (6) Although lysostaphin demonstrated potent efficacy against MRSA infections in 
different animal models, (10-12)  its therapeutic potential was hampered by the emergence 
of bacterial resistance. (10, 13) In the light of our previous results, showing enhancement 
of the antimicrobial effectiveness of lysostaphin against MRSA when combined with 
AMPs in vitro, (6) we moved forward with an in vivo experiment in a mouse model of 
MRSA skin infection. 
3.3 Materials and methods 
Bacterial isolate: 
Community-acquired methicillin-resistant S. aureus (CA-MRSA) strain NRS384 (MRSA 
USA300-0114 isolated from a wound from a patient in Mississippi, USA. The strain is 
resistant to erythromycin and tetracycline; positive for mec (subtype IV); pvl+-; MLST 
sequence type (ST) 8-; eGenomic spa type 1, eGenomic spa repeats YHGFMBQBLO; 
Ridom spa type t008; agr grp I. 
Peptides and antibacterial agents: 
RR and RRIKA were synthesized by GenScript (Piscataway, NJ). Recombinant 
lysostaphin was purchased from AMBI PRODUCTS LLC. (Lawrence, NY). Linezolid 





Mice infection:  
Female BALB/c mice (6-8 weeks old) were obtained from Harlan Laboratories, 
Indianapolis, IN. All procedures were approved by the Purdue University Animal Care 
and Use Committee (PACUC).  The murine model of MRSA skin infection has been 
described before. (14, 15) Eight groups of mice (n=5) were inoculated with 40 µl of 
MRSA USA300 (3×107) colony forming unit (CFU) intradermally. Forty-eight hours after 
infection and formation of an open wound, 6 groups were treated topically with either 2% 
fusidic acid, 2% RR, 2% RRIKA, 1% RRIKA, 0.5% lysostaphin or 1% RRIKA plus 0.5% 
lysostaphin formulated in 20 mg petroleum jelly. One group received vehicle only 
(petroleum jelly) and the last group was treated orally with linezolid (25 mg/kg). All 
groups were treated twice a day for 3 days. Twenty-four hours after the last treatment, the 
area around the wound was lightly swabbed with 70% ethanol and the wound was excised 
for bacterial counting after homogenization.  
Cytokines detection: 
Enzyme-linked immunosorbent assay (ELISA) development kits for detection of 
cytokines were purchased from R&D Systems, Inc. (Minneapolis, MN). Skin lesions 
(around 1 squared cm) were centrifuged at high speed for 10 minutes. The supernatant 
were removed and kept in -20 freezer till the time of assay.  The supernatant was examined 
for cytokine producion: tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and 
interleukin-1 beta (IL-1β) using ELISA as described before.  (16) Cytokine levels were 
expressed as percent change relative to negative control. 
Statistical analyses:  
 Data were presented as mean ± SD. Statistical analyses were assessed by GraphPad Prism 
6.0 (GraphPad Software, La Jolla, CA). P values were calculated by the two-tailed Student 
t test. P values of ˂ 0.05 were considered significant. 
3.4 Results and discussion 
As shown in Figure 3.1, all treatments significantly reduced the mean bacterial counts 
compared with the control group (P ≤ 0.01). Among groups treated with monotherapy, 
the group treated with 2% RRIKA had the highest reduction in CFU (2.08 ± 0.20 log10), 
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followed by 2% fusidic acid (1.94 ± 0.36 log10), 2% RR (1.83 ± 0.30 log10), and linezolid 
(1.74 ± 0.53 log10). Groups treated with 0.5 % lysostaphin or 1% RRIKA achieved a 
significant reduction of 1.79 ± 0.56 log10 and 1.08 ± 0.36 log10, respectively, when 
compared with the control group (P ≤ 0.01) Figure 3.1.  The combination therapy (0.5% 
lysostaphin with 1% RRIKA) was significantly more effective than treatment with 
RRIKA or lysostaphin alone and achieved statistically significant bacterial reduction of 
2.65 ± 0.44 log10 compared to the negative control (P ≤ 0.01). The bacterial reduction in 
the combined therapy was also statistically significant compared to monotherapy (P ≤ 
0.05) or control antibiotics (P ≤ 0.05). Although, there is 0.25 log10 difference between 
treatments of RRIKA (2%) and RR (2%), this is not statistically significant (P = 0.15). 
The reason for that is not clear. However, it may be explained as peptides have 
concentration dependent killing activity and at higher concentration (2%) they may 
behave the same (17, 18). 
Previously, RR and RRIKA showed potent immune-modulatory activities in vitro through 
inhibition of mitogen-activated protein kinase (MK2). (19, 20) In this study, topical 
treatment with RRIKA and RR significantly reduced TNF-α and IL-6 production in 
MRSA skin lesions. As shown in Figure 3.2 (A & B), 2% RR and 2% RRIKA reduced 
the TNF-α level by 49% and 56%, respectively, while the IL-6 level was reduced by 29% 
and 60%, respectively. Treatment with 0.5% lysostaphin and 2% fusidic acid caused 39% 
and 29% reduction of the TNF-α level, respectively, and 13% and 25% reduction of the 
IL-6 level, respectively, which is in agreement with previous findings. (21, 22) There was 
a synergistic anti-inflammatory response observed when 0.5% lysostaphin was combined 
with 1% RRIKA. The combined therapy significantly reduced TNF-α and IL-6 levels by 
62% and 67%, respectively. In this study, topical application of RR and RRIKA was 
shown to be very effective in reducing the bacterial load in MRSA skin lesions. Moreover, 
peptides reduced the release of TNF-α and IL-6 which might benefit the healing of 
infected wounds. (26-30) In addition, the combination of RRIKA with lysostaphin is 
significantly more effective in the treatment of MRSA skin lesions than treatment with 
either peptide alone. This combination therapy is also expected to overcome some of the 
limitations associated with lysostaphin monotherapy through hindering the emergence of 
bacterial resistance and lowering the required therapeutic dose.  In conclusions, our 
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findings in MRSA skin lesions should significantly impact and inform efforts to use a 
combination of anti-inflammatory and AMP therapies as novel topical treatment options 
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Figure 3.1. Efficacy of treatment of MRSA skin lesions with peptides and 
antibiotics.  
 
Mice were treated topically with RRIKA (2%), RR (2%), fusidic acid (2%), linezolid (25 
mg/kg), RRIKA (1%), lysostaphin (0.5%), combined therapy of RRIKA (1%) and 
lysostaphin (0.5 %) and petroleum jelly (negative control) twice daily for 3 days. The two 
tailed Student t test, was used to determine statistical significance (a P value of < 0.05 was 




Figure 3.2. The effect of peptides on cytokines (TNF-α, and IL-6) production in 
MRSA skin lesions. 
 
Tissue homogenate supernatants were examined for cytokine production using ELISA. 
Cytokine levels were expressed as percent change relative to negative control. Data are 
presented as mean ± SD from duplicates consisting of four mice per group. Statistical 
analysis was calculated by the two-tailed Student t test.  P values of ˂ 0.05 were 





CHAPTER 4. ANTIBACTERIAL ACTIVITY OF NOVEL 
CATIONIC PEPTIDES AGAINST CLINICAL ISOLATES OF 
MULTI-DRUG RESISTANT STAPHYLOCOCCUS 
PSEUDINTERMEDIUS FROM INFECTED DOGS 
(Mohamed, M.F., Hammac G.K., Guptill, L. and Seleem, M.N (2014) Antibacterial 
activity of novel cationic peptides against clinical isolates of multi-drug resistant 
Staphylococcus pseudintermedius from infected dogs. PLoS ONE 9(12): e116259. doi: 
10.1371/journal.pone.0116259)  
4.1  Abstract  
Staphylococcus pseudintermedius is a major cause of skin and soft tissue infections in 
companion animals and has zoonotic potential. Additionally, methicillin-resistant S. 
pseudintermedius (MRSP) has emerged with resistance to virtually all classes of 
antimicrobials. Thus, novel treatment options with new modes of action are required. Here, 
we investigated the antimicrobial activity of six synthetic short peptides against clinical 
isolates of methicillin-susceptible and MRSP isolated from infected dogs. All six peptides 
demonstrated potent anti-staphylococcal activity regardless of existing resistance 
phenotype. The most effective peptides were RRIKA (with modified C terminus to 
increase amphipathicity and hydrophobicity) and WR-12 (α-helical peptide consisting 
exclusively of arginine and tryptophan) with minimum inhibitory concentration50 (MIC50) 
of 1 µM and MIC90 of 2 µM. RR (short anti-inflammatory peptide) and IK8 “D isoform” 
demonstrated good antimicrobial activity with MIC50 of 4 µM and MIC90 of 8 µM. 
Penetratin and (KFF)3K (two cell penetrating peptides) were the least effective with 
MIC50 of 8µM and MIC90 of 16 µM. Killing kinetics revealed a major advantage of 
peptides over conventional antibiotics, demonstrating potent bactericidal activity within 
minutes. Studies with propidium iodide and transmission electron microscopy revealed 
that peptides damaged the bacterial membrane leading to leakage of cytoplasmic contents 
and consequently, cell death. A potent synergistic increase in the antibacterial effect of 
the cell penetrating peptide (KFF)3K was noticed when combined with other peptides and 
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with antibiotics. In addition, all peptides displayed synergistic interactions when 
combined together. Furthermore, peptides demonstrated good therapeutic indices with 
minimal toxicity toward mammalian cells. Resistance to peptides did not evolve after 10 
passages of S. pseudintermedius at sub-inhibitory concentration. However, the MICs of 
amikacin and ciprofloxacin increased 32 and 8 fold, respectively; under similar conditions. 
Taken together, these results support designing of peptide-based therapeutics for 
combating MRSP infections, particularly for topical application. 
4.2 Introduction 
Methicillin-susceptible Staphylococcus pseudintermedius (MSSP) and methicillin-
resistant S. pseudintermedius (MRSP) are a leading cause of skin and ear infections and 
post-operative wound infections in dogs and cats (1, 2). S. pseudintermedius isolates can 
also cause infections in humans as apparent zoonotic transfer from dogs has been reported 
(2-5). Similar to methicillin-resistant Staphylococcus aureus (MRSA), MRSP is a 
nosocomial pathogen that can colonize personnel in veterinary hospitals (1, 6). Recent 
studies reported that MRSP from Europe and North America emerged resistance to 
virtually all classes of antimicrobial agents used in veterinary medicine (7). Such 
dissemination of multidrug resistant staphylococci among dogs raises concern due to the 
few therapeutic options available for treatment (8). Therefore, there is an urgent need for 
novel antimicrobial compounds with new mechanisms of action. 
Antimicrobial peptides (AMPs) serve as an alternative novel therapeutic approach against 
microbial infections. AMPs constitute the first line of defense against invading pathogens 
in most multicellular organisms. They have been discovered from a broad range of 
organisms, from microorganisms to plants and from insects to mammals (9). AMPs are 
generally between 12 and 50 amino acids in length with a cationic charge and contains up 
to 50% hydrophobic amino acids. They have the ability to form an amphipathic secondary 
structure that allows the peptides to partition into the bacterial membrane lipid bilayer 
(10). 
The mechanism of action of AMPs involves binding to the negatively charged anionic 
phospholipids on lipopolysaccharide (LPS) of Gram-negative bacteria or to the teichoic 
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acids of Gram-positive bacteria. Once there are sufficient aggregated peptides, they 
destabilize the lipid head groups, to produce pores by one of various potential mechanisms 
(barrel-stave, carpet or toroidal-pore) leading to leakage of cytoplasmic contents and 
bacterial cell death (9, 11). However, membrane disruption is not the only proven 
mechanism of bacterial killing by AMPs. Instead, peptides can traverse bacterial 
membranes and induce killing through inhibition of specific macromolecular synthesis 
pathways (11).  
Several studies have reported the potency of AMPs in combating S. aureus infections (12, 
13); however, to our knowledge, there are limited data about their activity and potential 
use against S. pseudintermedius (14, 15). In the present study, we investigated the 
antimicrobial activity of six synthetic short peptides against clinical isolates of MSSP and 
MRSP from infected dogs. Moreover, we performed a series of experiments to explore 
their antibacterial mechanism of action. Finally, we examined their toxicity toward 
mammalian cells and assessed the ability of S. pseudintermedius to develop resistance to 
peptides. 
4.3 Materials and methods 
Peptides, antibiotics and reagents 
Peptides (RRIKA, RR, WR-12, IK8 “D isoform”, (KFF)3K and penetratin) were 
synthesized by GenScript (Piscataway, NJ) using solid-phase 9-fluorenylmethoxy 
carbonyl (Fmoc) chemistry and purified to a purity of 98% using reverse-phase high-
performance liquid chromatography (HPLC). Peptide mass was confirmed by mass 
spectrometry (Table 4.1).  Nisin (Sigma, N5764), melittin from honey bee venom (Sigma, 
M2272), ampicillin sodium salt (IBI Scientific), ciprofloxacin (Sigma), amikacin hydrate 
(Sigma) and propidium iodide (Molecular Probes, Life Technologies) were all purchased 
from commercial vendors. Mueller-Hinton broth (MHB) and Mueller-Hinton agar (MHA) 
were purchased from Sigma-Aldrich, while trypticase soy broth (TSB) and trypticase soy 





Forty isolates of S. pseudintermedius (30 MSSP and 10 MRSP) identified at the Indiana 
Animal Disease Diagnostic laboratory from specimens collected from dogs admitted to 
the small animal teaching hospital at Purdue University were included in the study (Tables 
4.2 and 4.3).  Clinical specimens were inoculated onto 5% sheep blood agar and incubated 
at 35°C for 18-24 hours.  White, beta-hemolytic colonies with morphology suggestive of 
Staphylococcus sp. were used to inoculate a coagulase tube test and were identified to the 
species level using the Vitek 2 (BioMérieux). Vitek identification of S. pseudintermedius 
was confirmed by a positive coagulase test. Antimicrobial susceptibility was determined 
by broth microdilution using the SensiTitre (Trek).  Isolates demonstrating resistance to 
oxacillin, a surrogate for methicillin, with a MIC greater than or equal to 0.5 μg/mL were 
screened for mecA by PCR as previously described (16). A mecA positive result was 
assigned to samples with a visible 310 bp band on a 1.5% agarose gel. 
Antibacterial assays 
The broth microdilution technique was used to determine the minimum inhibitory 
concentrations (MIC) of peptides and antibiotics in MHB in accordance with the Clinical 
and Laboratory Standards Institute (CLSI) guidelines (17). Peptides were dissolved in 
sterile distilled water containing 0.02% acetic acid. MIC assays were carried out with an 
initial bacterial inoculum of 5×105 colony forming unit (CFU/ml). Peptides and antibiotics 
were added to Polystyrene 96 well plates (CytoOne, CC7672-7596) at desired 
concentrations and plates were incubated for 24 hr at 37 ºC.  MIC was defined as the 
lowest concentration of peptide which inhibited the visible growth of bacteria. MIC was 
done in triplicates and the highest value was reported. 
Time kill assay 
One strain of MRSP (SP3) was grown overnight in MHB, then diluted in fresh MHB and 
incubated for 2 hr until logarithmic growth phase was achieved. Then bacteria were 
centrifuged and washed twice with phosphate buffered saline (PBS) and adjusted to 
~5×105 CFU/ml in MHB. Peptides and antibiotic (amikacin) at 5X MIC were added in 
triplicates to adjusted bacteria, and incubated aerobically at 37 ºC. Aliquots at specified 
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time points were taken, serially diluted in PBS and plated in triplicate on MHA. CFUs 
were counted after incubation of plates for 24 hr at 37 ºC.  
Growth Kinetics 
The turbidity of bacterial culture after exposure to peptides was measured as described 
previously (13). Briefly, logarithmic growth of SP 3 was diluted in MHB to reach OD600 
≈ 0.25. One mL of diluted bacteria was added to a plastic cuvette (light path 1 cm). 
Peptides and antibiotics were added to cuvettes at a concentration equivalent to 5 X MIC 
as determined in antibacterial assays above. Cuvettes were incubated aerobically at 37 ºC. 
At specific time points, OD was measured at 600 nm wavelength by spectrophotometer. 
Cuvettes containing MHB without bacteria and with the same concentrations of peptide 
or antibiotic served as blanks. Nisin at 5 X MIC and untreated bacteria were used as 
positive and negative controls, respectively. The assay was repeated twice and the average 
was reported. 
Bacterial membrane permeability 
Bacterial membrane damage was assessed by fluorescence change of propidium iodide 
dye as described previously (18). Briefly, SP3 was grown in MHB to logarithmic phase 
of growth then diluted to OD600 ≈ 0.25. Propidium iodide was mixed with bacteria to a 
final concentration of 10 µM. Aliquots of 200 µL were then loaded into black wall 96 
microplates and drugs were added at 5 X and 10 X MIC in triplicate. Fluorescence was 
monitored for 30 minutes at excitation and emission wavelengths of 585 and 620 nm, 
respectively, using a fluorescence plate reader (FLx800 model BioTek® Instruments, Inc. 
Winooski, Vermont). The percentage of membrane permeabilization was calculated as the 
percent of fluorescent intensity of peptide-treated samples with respect to fluorescence 
intensity of propidium iodide-loaded, peptide untreated samples. 
Transmission electron microscopy 
SP3 was grown to OD600 0.2. Bacterial cells were harvested by centrifugation, 
resuspended in PBS, and treated with peptides at 10 X MIC for 30 minutes. RRIKA and 
penetratin were also tested at lower concentration 1 X MIC to study the concentration-
dependent effect of peptides. After treatment with peptides, the bacterial pellets were fixed 
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with 2.5% buffered glutaraldehyde for 1 hour. After fixation, cells were treated with  1% 
buffered osmium tetroxide for 1 hour, stained en bloc with 1% uranyl acetate, dehydrated 
in a graded series of ethanol, and embedded in white resin. The buffer used was 0.1M 
sodium cacodylate, pH 7.4. Ultrathin sections were prepared on Formvar-coated grids and 
stained with 1% uranyl acetate and lead citrate. Microscopy was performed with a Philips 
CM-100 microscope under standard operating conditions. 
Synergism studies 
The synergistic effect between peptides and antimicrobial agents was determined by the 
combination assay as described previously (19). Peptide MICs against SP3 were 
determined in triplicate. Two-fold serial dilutions of antimicrobials (antibiotic and 
peptides) were tested in the presence of a fixed concentration of peptide of concern (equal 
to ¼ × peptide MIC, which did not inhibit the growth of bacteria alone). The fractional 
inhibitory concentration (FIC) index was calculated as follows: FIC of drug A = MIC of 
drug A in combination/MIC of drug A alone, FIC of drug B = MIC of drug B in 
combination/MIC of drug B alone, and FIC index = FIC of drug A + FIC of drug B. An 
FIC index of ≤ 0.5 is considered to demonstrate synergy. Additive was defined as an FIC 
index of 1. Antagonism was defined as an FIC index of > 4.  
Cytotoxicity analysis 
Peptides were assayed at different concentrations against macrophage-like cell line 
(J774A.1) and human keratinocyte (HaCat) to determine the potential toxic effect in vitro. 
Briefly,  J774A.1 and HaCat cells were seeded at a density of 1.5 x 104 per well in a tissue 
culture 96-well plate (CytoOne, CC7682-7596) in DMEM media supplemented with 10% 
fetal bovine serum (FBS), and incubated at 37°C in a 5% CO2 atmosphere for 24 hours. 
The cells were treated with peptides at concentrations range from 8 to 256 µM for 24 
hours. Untreated cells were used as a negative control. Melittin 5 µM and DMSO 10% 
were used as a positive control for J774A.1 and HaCat cells, respectively. After incubation, 
the cells were washed three times with PBS and the media in each well were replaced with 
100 µL of DMEM media and 20 µL of assay reagent, MTS 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, 
WI, USA). The cells were incubated further for 4 h at 37 ºC. Corrected absorbance 
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readings (actual absorbance readings for each treatment subtracted from background 
absorbance) were taken using a kinetic ELISA microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). Cell viability was expressed as percentage of absorbance in 
comparison to negative control, untreated cells. Therapeutic index of the peptides, was 
calculated as the ratio of mammalian IC50 (the concentration of peptide which inhibit 50% 
of mammalian cells) to geometric mean of the MIC of peptides against S. 
pseudintermedius. When there was no detectable cytotoxicity at 256 µM, we used a more 
than sign “>” to calculate the therapeutic index. Larger values of the therapeutic index 
indicate greater cell selectivity of peptides. (20) 
Multi-step resistance selection 
To assess the ability of S. pseudintermedius to develop resistance to the peptides and 
antibiotics we used amikacin and ciprofloxacin-susceptible strain (SP6) in a multi-step 
resistance selection experiment (Table 4.2). SP6 strain was exposed for ten passages over 
a period of ten days to various concentrations of the peptides (RRIKA and IK8 “D 
isoform”) and antibiotics (amikacin and ciprofloxacin). For each subsequent passage, the 
inoculum for the MIC determination was adjusted to a final density of approximately 5 × 
105 CFU/mL using the bacterial cells growing at sub-inhibitory concentration (1/2 X MIC). 
Bacteria were incubated for 16 hr and the MIC value was recorded for each passage. 
Results were expressed as the ratio of MIC value after each passage compared to the initial 
MIC value. 
Statistical analyses 
Cytotoxicity data were subjected to statistical analysis using GraphPad Prism 6.0 
(GraphPad Software, La Jolla, CA). Cytotoxicity data were analyzed using one-way 








The amino acid sequences and characteristics of the synthetic peptides used in this study 
are shown in Table 4.1.  All synthetic peptides demonstrated potent inhibitory activity. As 
shown in Table 4.2, the most effective peptides were RRIKA and WR-12 with MIC50 and 
MIC90 (the MICs at which 50% and 90% of the isolates were inhibited, respectively) were 
found to be 1 µM and 2 µM, respectively. RR and IK8 “D isoform” demonstrated good 
antimicrobial activity with MIC50 of 4 µM and MIC90 of 8 µM. Penetratin and (KFF)3K 
were the least effective with MIC50 of 8 µM and MIC90 of 16 µM.  
The MICs for MRSP were not significantly different from those for the nonresistant 
strains. Interestingly, some peptides (such as Penetratin and (KFF)3K) demonstrated lower 
MICs values for methicillin-resistant (MIC50 and MIC90 equal to 4 and 8 µM, respectively) 
compared to methicillin sensitive strains (Table 4.3). 
Time kill assay 
To determine the killing kinetics of peptides, we exposed a MRSP strain (SP3) to 5 X 
MIC of peptides and control antibiotic (amikacin). As depicted in Figure 4.1, all peptides 
demonstrated rapid bactericidal activity. RRIKA, RR and (KFF)3K were the most rapid 
in killing as viable MRSP were not detectable after 10 minutes. Penetratin, IK8 “D isoform” 
and WR-12 achieved more than 5 log10 reduction within 25, 45 and 60 minutes 
respectively. In contrast, amikacin achieved less than one log10 reduction within 3 hours 
and demonstrated bactericidal activity only after 12 hr (data not shown). 
Growth kinetics 
As a primary objective to understand the mechanism of action of peptides against S. 
pseudintermedius, we monitored the turbidity of SP3 culture exposed to 5 X MIC of 
peptides over time by a spectrophotometer. As shown in Figure 4.2, all peptides reduced 
the optical density of S. pseudintermedius suspensions, and the degree of reduction over 
time varied among peptides.  Results for RRIKA, RR and (KFF)3K were similar in rate 
and percentage to the rapidly acting membrane-damaging peptide, nisin (21). These 
peptides produced greater than 50% and 95% reductions in turbidity after 60 and 120 
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minutes, respectively. IK8 “D isoform” and WR-12 achieved a similar percentage of 
turbidity reduction as nisin albeit at a slower rate (after 3 and 7 hours). However, the 
culture turbidity of SP exposed to penetratin remained constant for 2 hours, and turbidity 
was reduced by less than 50% after 7 hours. In contrast, a DNA synthesis inhibitor, 
ciprofloxacin, and a protein synthesis inhibitor, amikacin, did not reduce the culture 
turbidity within the same time frame, indicating a different mechanism of action.  
Membrane permeability  
In order to observe the permeability effect of peptides on MRSP membrane, we monitored 
the fluorescent intensity of bacterial culture mixed with propidium iodide (PI) after 
exposure to peptides. As shown in Figure 4.3, fluorescence intensity remained stable 
during incubation of untreated bacteria in the presence of PI. This result confirmed the 
integrity of the bacterial membrane under control conditions. When exposed to peptides, 
the cells became permeable to PI and fluorescence increased within 2 minutes, suggesting 
very rapid membrane disruption activity. The permeabilization effect was concentration 
and time-dependent.  At 5X MIC; nisin, RRIKA, RR and IK8 “D isoform” were faster 
and more potent at membrane perturbation in comparison to (KFF)3K, WR-12 and 
penetratin (Figure 4.3A). However, when the concentration of peptides was increased to 
10 X MIC, similar pattern was observed for all peptides, suggesting dose dependent 
activity (Figure 4.3B). In contrast, ciprofloxacin, as expected, had no effect on membrane 
permeabilization, even at a higher concentration.  
Transmission electron microscopy 
 To explore the possible alternative mechanism of action of peptides on S. 
pseudintermedius, transmission electron microscopy (TEM) was done on thin sections of 
MRSP (SP3) that had been exposed to peptides for 30 min (Figure 4.4). TEM micrographs 
of control S. pseudintermedius in dividing cells (Figure 4.4A) and single cells (Figure 
4.4B) displayed round cocci with intact cell membranes and well-defined cell wall. The 
nucleoid region showed a non-homogenous electron density. However, after exposure to 
peptides, the cytoplasm showed a more homogenous electron density (Figures 4.4C, D 
and E). At a 1X MIC of RRIKA, multiple rounded double-layered mesosome-like 
structures were noticed as well as rounded bodies in the cytoplasm with similar electron 
84 
 
density as that of the septal cell wall layer (Figures 4.4C and D). At 10 X MIC of RRIKA, 
pore formation and lysed cells were observed (Figure 4.4E&F). RR (at 10 X MIC) showed 
the most damaging effect on the cell wall, including alteration in cell wall thickness and 
cell wall rupture (Figure 4.4G). (KFF)3K caused deviated septa and cytoplasmic 
inclusions. (Figure 4.4H). Cell wall disintegration and pore formation could be seen in 
IK8 “D isoform” treated bacteria (Figure 4.4I).  Furthermore, some large non-membrane-
enclosed bodies with similar electron density to that of the cell wall murein layer were 
seen in S. pseudintermedius cells at a 10 X MIC of WR-12 (Figure 4.4K). Penetratin at 1 
X MIC showed the lowest damaging effect (or didn’t show clear damaging effect) as most 
cells had normal appearance (data not shown) with the exception of small percentage of 
cells that displayed a disintegrated membrane separated from the cell wall (Figure 4.4L). 
However, at 10 X MIC, large pores were seen (Figure 4.4M). Taken together, these data 
demonstrate the membrane-damaging effect of the investigated peptides. 
Synergism studies 
As shown in Table 4.4, all peptides displayed synergistic interactions when combined 
together. The FIC index varied from 0.37 to 0.5. When peptides were combined with 
antibiotics; only (KFF)3K displayed potent synergism with amikacin and gentamicin with 
FIC index equal to 0.37 and 0.26, respectively. However, RRIKA, RR, WR-12, IK-8 and 
penetratin showed an additive effect with amikacin and gentamicin. Notably, there were 
no antagonistic effects observed between peptides and antibiotics. 
Cytotoxicity studies 
To evaluate the safety of the peptides toward mammalian cells, we assessed the cytotoxic 
effect of different concentration of peptides on macrophage-like cell line (J774A.1) and 
human keratinocyte (HaCat) by the MTS assay. RR, IK8 “D isoform”, (KFF)3K and 
penetratin peptides were not toxic to mammalian cells at concentrations up to 64µM 
(Figure 4.5). RRIKA and WR-12, were not toxic up to 32 µM, however they exhibited 
toxicity at 64 µM (P <0.01). In contrast, melittin peptide was toxic to J774A.1at 5 µM (P 
<0.01); this concentration is equal to the MIC of the melittin (Figure 4.5).  
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Table 4.5 shows the therapeutic index of the peptides. All peptides displayed higher cell 
selectivity with therapeutic index of RRIKA, RR, WR-12, IK8 “D isoform”, (KFF)3K and 
penetratin equal to 55.6, 31, 85.3, >51.2, 33 and >29.2, respectively, in case of 
macrophage-like cell line and 111.2, 62, 85.3, >51.2, >33 and >29.2, respectively, in 
case of human keratinocyte suggesting a favorable drug safety profile. On the other hand, 
melittin exhibited a very low therapeutic index of 1 (TI=1) in case of macrophage-like cell 
line.  
Multi-step resistance selection 
In order to investigate if the physical perturbation and disruption of microbial membranes 
by peptides can adequately overcome conventional mechanisms of drug resistance, SP6 
isolate exposed to sub-inhibitory concentrations of IK8 “D isoform” and RRIKA were 
subcultured for ten serial passages to determine if a shift in the MIC of each peptide tested 
would be observed against MSSP. Two classes of clinically used antibiotics including the 
protein synthesis inhibitor, amikacin and DNA synthesis inhibitor, ciprofloxacin were 
included as controls in this study. As shown in Figure 4.6, MSSP was not able to develop 
resistance to the peptides despite the repeated exposure with sub-lethal doses of peptides. 
However, treatment of SP6 with amikacin induced a shift in the MIC as early as passage 
4. There was a 32 fold increase in the MIC against amikacin by passage 10. Ciprofloxacin 
mediated a slightly delayed onset of drug resistance, with doubling of MIC occurring later 
at passage 6 which subsequently increased to 8-fold the original MIC value by passage 
10. 
4.5 Discussion 
The rapid emergence of bacterial resistance among S. pseudintermedius isolates and the 
dearth of effective antimicrobials call for alternative strategies to battle infections caused 
by this pathogen. One approach which warrants attention as a potential novel therapy for 
S. pseudintermedius infections is antimicrobial peptides (AMPs). There are very few 
reports describing the antimicrobial activity of naturally-derived AMPs against S. 
pseudintermedius (14, 15).  Additionally, there are several drawbacks of naturally-derived 
AMPs, including high toxicity and increased cost of production due to the complexity of 
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their design and their large size, which will limit their translational clinical applications 
(3, 4). Given the significant problem posed by the rapid emergence of multidrug-resistant 
S. pseudintermedius and the potential benefits of using AMPs as an alternative therapy, 
more effort and attention needs to be focused on developing potent, short, and less toxic 
AMPs to overcome their therapeutic limitations. In the present study, six synthetic 
peptides were investigated for their ability to inhibit clinical isolates of MSSP and MRSP 
(Table 4.1). These peptides were chosen due to their short sequence (8-16 amino acids), 
their simple composition, and their cationic charge. The AMPs, RR and RRIKA, are 
derivatives of an anti-inflammatory cell-penetrating peptide (13, 22, 23). Previously, the 
efficacy of these two peptides against human MRSA clinical isolates were shown in vitro 
and in a mouse model of MRSA skin infection (13, 23). In light of our previous success 
in targeting MRSA (13, 23), we tested these two peptides against MSSP and MRSP. RR 
exhibited potent antimicrobial activity against clinical isolates of S. pseudintermedius with 
MIC50 and MIC90 of 4 µM and 8 µM, respectively. Furthermore, addition of three amino 
acids (I, K and A) in the C terminus of RR significantly enhanced the antimicrobial 
activity fourfold against S. pseudintermedius. This enhancement of activity is probably 
due to the enhanced amphipathicity, hydrophobicity, and net charge of the newly derived 
peptide RRIKA. RRIKA exhibited antimicrobial activity against clinical isolates of S. 
pseudintermedius with MIC50 and MIC90 of 1 µM and 2 µM, respectively. Additionally, 
further advantage of using these two peptides has been demonstrated by their potent 
activity in physiological concentrations of NaCl and MgCl2, in contrast to most natural 
AMPs (13, 24). 
Previous studies demonstrated the activity of WR-12 and IK8 “D isoform” peptides 
against S. aureus (25, 26). However, their activity against S. pseudintermedius was not 
investigated. WR-12 is a broad-spectrum AMP and consists exclusively of arginine and 
tryptophan, arranged to form idealized amphipathic helices (25). In our study, WR-12 
demonstrated potent antimicrobial activity against MSSP and MRSP with MIC50 and 
MIC90 of 1 µM and 2 µM, respectively. Peptide IK8 “D isoform” in a previous study 
showed potent antimicrobial activities against MRSA (26). Additionally, the D-amino 
acids substitution of this peptide prevented proteolytic degradation by mammalian or 
microbial proteases, which makes it an excellent candidate for in vivo applications (26). 
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Peptide IK8 “D isoform” in our study exhibited MIC50 and MIC90 of 4 µM and 8 µM, 
respectively, against MSSP and MRSP.   
The antimicrobial activities of the cell-penetrating peptides (CPPs) have been widely 
explored due to their low toxicity and their potential clinical applications (27-31). We 
sought to investigate the antimicrobial activity of two CPPs, penetratin and (KFF)3K, that 
share the same characteristic of AMPs, including basic amino acids composition and 
cationic charge.  The CPPs showed antimicrobial activity against MSSP with MIC50 and 
MIC90 of 8 µM and 16 µM, respectively. Furthermore, they showed improved activity 
against MRSP with MIC50 and MIC90 of 4 µM and 8 µM, respectively.  
We assessed the bacterial killing kinetics of the peptides in comparison with the 
aminoglycoside antibiotic, amikacin. The peptides showed total and rapid elimination of 
S. pseudintermedius within minutes, while amikacin exhibited a much slower killing 
kinetic with only 3 log10 reduction after 12 hours incubation (Figure 4.1). This fast 
bacterial elimination by the AMPs represents a unique advantage of the peptides over 
conventional antibiotics that should lead to better treatment outcomes. 
Understanding the mechanism of antimicrobial activity of these AMPs on S. 
pseudintermedius is an essential step for enhancing their activity, reducing their toxicity, 
and furthering their development as a potential therapeutic option. Hence, we explored S. 
pseudintermedius membrane-perturbing abilities of these peptides. Growth kinetics study 
of S. pseudintermedius incubated with the peptides and control antibiotics revealed a 
membrane-damaging activity and a lytic mechanism of action similar to the lytic peptide 
nisin (Figure 4.2). The membrane-damaging activity of the peptides was further confirmed 
by the ability of propidium iodide (PI) to enter damaged S. pseudintermedius and 
intercalate with bacterial DNA. The fluorescence intensity of PI increased significantly 
after 2 minutes of addition of the peptides, clearly demonstrating their fast 
permeabilization characteristic (Figure 4.3). Additionally, transmission electron 
microscopy of S. pseudintermedius that had been exposed to the peptides for 30 minutes 
showed the presence of mesosome structure and damaged membranes (Figure 4.4). The 
observed membrane-damaging effect is similar to those seen with well-characterized 
AMPs such as defensins and bactenecins (32, 33).  
88 
 
The checkerboard assay was utilized to ascertain whether these peptides have potential to 
be combined with each other or with antibiotics against S. pseudintermedius (34). 
Although peptides that work by the same mechanism of action are less likely to exhibit 
synergistic activity, our peptides were found to exhibit a synergistic relationship with each 
other against S. pseudintermedius (Table 4.4). This finding suggests that, although these 
peptides share a common mechanism of action by damaging the bacterial membrane, they 
may use different pathways such as barrel-stave, carpet or toroidal-pore to permeabilize 
the bacterial membrane (9, 11). Collectively, these results provide valuable insight into 
potential combination therapy that could reduce the dose of each peptide and minimize 
potential host toxicity and emergence of resistant pathogens. With the exception of 
(KFF)3K, none of the peptides showed synergistic activity with antibiotics. This result is 
probably due to their rapid bactericidal activity that masked the activity of antibiotics (19, 
35, 36). However, (KFF)3K is the only peptide that displayed potent synergism with the 
antibiotics, gentamicin and amikacin. That synergism could be explained by their ability 
to permeabilize the membrane, at low concentration, without killing the bacteria, which 
will enhance entrance of antibiotics inside bacterial cells.   
A significant challenge facing AMPs which has limited their use in therapeutic 
applications is associated cytotoxicity to host tissues (37). However, our peptides 
demonstrated high therapeutic profiles, and there was no toxicity observed on mammalian 
cells (J774A.1 and HaCat) at concentrations several times higher than their bactericidal 
concentrations (Table 4.5 and Figure 4.5).  
After confirming the potent bactericidal activity of the peptides and their mechanism of 
action against S. pseudintermedius, we next turned our attention to assessing the 
likelihood that S. pseudintermedius would quickly develop resistance to these peptides. 
Repeated subculturing of S. pseudintermedius, in the presence of sub-inhibitory 
concentration, in a multi-step resistance selection for ten serial passages did not result in 
the development of bacterial resistance to the peptides. On the other hand, amikacin- and 
ciprofloxacin-resistant mutants of S. pseudintermedius readily emerged. The low 
frequency of emerging bacterial resistance to AMPs is attributed to the complexity of their 
mechanism of action and the extremely difficult changes required by the outer membrane 
to create a mutant, which cannot be acquired by simple bacterial mutation (10, 38).   
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We have successfully demonstrated the potential usage of AMPs against MSSP and 
MRSP clinical isolates. The AMPs were superior to antibiotics, demonstrating potent and 
rapid bactericidal activity against multidrug resistant S. pseudintermedius and low 
frequency of resistance. Moreover, AMPs such as RR and RRIKA (23) have been shown 
to possess potent anti-inflammatory properties and antibiofilm properties and to enhance 
wound healing. These are essential qualities for efficient treatment of skin infections 
caused by S. pseudintermedius. Taken together, the characteristics of these AMPs as 
antimicrobial agents may offer a significant improvement over current approaches and 
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RR WLRRIKAWLRR 11 1553.9 + 5 54 % 
RRIKA WLRRIKAWLRRIKA 14 1866.3 + 6 57 % 
WR-12 RWWRWWRRWWRR 12 2072.4 + 6 50 % 
IK8 “D 
isoform” 1  
irikirik 8 1040.28 + 4 50 % 
(KFF)3K KFFKFFKFFK 10 1413.7 + 4 60 % 
penetratin RQIKIWFQNRRMKWKK 16 2246.7 + 7 37 % 
1D-amino acid substitution 
aSmall underlined residues represent D-amino acids 
 
 
Table 4.2. Minimum inhibitory concentration (MIC) of peptides against methicillin 








































SP1 urine 1 4 2 4 4 8 PEN, AMP 
SP2 urine 2 8 2 8 16 16 
PEN, AMP, CLIN, ENRO, ERYTH, 
GEN,MARBO,  TMP-SMX 
SP4 urine 2 4 4 8 16 16 PEN, AMP, TMP-SMX 
SP6 ear  2 4 1 4 16 8 - 









Table 4.3. continued 
SP10 urine 1 4 1 4 8 8 PEN,AMP,CLIN, ERM, TMP-SMX 

















4 8 8 PEN,AMP 
SP14 ear  2 4 4 4 8 8 PEN,CHL,CLIN,ERM, 
























1 4 1 4 8 8 PEN,AMP,CEF 














SP23 wound  1 4 1 4 8 8 PEN,AMP, 

































1 4 1 4 8 8 PEN,AMK,CLIN,ERM,GEN, TMP-SMX 
SP31 abscess  1 4 1 4 4 8 - 
SP32  abscess 1 4 
0.
5 







4 8 8 BAC,CIP,ERM,MOX,NEO,OXY, TMP-SMX 
SP34 urine 2 4 2 8 8 8 - 









4 2 4 8 8 PEN and AMP 
MIC50 1 4 1 4 8 8 
 





Abbreviation: PEN: penicillin, AMP, ampicillin, AMK: amikacin, CEF: cefpodxime, 
CLIN: clindamycin, GEN: gentamicin, CHL: chloramphenicol, ENR: enrofloxacin, 
MARB: marbofloxacin, ERM: erythromycin, BAC: bacitracin, NEO: neomycin, TOB: 






Table 4.5. Minimum inhibitory concentration (MIC) of peptides against methicillin 
resistant Staphylococcus pseudintermedius (MRSP) strains 
Abbreviation:OXA: oxacillin, AMK: amikacin, CEF: cefpodxime, CLIN: clindamycin, 
GEN: gentamycin, CHL: chloramphenicol, ENR: enrofloxacin, MARB: marbofloxacin, 
ERM: erythromycin, BAC: bacitracin, NEO: neomycin, TOB: tobramycin, CIP: 
ciprofloxacin, OXY: Oxytetracyclin, TMP-SMX: trimethoprime sulphamethoxazole, TIC: 
ticarcillin, IMI: imipenem.  
 












































1 4 0.5 4 8 4 CEF,ERM,CLIN ,IMI, ,OXA,TIC 
SP5 urine 1 4 1 4 4 8 
AMK,CEF,CHL,CLIN,ENR,ERM,GEN,IMI,M
ARB,OXA,TIC,  TMP-SMX 




1 4 0.5 4 8 8 
AMK,CEF,CHL,CLIN,ENR,ERM,GEN,IMI,M
ARB,OXA,TIC,  TMP-SMX 
SP25 urine 1 2 0.5 2 4 4 
AMK,CEF,CHL,CLIN,ENR,ERM,GEN,IMI,M




1 4 2 4 8 8 
AMK, 
CEF,CHL,CLIN,ENR,ERM,GEN,IMI,MARB,
OXA,TIC,  TMP-SMX 
SP38 implant 0.5 2 0.5 4 2 4 
CEF,CHL,CLIN,ENR,ERM,GEN,IMI,MARB, 
OXA,TIC,  TMP-SMX 
SP39 ear 0.5 0.5 0.5 2 0.5 2 
AMK, 
CEF,ENR,ERM,GEN,IMI,MARB,OXA,TIC 
SP40 ear 2 4 2 4 8 8 CEF,ENR,ERM,CLIN ,IMI,MARB,OXA,TIC 
Sp41 urine 1 4 1 4 8 8 
AMK, 
CEF,CHL,CLIN,ENR,ERM,GEN,IMI,MARB,
OXA,TIC,  TMP-SMX 
MIC50 1 4 0.5 4 4 4 
 
MIC90 1 4 2 4 8 8 
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Table 4.6. The values of FIC index for the combination of peptides and antimicrobial 
compounds against Staphylococcus pseudintermedius (SP3) 
Compound 
FIC indexa  




RRIKA - 0.5 0.5 0.5 0.37 0.37 
RR 0.5 - 0.5 0.5 0.5 0.37 
WR-12 0.37 0.5 - 0.5 0.5 0.5 
IK8 “D 
isoform” 
0.5 0.5 0.5 - 0.75 0.5 
Penetratin 0.5 0.37 0.5 0.5 - 0.37 
(KFF)3K 0.37 0.37 0.5 0.5 0.37 - 
Amikacin 1 0.75 1 0.75 0.75 0.37 
Gentamicin 1 0.75 0.75 1 1 0.26 
  a  The FIC index was determined in the presence of a constant amount of peptide, equal 
to one -quarter of the peptide MIC. 
 
 
Table 4.7. Cytotoxicity and therapeutic index of peptides 
Peptide 






RRIKA 1.15 64/128 55.6/111.2 
RR 4.12 128/256 31/62 
WR-12 1.5 128/128 85.3/85.3 
IK8 “D isoform” 5 >256/>256 >51.2/>51.2 
Penetratin 8.76 >256/>256 >29.2/>29.2 
(KFF)3K 7.75 256/>256 33/>33 
Melittin 2 2/ND 1/ND 
a GM, geometric mean of the MICs of the peptides against S. pseudintermedius strains.  
b IC50 (Inhibitory Concentration 50), peptide concentration that inhibits 50 % of 
macrophage cell line (J774A.1) or human keratinocyte (HaCaT). 
cTI ( Therapeutic index), the ratio of the IC50 over the geometric mean MIC value. 




Figure 4.1. Bacterial killing kinetics of peptides against S. Pseudointermedius. 
 
SP 3 exposed to peptides (RRIKA, RR, WR-12, KFF3K, IK8 “D isoform” and penetratin) 
and antibiotic (amikacin) at 5X MIC in MHB (Mueller Hinton broth). Samples treated 
with peptide diluent (sterile water plus 0.2% acetic acid) were used as a control. The 
killing curves were identical (overlapping in the figure) for RRIKA, RR and KFF3K.  The 
results are given as means ± SD (n = 3; data without error bars indicate that the SD is too 
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Figure 4.2. Growth kinetics of SP3 exposed to 5X MIC of peptides. 
 
SP3 exposed to 5X MIC of peptides, antibiotics and sterile water (control) and OD600 was 
measured by spectrophotometer over time. Results are representative of two separate 


























0 .8 C o n tro l
N is in
R R IK A
R R
W R -1 2
IK 8  "D  iso fo rm "
P enetra tin
K F F 3 K
A m ik a c in






Figure 4.3. Permeabilization of the cytoplasmic membrane of SP3 as a function of 
peptide concentration. 
Peptides at 5X MIC (A) and 10 X MIC (B) incubated with bacteria and leakage was 
indicated by percent of propidium iodide fluorescence. Each experiment was done in 
triplicate, and the values represent means ± standard deviations. 
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Figure 4.4. TEM micrographs of untreated and peptide treated S. pseudintermedius 
SP3. 
 
Control bacteria either dividing cells (A) or single celled (B), the cells are round and intact, 
with a well-defined cell membrane. The intracellular DNA region exhibits a highly 
inhomogeneous electron density. C&D: 1X MIC RRIKA; E&F: 10X MIC RRIKA, G:  
10X MIC RR; H: 10X MIC KFF3K; I: 10X MIC, IK8 “D isoform”; K: 10X MIC WR-12; 




Figure 4.5. Cytotoxicity assay of peptides against mammalian cell lines. 
  
Cytotoxicity assay showing the percent mean absorbance at 490 nm after incubating 
macrophage cell line (J774.1) (A &B) and human keratinocyte (HaCaT) (C&D) with 
peptides at different concentrations. Melittin and DMSO served as positive control in 
J774.1 and HaCat cells, respectively. Water (peptide diluent) served as negative control. 
Cell viability was measured by MTS assay. Results are expressed as means from three 
measurements ± standard deviation. Data were analyzed using one-way ANOVA, with 
post hoc Tukey’s multiple comparisons test to determine statistical significance. Two 
asterisks (**) means statistical different (p< 0.01) from the negative control while (ns) 




Figure 4.6. Drug resistance development profiles of S. pseudintermedius (SP6) 
exposed to peptides. 
 
S. pseudintermedius (SP6) was exposed to ½ X MIC concentrations of peptides (IK8 “D 
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CHAPTER 5. EVALUATION OF SHORT SYNTHETIC 
ANTIMICROBIAL PEPTIDES FOR TREATMENT OF DRUG-
RESISTANT AND INTRACELLULAR STAPHYLOCOCCUS 
AUREUS  
(Mohamed, M.F., Ahmed Abdelkhalek and Seleem, M.N (2016) Evaluation of short 
synthetic antimicrobial peptides for treatment of drug-resistant and intracellular 
Staphylococcus aureus. Scientific reports, Scientific Reports 6, Article number: 29707 
(2016) doi:10.1038/srep29707) 
5.1 Abstract 
Methicillin-resistant Staphylococcus aureus (MRSA) infections present a serious 
challenge because of the emergence of resistance to numerous conventional antibiotics. 
Due to their unique mode of action, antimicrobial peptides are novel alternatives to 
traditional antibiotics for tackling the issue of bacterial multidrug resistance. Herein, we 
investigated the antibacterial activity of two short novel peptides (WR12, a 12 residue 
peptide composed exclusively of arginine and tryptophan, and D-IK8, an eight residue β-
sheet peptide) against multidrug resistant staphylococci. In vitro, both peptides 
exhibited good antibacterial activity against MRSA, vancomycin-resistant S. aureus, 
linezolid-resistant S. aureus, and methicillin-resistant S. epidermidis. WR12 and D-IK8 
were able to eradicate persisters, MRSA in stationary growth phase, and showed 
significant clearance of intracellular MRSA in comparison to both vancomycin and 
linezolid. In vivo, topical WR12 and D-IK8 significantly reduced both the bacterial load 
and the levels of the pro-inflammatory cytokines including tumor necrosis factor-α (TNF-
α) and interleukin-6 (IL-6) in MRSA-infected skin lesions. Moreover, both peptides 
disrupted established in vitro biofilms of S. aureus and S. epidermidis significantly more 
so than traditional antimicrobials tested. Taken together, these results support the potential 
of WR12 and D-IK8 to be used as a topical antimicrobial agent for the treatment of 




The rapid development and spread of bacterial resistance to conventional antibiotics, 
particularly those associated with staphylococcal infections, has become a serious global 
concern. Nearly 11,000 people die each year from a methicillin-resistant Staphylococcus 
aureus (MRSA)-related infection alone in the United States; this figure represents nearly 
half of all fatalities caused by antibiotic-resistant bacteria pathogens (1, 2). 
Staphylococcus aureus is the pathogen most frequently isolated from human skin and 
wound infections (2, 3). Staphylococcal biofilms and toxins can evade the host immune 
system, leading to recurring/chronic infections, prolonging inflammation, and hindering 
the process of wound healing (4, 5). Furthermore, the emergence of MRSA strains 
exhibiting resistance to topical drugs of choice, including mupirocin and fusidic acid, is a 
significant public health challenge that requires novel therapeutic alternatives (6, 7). 
Antimicrobial peptides (AMPs) have shown significant promise in recent years as novel 
therapeutic agents to treat infections caused by multidrug-resistant pathogens (1). AMPs 
are a major component of the human skin’s innate immunity and a decrease in the 
production of AMPs in the dermis is associated with increased susceptibility to skin 
infection with S. aureus in humans(8). In addition to possessing potent antibacterial 
activity, AMPs have several unique advantages over traditional antibiotics. These 
advantages include AMPs possess a broad spectrum of activity, low potential for 
resistance development, ability to neutralize virulence factors released by pathogens, and 
ability to modulate the host immune response(1). However, there are several limitations 
for utilizing naturally-derived AMPs, particularly for treatment of invasive infections. 
These limitations include host toxicity, degradation by proteases, extensive serum binding, 
loss of antimicrobial activity in the presence of physiological concentration of salts, and 
high cost of production due to their complex design. These limitations need to be 
addressed, and new avenues need to be pursued in order to transform AMPs into novel 
therapeutic agents capable of being used clinically. One avenue gaining momentum is the 
utilization of AMPs as topical antibacterial agents. Multiple AMPs have already reached 
various stages of clinical trials for the treatment and prevention of bacterial infections(1). 
In the present study, the in vitro and in vivo antibacterial activity of two unique AMPs, 
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WR12 and IK8 all D (D-IK8), was investigated against multidrug-resistant S. aureus. 
These two peptides have several advantages, including potent antibacterial activity, high 
selectivity, and short and simple sequences (8-12 amino acids). Their simplified sequences 
should facilitate their rapid production, decrease their cost of synthesis, and accelerate 
their translational clinical applications (9, 10). WR12 (RWWRWWRRWWRR) is a de 
novo designed short peptide composed of 12 amino acids with broad-spectrum 
antibacterial activity. It is composed exclusively of arginine and tryptophan and is 
designed to form standard amphipathic helices with six cationic charges and 50% 
hydrophobicity(9). Peptide D-IK8 (irikirik) is a short synthetic β-sheet forming peptide 
composed only of eight amino acids with four cationic charges and 50% hydrophobicity. 
Importantly, substitution of the L-amino acids of IK8 with the D-isoform provides 
resistance to enzymatic degradation by animal and bacterial proteases (10). Both WR12 
and D-IK8 kill bacteria by disrupting bacterial membranes, leading to leakage of 
intracellular contents and, consequently, bacterial death. This mechanism explains the low 
emergence of bacterial resistance observed after serial passage with sub-inhibitory 
concentrations of peptides (9, 10). 
The aim of this study was to investigate the spectrum of antibacterial activity of the 
designed peptides against a collection of important multidrug-resistant strains of 
staphylococci isolated from clinical settings, to assess their ability to kill persisters and 
MRSA in stationary phase of growth, to explore their antibiofilm activity and their ability 
to clear intracellular infections, to investigate their ability to be used in combination with 
conventional antibiotics, and to assess their efficacy and immune-modulatory effect in a 
murine model of MRSA skin infection. 
5.3 Materials and methods 
Bacterial isolates, peptides and reagents 
Methods were carried out in accordance with approved guidelines. Peptides, WR12, D 
isoform of IK8 (“here we refer to it as “D-IK8”), LL-37 and pexiganan (Table 5.1) were 
synthesized by GenScript (Piscataway, NJ) using solid-phase 9-fluorenylmethoxy 
carbonyl (Fmoc) chemistry and purified to a purity of 95% using reverse-phase high-
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performance liquid chromatography (HPLC). Peptide mass was confirmed by mass 
spectrometry (supplementary materials). Clinical isolates of Staphylococci are presented 
in Table 5.2 and 5.3. Antibiotics were purchased from commercial vendors, vancomycin 
hydrochloride (Gold Biotechnology, St. Louis, MO), linezolid (Selleck Chemicals, 
Houston, TX), clindamycin (TCI chemicals, Portland, OR), erythromycin, gentamicin 
were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was 
purchased from Sigma-Aldrich (St. Louis, MO). Dulbecco's Modified Eagle's 
medium (DMEM) was purchased from Life technologies. MTS reagent was purchased 
from Promega (Madison, WI). Mueller-Hinton broth (MHB) was purchased from Sigma-
Aldrich, while Trypticase soy broth (TSB) and Trypticase soy agar (TSA) were purchased 
from Becton-Dickinson, Cockeysville, MD. Mannitol salt agar (MSA) was purchased 
from Hardy Diagnostics (Santa Maria, CA). Enzyme-linked immunosorbent 
assay (ELISA) development kits for cytokines detection were purchased from R&D 
Systems, Inc. (Minneapolis, MN). 
Antibacterial assays 
The minimum inhibitory concentrations (MIC) of peptides and antibiotics were 
determined by the broth microdilution technique according to the guidelines of the 
Clinical and Laboratory Standards Institute (CLSI) (56). MIC assays were carried out with 
an initial bacterial inoculum of 5×105 colony forming units (CFU/ml) in MHB. Peptides 
and antibiotics were added to polystyrene 96-well plates at desired concentrations. MHB 
were supplemented with 50 mg/liter Ca2 in case of daptomycin. MIC was defined as the 
lowest concentration of peptide or antibiotic which inhibited the visible growth of bacteria.  
Antibacterial assays in presence of salts: 
To investigate the activity of peptides in the presence of high salt concentrations, WR12, 
D-IK-8 and pexiganan were tested against MRSA USA300 in a cation-adjusted MHB or 
in MHB with added concentrations of NaCl (150 mM) or MgCl2 (2 mM). The MIC was 
subsequently identified, as described before and according to the guidelines of the Clinical 
and Laboratory Standards Institute (CLSI) (56) 
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To determine the effect of protease digestion on the antimicrobial activity of the peptides, 
each peptide was first incubated with trypsin at a molar ratio of 500: 1 (peptide: enzyme) 
in the digestion buffer (50 mM Tris–HCl, pH 7.4) at 37°C for 4 hours. After incubation, 
the digestion mixture was heated at 80°C for 10 min to halt the enzyme reaction. After 
these treatments, the procedures conducted were the same as the MIC assay described 
above. 
Membrane permeabilization assay (Calcein leakage assay) 
Membrane permeabilization of S. aureus by peptides was monitored and quantified by the 
leakage of the preloaded fluorescent dye, calcein, as described before (57). MRSA 
USA300 and VRS10 was grown in MHB to logarithmic phase at 37°C. Cells were then 
harvested by centrifugation, washed twice with PBS, and then adjusted 
spectrophotometrically to an OD600 of 1.0 (≈10
9 CFU/ml) in PBS containing 10% (vol/vol) 
MHB. Then MRSA cells were incubated with 3 µM calcein AM for 1 hr at 37°C. Calcein-
loaded cells were harvested by centrifugation (3,000 × g, 10 min), suspended in PBS, and 
diluted to achieve a final inoculum of 107 CFU/ml. Aliquots of 100 µL were then added 
into a sterile black-wall 96-well plate. In case of MRSA USA300, WR12 and D-IK8 were 
added in concentrations equivalent to 5 × and 10 × MIC. In case of VRS10, WR12 and 
D-IK8 were added in concentrations equivalent to 0.5 × MIC and incubated for 1 hr. 
Bacteria treated with peptide diluent (sterile water) served as negative controls. Calcein 
leakage was measured for 120 min using a fluorescence plate reader (FLx800 model 
BioTek® Instruments, Inc. Winooski, Vermont). Membrane permeabilization (%) was 
calculated as the absolute percent calcein leakage by peptides with respect to calcein-
loaded with no-peptide treated cells. Experiments were done in triplicate and repeated 
independently twice.  
Time-kill assay 
MRSA USA300 was grown overnight in MHB, then diluted in fresh MHB and incubated 
aerobically at 37 ºC until bacteria reached logarithmic phase of growth (OD600 = 0.2). 
Then bacteria were diluted to 5.6 ×106 CFU/ml in MHB. Peptides (at 5 × and 10 × MIC) 
and antibiotics at 10 × MIC were added to diluted bacteria, and incubated aerobically at 
37 ºC in a shaking incubator at 250 r.p.m. Aliquots at specified time points were taken, 
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serially diluted in phosphate-buffered saline (PBS) and plated, in triplicate, on TSA. CFUs 
were counted after incubation of plates for 24 hours at 37 ºC. The kinetics of killing against 
stationary phase bacteria was done as described previously (24, 27, 28). MRSA USA300 
was grown in MHB with aeration at 250 r.p.m. at 37 ºC overnight. Then bacteria were 
exposed to peptides and antibiotics at 10 × MIC. Aliquots were taken and plated as 
described above. Formation of persister cells was done as described before (24, 27, 28). 
Briefly, MRSA USA300 was grown overnight in MHB, then diluted in fresh MHB and 
incubated until cells reached logarithmic phase of growth. Bacteria were then exposed 
to10 × MIC ciprofloxacin for 6 hours. Peptides and antibiotics, at 10 × MIC, were added 
to bacteria after 6 hours from ciprofloxacin treatment. Bacteria were incubated aerobically 
at 37ºC in a shaking incubator at 250 r.p.m. Aliquots at specified time points were taken 
and counted as described above. 
Efficacy of peptides on Staphylococcus biofilms 
The efficacy of peptides to disrupt biofilms was conducted as described before (57). 
Briefly, isolates of S. aureus (ATCC 6538) and S. epidermidis (ATCC 35984) grown 
overnight were diluted 1:100 in TSB + 1% glucose and incubated in 96-well plates at 37°C 
for 24 hours or 48 hours. After removing media, wells were rinsed with PBS to remove 
planktonic bacteria before re-filling wells with fresh MHB. Peptides and antibiotics were 
added at desired concentrations and plates were incubated at 37°C for 24 hours. After 
incubation, wells were washed and biofilms were stained with 0.5% (w/v) crystal violet 
for 30 minutes. The dye was solubilized with ethanol (95%) and the optical density (OD) 
of biofilms was measured. 
Combination therapy analysis  
The synergistic effect between peptides and antibiotics was assessed by the combination 
assay as described previously (57). Two-fold serial dilutions of antimicrobials (WR12, D-
IK8, and antibiotics) were tested in the presence of a fixed concentration of peptide equal 
to ¼ × peptide MIC, which did not inhibit the growth of bacteria alone. The fractional 
inhibitory concentration (FIC) index was calculated as follows: FIC of drug A = MIC of 
drug A in combination/MIC of drug A alone, FIC of drug B = MIC of drug B in 
combination/MIC of drug B alone, and FIC index = FIC of drug A + FIC of drug B. An 
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FIC index of ≤ 0.5 was classified as synergism. Additive was defined as an FIC index of 
1. Antagonism was defined as an FIC index of > 4.  
Re-sensitization of VRSA to vancomycin, teicoplanin and oxacillin in the presence of 
subinhibitory concentration of peptides 
Resensitization of VRSA strains to antibiotics (vancomycin, teicoplanin and oxacillin) 
was done as described previously (58). Briefly, ½ × MIC of WR12 and D-IK8was 
incubated with VRSA (bacterial inoculum of 5×105 colony forming unit (CFU/ml)) in 
MHB at room temperature for 60 minutes. After incubation, peptide-treated bacteria were 
added in 96-well plates. Antibiotics, at a concentration equal to their MIC, were added to 
the first row and diluted. Bacteria treated with ½ × MIC of WR12 and D-IK8served as the 
negative control as we didn’t observe bacterial inhibition at this concentration. The plate 
was incubated for 24 hours at 37 ºC and the MIC was recorded. 
Sub-inhibitory concentration of WR12 and D-IK8 increase the uptake and binding 
of bodipy vancomycin  
We investigated the binding and association of fluorescently labeled vancomycin (bodipy 
vancomycin) with VRSA. Briefly, VRS10 was incubated with sub-inhibitory 
concentration of WR12 and D-IK8 (0.5 X MIC) for one hour and then treated with bodipy 
vancomycin (16 µg/ml) for 30 minutes. Samples treated with bodipy vancomycin only 
served as a control. After incubation, bacteria were centrifuged at 9,000×g for 5 min, 
washed four times with PBS, and resuspended in a small volume of PBS. Bacterial pellets 
were fixed with 4% paraformaldehyde, and visualized under 40X oil objective of Nikon 
A1R multi-photon inverted confocal microscope.  
Toxicity of peptides on human keratinocytes 
Peptides were assayed for potential in vitro toxicity against human keratinocytes (HaCaT) 
as described before(59). Briefly, cells were seeded at a density of 1.5 × 104 per well in a 
tissue culture 96-well plate (CytoOne, CC7682-7596) in DMEM supplemented with 10% 
fetal bovine serum (FBS), and incubated at 37°C in a 5% CO2 atmosphere for 24 hours. 
The cells were treated with compounds at different concentrations for 24 hours. After 
incubation, the cells were washed and incubated with 100 µL of DMEM media containing 
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20 µL of MTS reagent for 4 hours at 37 ºC. Corrected absorbance readings were taken 
using an ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA).  
Intracellular antibacterial efficacy of peptides in human keratinocytes 
Infection of human keratinocytes (HaCaT) was done as described previously (46). Briefly, 
HaCaT cells were seeded and incubated as described above. Following incubation, the 
cells were infected either with methicillin-sensitive S. aureus ATCC 6538 or methicillin 
resistant S. aureus USA300, (at a multiplicity of infection 50:1) in DMEM + 10% FBS 
for 2.5 hours. After infection, the wells were washed with 200 µl media with lysostaphin 
(10 µg/ml) and further incubated for 30 minutes with lysostaphin to kill any remaining 
extracellular bacteria. Drugs were diluted in DMEM + 10% FBS to the desired 
concentrations (4 × MIC) and wells were treated with 100 µl of DMEM +10% FBS 
containing drugs for 24 hours. Medium alone was used as a negative control. After 
incubation, the media were aspirated and washed twice with PBS to remove any residual 
drugs. HaCaT cells were lifted with trypsin. Then 100 µl of PBS with 0.01% triton X was 
added in each well to lyse HaCaT cells. Subsequently, bacteria were diluted and plated on 
TSA plates. Plates were incubated at 37 ºC for 24 hours. After incubation, bacteria were 
counted and analyzed. Experiments were repeated twice independently and the average 
was reported. 
Confocal Microscopy: Uptake of WR12-FITC in mammalian cells  
J774A.1 cells were seeded at a density of 1.5 x 105 cells/well in a 4-well Lab-Tek 
chambered slides in DMEM media supplemented with 10% fetal bovine serum (FBS), 
and incubated at 37°C in a 5% CO2 atmosphere for 20 hours. The media were aspirated 
and the cells were washed 1X with 400 µL PBS. Following incubation, the cells were 
washed once with DMEM media. Then the cells were incubated with WR12-FITC (10 
µM) for 3 hours at 37 ºC and 5% CO2. The cells were washed 3X with PBS and visualized 
under 60X oil objective of Nikon A1R multi-photon inverted confocal microscope.  
Efficacy of peptides in mice model of MRSA skin infection 
The animal care and all experiments were approved and performed in accordance with the 
guidelines approved by Purdue University Animal Care and Use Committee (PACUC). 
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Female BALB/c mice (6-8 weeks old) were obtained from Harlan Laboratories, 
Indianapolis, IN. All procedures were approved by the Purdue University Animal Care 
and Use Committee (PACUC) (protocol no: 1207000676). The murine model of MRSA 
skin infection was done as described previously (47, 48). Briefly, the posterior upper backs 
of mice were shaved and mice were injected intradermal by 40 µl of MRSA USA300 (3 
× 107 CFU/40 µl) in sterile phosphate-buffered saline (PBS) using a 27-gauge insulin 
syringe. Mice were randomly divided into five groups and each group contained five 
animals. Forty-eight hours after infection and formation of open wound, groups of mice 
were treated topically either with 2% fusidic acid, 2% WR12 or 2% D-IK8 formulated in 
20 mg petroleum jelly. One group received vehicle only (petroleum jelly) and the last 
group was treated orally with linezolid (25 mg/kg). All groups were treated twice a day 
for 3 days. Twenty-four hours after the last treatment, mice were euthanized, and the skin 
lesion was removed and homogenized in 1 ml tryptic soy broth. Samples were diluted, 
plated in mannitol salt agar in triplicate, and incubated aerobically at 37°C. After 24 hours 
incubation, the colony forming units (CFU) were counted. Cytokine detection of tumor 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in skin lesions was done using ELISA 
as described before and according to manufacturer instructions (47). Cytokine levels were 
expressed as percent change relative to negative control.  
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad 
Software, La Jolla, CA, USA). Comparison between two groups were analyzed using two-
tailed unpaired Student t-tests. Comparison between three groups or more were analyzed 
using one-way ANOVA, with post hoc Tukey’s multiple comparisons test. P-values of ˂ 
0.05 were considered significant. 
5.4 Results and discussion 
Antimicrobial activity 
We explored the antibacterial activity of WR12 and D-IK8 against multidrug-resistant 
strains of staphylococci, including methicillin-sensitive S. aureus (MSSA), MRSA, 
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vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA), 
linezolid-resistant S. aureus and methicillin-resistant S. epidermidis (MRSE) (Table 5.2 
and 5.3). WR12 exhibited strong antibacterial activity against MRSA, inhibiting 50% of 
the strains (MIC50) at a concentration of 2 µM and inhibiting 90% of the strains (MIC90) 
at a concentration of 8 µM. The MIC50 and MIC90 of D-IK8 against MRSA strains were 
found to be 8 and 16 µM, respectively. Moreover, WR12 and D-IK8, demonstrated good 
activity against multiple clinical isolates of MRSA, particularly MRSA USA300, a 
community-associated strain responsible for major outbreaks of staphylococcal skin and 
soft-tissue infections (SSTI) (3). Similarly, potent antibacterial activity of these peptides 
was observed against other important clinical MRSA isolates (USA500, USA200, and 
USA100) that exhibit resistance to various antibiotic classes, including fluoroquinolones, 
macrolides, lincosamides, and aminoglycosides.  
WR12 and D-IK8 also showed potent antibacterial activity against all tested VRSA 
isolates that were resistant to vancomycin and teicoplanin, with MIC values ranging from 
4-8 and 8-16 µM, respectively (Table 5.3). It is important to note that 85% of the VRSA 
strains we examined were isolated from wounds; thus the studied AMPs have potential to 
be used as a topical antimicrobial agent for the treatment of multidrug-resistant 
staphylococcal skin and wound infections (11).  
The superior antibacterial activity of WR12 over D-IK8 may be attributed to the higher 
cationic charge and the increased length of amino acids of WR12 (12 residues) compared 
to D-IK8 (8 residues) (Table 5.1). Indeed, WR12 permeabilized the staphylococcal 
membrane more potently than D-IK8. As demonstrated in figure 5.1, at 5 × MIC, WR12 
and D-IK8 caused more than 95% and 76% leakage of preloaded calcein dye within 60 
minutes, respectively. 
In contrast to WR12 and D-IK8, we detected very low activity and high level of resistance 
in staphylococci strains against the natural derived human AMP cathelicidin (LL-37) that 
protects human skin from bacterial infections (12). LL-37 showed activity only against 
two strains of staphylococci (S. aureus ATCC 6538 and S. epidermidis ATCC 35984 
“NRS 101”) with a MIC value equal to 16 µM. The MIC values of LL-37 against all other 
strains were more than 128 µM. Our results correlate with previous reports that have found 
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high levels of resistance to LL-37 in clinical MRSA strains compared with MSSA 
bacterial isolates(13). The emergence of resistance among clinical isolates to natural 
peptides, such as LL-37, could be one of the factors that has contributed to their global 
epidemic(14). 
We evaluated the activity of pexiganan against four isolates of staphylococci represent 
different antibiotic susceptibility phenotypes: MSSA, MRSA, MRSE, and VRSA.  
Pexiganan is an analog of the magainin peptides isolated from the skin of the African 
clawed frog. Pexiganan is the first AMPs that has advanced furthest in clinical trials for 
the treatment of diabetic foot ulcers. Pexiganan demonstrated comparable activity to D-
IK8 and less activity than WR12 against MSSA, MRSA and VRSA (MIC of pexiganan is 
16, 16, 32 µM against MSSA, MRSA and VRSA, respectively). However, pexiganan 
demonstrated enhanced activity than WR12 and D-IK8 against MRSE (MIC, 1 µM). Ge 
et al reported that the MIC50 and MIC90 of pexiganan against large panel of S. aureus 
isolates were 8 and 16 µg/ml, respectively (15). A more recent study reported that 
pexiganan MIC values among MSSA and MRSA strains isolated from diabetic foot 
infections ranged from 16 to 32 µg/ml(16). It is important to note that pexiganan have 22-
amino-acid residues in contrast to WR12 (12 residues) and D-IK8 (8 residues). This 
ensures a relatively lower cost of production of WR12 and D-IK8 compared to pexiganan.  
Antimicrobial activity in physiological concentrations of salts 
One major limitation with the clinical translation of AMPs is their potential inactivation 
by salts present in the human body. Therefore, we tested the MIC of peptides against 
MRSA USA300 in cation-adjusted Mueller Hinton medium and in regular MHB, for 
comparison (Table 5.4). We did not find a significant difference in the MIC value of the 
peptides in the two conditions (there is no difference in the MIC of WR12 and only one 
fold increase of D-IK8 and pexiganan in the presence of cation-adjusted Mueller Hinton 
medium). To ensure that these peptides remain active in the presence of higher 
concentrations of cations, we tested the peptides in higher concentration of salts. As 
demonstrated in supplementary Table 5.4, there was no difference in the MIC of WR12 
in the presence of 150 mM NaCl. However, there was a two-fold increase in the MIC 
observed for D-IK8 and pexiganan at the same conditions. In the presence of a 
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physiological concentration of MgCl2 (2 mM), we observed a one-fold increase in the 
MIC of WR12 and a two-fold increase in the MIC of D-IK8 or no change in the MIC of 
pexiganan, compared to regular MHB (Table 5.4). The superior salt stability of WR12 
compared to D-IK8 and pexiganan is attributed to its amino acid composition. WR12 is 
composed of tryptophan and arginine residues which are known to improve antimicrobial 
activity under challenging salt conditions (9, 17, 18). In contrast, many well-studied 
AMPs (such as LL-37, human β-defensin-1, gramicidins, bactenecins, and magainins) 
demonstrated substantially reduced antibacterial activities under the same conditions (19).  
Previously, Turner et al. reported that LL-37 and HNP-1 demonstrated a 12-fold and 100-
fold increase in the MIC of MRSA, respectively, when 100 mM NaCl was added to the 
test medium (20). The ability to resist the effects of salt provide a selective advantage for 
WR12 peptide for potential therapeutics in physiological solutions. 
Bacterial killing kinetics 
After confirming that the AMPs possessed excellent antimicrobial activity against 
multidrug-resistant staphylococcal clinical isolates, we next assessed the killing kinetics 
of these AMPs. Both peptides showed concentration-dependent killing of MRSA USA300. 
WR12 showed fast bactericidal activity and was capable of completely eliminating a high 
starting inoculum of MRSA USA300 (5.6 x 106 CFU/ml) within 30 minutes and 240 
minutes at 10 × and 5 × MIC, respectively (figure 5.2a). D-IK8 showed slower bactericidal 
activity with complete clearance of MRSA within 90 minutes and 180 minutes at 10 × 
MIC and 5 × MIC, respectively. The rapid bactericidal activity of WR12, when compared 
to D-IK8, is mainly attributed to its ability to more rapidly permeabilize the staphylococcal 
membrane. In contrast to AMPs, conventional antibiotics demonstrated slower killing 
kinetics at 10 × MIC. As shown in figure 5.2b, vancomycin only produced a 2.5-log 
reduction after 12 hours of exposure and required 24 hours to completely eliminate MRSA 
USA300. It is worth noting that frequent clinical failure in MRSA patients receiving 
vancomycin treatment has been linked to the poor bactericidal activity of this drug (21). 
Ciprofloxacin showed bactericidal activity by reducing the starting inoculum of MRSA 
USA300 3-log within six hours; however, complete clearance was not achieved, even after 
24 hours of exposure. Linezolid, as expected, showed a bacteriostatic effect reducing 
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MRSA USA300 starting inoculum by 1.3-log after 24 hours of treatment.  AMPs with fast 
bactericidal activity have several advantages over their counterparts, conventional 
antibiotics, including limiting spread of infection, improving outcome of the disease, 
reducing the potential emergence of bacterial resistance, and reducing duration of 
treatment (22). 
Efficacy of peptides on persister cells and stationary phases of MRSA 
 Persister cells are phenotypic variants of the normal bacterial population. They are 
extremely tolerant to antimicrobials and contribute to chronic and latent infections (23-25) 
(26). To assess the ability of AMPs to eradicate persister cells, MRSA was treated with 
ciprofloxacin in order to produce persister cells. When treated with ciprofloxacin, MRSA 
USA300 (in exponential growth phase) produces a biphasic killing pattern that results in 
surviving persister cells (figure 5.2c). The subsequent addition of conventional 
antimicrobials such as vancomycin or linezolid had minimal impact in reducing the 
number of persisters, which is in agreement with previous studies (24, 27, 28). However, 
treatment with WR12 and D-IK8 resulted in complete eradication of persister cells after 
2 and 24 hours, respectively (figure 5.2c).  
The ability of both WR12 and D-IK8 to kill MRSA persisters led us to next assess their 
impact on stationary-phase S. aureus which is known to be tolerant to many antimicrobial 
agents (24, 27, 28). Treatment of stationary-phase MRSA USA300 with WR12 and D-
IK8 resulted in complete eradication of MRSA after 2 and 6 hours, respectively (figure 
5.2d). With the exception of vancomycin, conventional antibiotics (ciprofloxacin and 
linezolid) did not have any effect on stationary-phase MRSA. Vancomycin had minimal 
impact in reducing the number of stationary-phase MRSA by only 2.4-log after 48 hours 
of exposure. The superior activity of our AMPs, when compared to conventional 
antibiotics, against persisters and stationary phase MRSA could be explained by their 
unique antimicrobial mechanism of action. Many antibiotics require growing and 
metabolically active bacteria to exert their antimicrobial effects and inhibit intracellular 
bacterial targets including nucleic acids (ciprofloxacin) or protein (linezolid) or cell wall 
synthesis (vancomycin) (29). In contrast, the positive charge present in WR12 and D-
IK8serves as a point of attraction with cell membranes and consequently targeted-
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disruption of bacterial membrane and leakage of intracellular contents (9, 10). This unique 
mechanism of action of AMPs does not require cells to be metabolically active and is not 
impaired by the dormant and quiescent state of bacteria (stationary and persister cells) 
(29). The results garnered lend valuable insight into using AMPs as a possible future 
therapeutic option for the treatment of persistent bacterial infections.  
Efficacy of peptides on Staphylococcus biofilms 
Biofilm formation is one of the major virulence factors of S. aureus (30). The 
polysaccharide matrix of biofilm protects bacteria from host immune defenses and hinders 
the ability of antibiotics to target deep-seated bacteria residing within the biofilm(31). 
Furthermore, biofilms act as an infectious niche with sustained release of bacteria inside 
the host, which leads to chronic infection, relapses, life-threatening bloodstream infections, 
and treatment failure (30). Given the serious challenges associated with staphylococcal 
biofilms and their role in promoting recurring infections in the host, we next moved to 
assess whether our peptides are capable of disrupting mature biofilms (formed after 24 
and 48 hours) of both S. aureus and S. epidermidis. As shown in figure 5.3a, both peptides 
(at 4 × MIC) significantly disrupted the 24 hour mature biofilms of S. aureus, reducing 
biofilm mass by 50%. Vancomycin and linezolid were required at a higher concentration 
(16 × MIC) to reduce the same percentage of biofilm mass (p < 0.05) (figure 5.3a). 
Although some conventional antibiotics might be capable of disrupting 24 hour-mature 
bacterial biofilm, most antibiotics are not effective against 48 hour-mature biofilms due 
to the dormant state of growth of the bacterial cells present within the mature-biofilms(32). 
To examine whether the potential therapeutic application of WR12 and DIK-8 could be 
expanded beyond just inhibition of 24 hour biofilm, the ability of both peptides to disrupt 
48 hours-mature staphylococcal biofilm was tested. As expected, we observed that the 
mature 48 hour S. aureus biofilms were resistant to antibiotics with no significant 
reduction in the biofilm mass observed, even at very high concentrations (64 × MIC) 
(figure 5.3b). Interestingly, WR12 and DIK-8 (at 4 × MIC) showed more than 50% 
reduction of biofilm mass (p < 0.05) (figure 5.3b). 
Next, we evaluated the ability of our peptides to disrupt established biofilms of S. 
epidermidis ATCC 35984 (NRS 101), a clinical high slime producer strain isolated from 
118 
 
septicemic patients with a colonized intravascular catheter (33). This strain is a multidrug-
resistant strain, exhibiting resistance to methicillin, erythromycin, kanamycin, gentamicin, 
clindamycin, and trimethoprim. The great thickness of the slime matrix of S. epidermidis 
biofilms makes it extremely resilient to antibiotic penetration (34). Hence, the 24 hour-
mature S. epidermidis biofilms were less susceptible to vancomycin and linezolid, even at 
64 × MIC, showing only 30-35% biofilm inhibition. The 48 hour-mature biofilms were 
not susceptible to the effect of both antibiotics action, even at a very high concentration 
(256 × MIC). WR12 and DIK-8 (at 8 × MIC) significantly reduced biofilm mass by more 
than 70% and 50% in 24 and 48 hour-mature biofilms, respectively (p < 0.05) (figures 
5.3c&d). The studied peptides proved to be far superior to antibiotics against biofilm due 
to their amphipathic nature and their high cationic charge, which may facilitate their 
penetration through the extracellular biofilm matrix. Furthermore, we included the known 
biofilm inhibitor, LL-37, as a control (35). In our studies, LL-37 disrupted both biofilms 
of staphylococci regardless of the maturation stage of the biofilm. Interestingly, WR12 
and D-IK8showed improved activity compared to LL-37, particularly in 48 hour mature 
biofilms of both species of staphylococci (figure 5.3). This may be related to the more 
potent antimicrobial activity and amphipathicity of the designed peptides compared to LL-
37.  
Combination therapy analysis  
The potent antimicrobial activity of the AMPs indicated that they have the potential to be 
used alone for treatment of skin infections caused by S. aureus. Although the use of a 
single agent to treat skin infections caused by S. aureus is the most commonly used 
practice in clinical settings, combination therapy has several advantages. These 
advantages include minimizing the likelihood of emergence of bacterial drug-resistance, 
lowering the doses required for each antibacterial agent thus mitigating drug toxicity, and 
expanding the spectrum of pathogens that can be targeted (36). Furthermore, several 
topical treatments currently used for treatment of skin infections involve a combination of 
more than one antibiotic, such as Polysporin (bacitracin, polymyxin B sulfate, and 
gramicidin) and Neosporin (bacitracin, neomycin, and polymyxin B sulfate) (37). Thus, 
identifying AMPs to pair with conventional antibiotics used for treatment of S. aureus 
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infections has good potential to expand available treatment options. Keeping the above 
points in mind, we were curious to assess the synergistic action of WR12 and D-IK8in 
combination with each other and with conventional antibiotics against four staphylococcal 
isolates. The isolates were chosen to represent different antibiotic susceptibility 
phenotypes: MSSA, MRSA, MRSE, and VRSA. 
As presented in Table 5.5, WR12 and D-IK8 displayed synergistic activity when 
combined against MSSA, MRSA, and MRSE but not against VRSA. The FIC indices 
against all isolates except VRSA varied from 0.27 to 0.38. When our peptides were 
combined with antibiotics, WR12 proved to be superior to D-IK8, as it displayed potent 
synergism with most topical antibiotics (fusidic acid and mupirocin) and systemic 
antibiotics (daptomycin, teicoplanin, vancomycin, linezolid, ciprofloxacin, meropenem 
and oxacillin) against most tested strains with FIC indices ranging from 0.26 to 0.5. D-
IK8 demonstrated synergism with fusidic acid and daptomycin in all four strains tested 
with FIC indices ranging from 0.26 to 0.5. D-IK8 also showed synergism with teicoplanin 
in two strains and with oxacillin, vancomycin, meropenem, and linezolid in one strain.  
 Remarkably, we found that both WR12 and D-IK8 showed potent synergism with 
vancomycin against a VRSA isolate (with a low FIC index of 0.27)). Since vancomycin 
is considered to have nephrotoxicity at higher concentrations, decreasing the therapeutic 
doses required to treat staphylococcal infection is beneficial, as it will reduce the adverse 
side effects in affected patients (36). Notably, there were no antagonistic interactions 
recorded between the peptides and antimicrobials. The synergistic interaction between 
peptides and antibiotics could be a result of the membrane permeabilization action of 
peptides, leading to more penetration of antibiotics inside bacterial cells and augmented 
killing13,14. The potent and broad synergism observed for WR12 compared to D-IK8 is 
attributed to its rapid and more potent membrane permeabilization (figure 5.1). 
Re-sensitization of VRSA to vancomycin, teicoplanin, and oxacillin in the presence 
of a sub-inhibitory concentration of peptides 
As a strong synergistic relationship was observed with the peptides and vancomycin 
against the VRSA10 strain, we hypothesized that these peptides could be used to re-
sensitize vancomycin and teicoplanin-resistant S. aureus (VRSA) strains to the effect of 
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vancomycin, teicoplanin and oxacillin. To assess this, we incubated VRSA strains with a 
subinhibitory concentration of the peptides for one hour. Afterward, the broth 
microdilution assay was used to determine the sensitivity of VRSA strains to antibiotics. 
Both peptides demonstrated the ability to re-sensitize VRSA strains to the effect of 
vancomycin, teicoplanin, and oxacillin. Pretreatment with subinhibitory concentrations of 
WR12 resulted in an 8- to 256-fold reduction in the MICs of vancomycin, teicoplanin, and 
oxacillin in the four VRSA strains tested. Pretreatment of VRSA strains with sub-
inhibitory concentrations of D-IK8 resulted in a 2- to 256-fold reduction in the MICs of 
vancomycin, teicoplanin, and oxacillin. This study confirmed that, in addition to being 
used as antimicrobial agents alone or in combination with antibiotics in the treatment of 
staphylococcal infections, the peptides have the potential to suppress resistance of VRSA 
to conventional antibiotics. Clearly, further studies are needed to understand the 
mechanism of re-sensitization and their potential clinical applications. To explore the 
mechanism of re-sensitization, we monitored the leakage of preloaded calcein dye after 
exposure of VRSA to ½ × MIC of peptides for one hour. As demonstrated in 
supplementary figure 5.4, WR12 and D-IK-8 demonstrated leakage of calcein dye without 
affecting the survival of the VRSA strain (figure 5.4). This demonstrates that at 
subinhibitory concentrations, the peptides permeabilized the membrane potentially 
leading to increased access of antibiotics to their target. To confirm this hypothesis, VRSA 
(VRS10) was incubated with a sub-inhibitory concentration (½ × MIC) of WR12 and D-
IK8 for one hour. Then treated with fluorescently labeled vancomycin (bodipy 
vancomycin) for 30 minutes. Bacterial pellets were fixed with 4% paraformaldehyde, and 
visualized under confocal microscope. As demonstrated in figure 5.5, pre-treatment of 
VRSA with WR12 and D-IK8 led to increased uptake and binding of fluorescently labeled 
vancomycin in contrast to non-peptide pre-treated samples. The fluorescence was 
maximized at the cell division septa and the cell wall of VRSA. Several studies reported 
that membrane acting antimicrobials re-sensitize resistant bacteria to antibiotics by similar 
mechanisms. For example, the protein-lipid complex from human milk, HAMLET 
(human alpha-lactalbumin made lethal to tumor cells) was able to resensitize MRSA to 
methicillin and VISA to vancomycin by depolarization of the bacterial membrane and 
dissipation of the proton motive force leading to more access and increased cell-associated 
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binding of antibiotics (38, 39). Moreover, Minahk et al reported that sub-lethal 
concentrations of enterocin synergize with antibiotics by dissipation of the proton motive 
force leading to inhibition of bacterial efflux systems and more accumulation of 
antibiotics intracellularly (40).  The amphibian antimicrobial peptide, esculentin-1b (1–
18) was also reported to cause permeabilization of bacterial membranes at subinhibitory 
concentrations leading to synergism with conventional antibiotics against E. coli (41). The 
peptidomimetic OAK (oligo-acyl-lysyl), was able to resensitize erythromycin-resistant 
Escherichia coli to erythromycin both in vitro and in an animal model of infection. The 
authors explained the mechanism of resensitization to be transient depolarization of the 
membrane potential at subinhibitory concentrations (42).  
Toxicity of peptides on human keratinocytes 
One of the major limitations for advancement of AMPs for clinical applications is toxicity 
to host tissues(1). Here, we evaluated the cytotoxic effect of IDK-8 and WK12 on human 
keratinocytes (HaCaT cells) using the MTS assay. The half maximal effective 
concentrations (EC50) of WR12 and D-IK8were 128 and >256 µM, respectively (figure 
5.6a). These values correlate to 64- and >32-fold of the MIC50 for WR12 and D-IK8, 
respectively. These results suggest that these AMPs have a favorable drug safety profile. 
The low toxicity of peptides against mammalian cells compared to their potent 
antimicrobial activity suggests their selective actions against the negatively charged 
bacterial membranes compared to the zwitterionic mammalian membranes.  
Intracellular antibacterial efficacy of peptides in human keratinocytes 
Although S. aureus is not considered a typical intracellular pathogen, it can invade and 
thrive inside mammalian host cells. Moreover, treatment with conventional antimicrobials 
during the S. aureus intracellular invasion phase is a daunting task because most 
antimicrobials are unable to access intracellular replicative niches and achieve the 
optimum therapeutic concentrations within the infected cells(43). Accordingly, treatment 
with conventional drugs of choice (such as vancomycin and aminoglycosides) is often 
associated with high clinical failures that exceed 40% in intracellular MRSA infections 
due to poor intracellular penetration of these drugs (44, 45). Since intracellular persistence 
of S. aureus constitutes a potent virulence component for various skin diseases such as 
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impetigo and folliculitis (46), we chose to assess the ability of AMPs to kill invasive 
intracellular MRSA infections. Due to the fact that MRSA and MSSA infect, reside, and 
replicate inside human keratinocytes, it was important to test the activity of WR12 and D-
IK8against MRSA and MSSA infected human keratinocytes. As depicted in figure 5.6b, 
both peptides showed significant reduction of intracellular MRSA and MSSA at 4 × MIC. 
D-IK8displayed the most potent activity with significant reduction of 96% ± 1.15 and 
91.08% ±14.94 of intracellular MRSA and MSSA, respectively at 4 × MIC. WR12 at 4 × 
MIC demonstrated significant reductions of 40.98% ± 8.03 and 45% ± 6.23 of intracellular 
MRSA and MSSA, respectively. In contrast, antibiotics showed either low reduction 
(linezolid, 30-35%) or nonsignificant reduction (vancomycin) against intracellular 
staphylococci at 4 × MIC (figure 5.6b). Taken together, these results show that AMPs 
exhibits potent intracellular anti-staphylococcal efficacy in infected keratinocytes. These 
peptides, with their potent intracellular activity, could be useful in treating certain chronic 
exacerbating skin diseases such as Darier’s disease (keratosis follicularis) where S. aureus 
persists inside keratinocytes, leading to recurrent infections and treatment failure(46). 
Interestingly, D-IK8was more efficient than WR12 against MRSA and MSSA in infected 
keratinocytes compared to results obtained in pure culture. We hypothesized that the weak 
intracellular anti-staphylococcal activity of WR12 may be due to lack of intracellular 
penetration or due to reduced stability inside mammalian cells. To differentiate between 
the two possibilities, we conducted two experiments, (confocal study and stability study). 
Confocal studies of WR12-FITC demonstrated that this peptide penetrates and 
accumulates inside mammalian cells (figure 5.7). However, when WR12 was treated with 
trypsin for 4 hours, its anti-staphylococcal activity was abolished compared to D-IK8 
(Table 5.4). This supports our hypothesis that the weak intracellular anti-staphylococcal 
activity of WR12 may be due to the reduced stability of this peptide intracellularly. 
Efficacy of peptides in mice model of MRSA skin infection 
In light of our successful in vitro experiments, we moved forward with an in vivo 
experiment with a murine model of MRSA skin infection (47, 48). Briefly, groups of mice 
(n=5) were injected with a highly virulent community-acquired MRSA strain USA300-
0114. This clinical strain was isolated from a skin and soft-tissue outbreak in a state prison 
in Mississippi, USA(49). Twenty-four hours after the intradermal injection, mice 
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developed an abscess at the injection site. Within 48 hours of infection, the abscess further 
developed into an open wound. Open wounds were treated topically with either 2% 
peptides, 2% fusidic acid, or vehicle alone (petroleum jelly). An additional group was 
treated orally with 25 mg/kg linezolid. All groups of mice were treated twice daily for 
three days. As presented in figure 5.8a, all treatments significantly reduced the mean 
bacterial counts of MRSA in wounds compared to the control group (P ≤ 0.05). WR12 
and D-IK8showed 1.71 ± 0.07 and 1.78 ± 0.07 log reduction of MRSA USA300, 
respectively. The group treated with fusidic acid produced a 1.94 ± 0.352 log reduction in 
bacterial count. The group treated with oral linezolid generated a 1.678 ± 0.38 log 
reduction in bacterial load. These results reveal that our peptides are very effective in 
reducing the bacterial load in MRSA skin lesions.  
The clinical severity of skin infections caused by S. aureus is driven by excess production 
of host pro-inflammatory cytokines more so than by bacterial burden. In addition, 
excessive host inflammation delays the wound healing process and leads to more scar 
formation(50) (51). We hypothesized that therapeutics with combined antibacterial and 
anti-inflammatory properties should be superior to traditional antibiotics for treatment of 
S. aureus skin infections. To confirm, we investigated the immune-modulatory effect of 
our peptides by measuring the levels of pro-inflammatory cytokines produced normally 
during infection, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) (52). 
As shown in figures 5.8b and 5.8c, both peptides produced a significant reduction in TNF-
α and IL-6 levels compared to the untreated control and antibiotic-treated groups. WR12 
and D-IK8reduced the TNF-α level by 50% and 44%, respectively, while the IL-6 level 
was reduced by 48% and 42%, respectively. However, treatment with 2% fusidic acid 
reduced TNF-α and IL-6 levels by only 29% and 25%, respectively, which is in agreement 
with previous findings(53). Linezolid, on the other hand, did not show any significant 
reduction in the levels of cytokines when compared to the control group. The combined 
antimicrobial and immunomodulatory effects of the AMPs should confer an added 
advantage in the treatment of S. aureus skin infection and might help in promoting 
epithelization and accelerating wound healing processes. Some AMPs have reached 
preclinical and clinical phases for topical treatment of bacterial infection. One of the 
AMPs that has advanced furthest in clinical trials is pexiganan for curing diabetic foot 
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ulcers (54). Topical application of 2% pexiganan cream showed therapeutic resolution 
equivalent to oral ofloxacin for treatment of mild infections of diabetic foot ulcers (54). 
Interestingly, no significant resistance to pexiganan emerged among patients who received 
pexiganan. However, bacterial resistance to ofloxacin emerged in some patients who 
received ofloxacin (54). Currently, pexiganan is undergoing phase 3 development as a 
topical agent for treatment of mild infections of diabetic foot ulcers (ClinicalTrials.gov 
registration numbers NCT01594762 and NCT01590758). Another compound that showed 
success in clinical trials is the peptidomimetic, brilacidin. Brilacidin is a defensin-mimetic 
that targets the bacterial membrane, similar to AMPs. The MIC90 of brilacidin against a 
collection of multidrug-resistant S. aureus isolates was 2 μg/ml. Brilacidin demonstrated 
clinical efficacy and safety on two studies of phase II clinical trials for the treatment of 
acute bacterial skin and skin structure infections (ABSSSI). The FDA approved brilacidin 
to advance into Phase III clinical trials (55). Lytixar (LTX-109) is a synthetic, membrane-
degrading peptide that has been developed by Lytix Biopharma (Oslo); this peptide has 
completed a Phase I/IIa clinical trial for nasally colonized MRSA. A significant effect on 
nasal decolonization of MRSA and MSSA was observed after only two days of LTX-109 
treatment in subjects treated with 2% or 5% LTX-109, compared to the vehicle. The 
success of pexiganin, brilacidin, and LTX-109 demonstrates the promise that 
antimicrobial peptides have as potential therapeutic agents for treatment of multidrug-
resistant pathogens. 
5.5 Conclusion 
We have successfully demonstrated the potential utility of WR12 and D-IK8against 
MRSA and VRSA clinical isolates. WR12 and D-IK8were superior to antibiotics, 
demonstrating potent and rapid eradication of persister cells and MRSA cells in stationary 
phase of growth. Moreover, WR12 and D-IK8 disrupted the mature biofilms of 
staphylococci and were able to kill intracellular staphylococci at a more significant rate 
than antibiotics of choice. Additionally, WR12 and D-IK8augmented the antibacterial 
action of topical and systemic antibiotics, which will increase the clinical uses of these 
antibiotics and decrease their adverse effects. Finally, WR12 and D-IK8 significantly 
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reduced the count of MRSA in skin lesions and displayed potent immunomodulatory 
effects. Collectively, the qualities of WR12 and D-IK8 presented here have the potential 
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WR-12 RWWRWWRRWWRR 12 2072.4 + 6 50 % 
D-IK8  irikirik 8 1040.28 + 4 50 % 
Pexiganan GIGKFLKKAKKFGKAFVKILKK 22 2478.163 +9 45% 
aSmall underlined residues represent D-amino acids 
                  
Table 5.2. Minimum inhibitory concentration (MIC) of peptides and antibiotics 
against clinical and drug-resistant staphylococci isolates 




















































































































































8 >128 4 1 8 >128 0.5 2 
USA800 
(NRS387) 














8 >128 4 1 
< 
0.25 
1 0.5 2 
NRS194 
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8 >128 4 0.5 32 >128 4 >128 
NRS119 
(LinR) 
4 16 >128 128 0.5 
< 
0.25 
>128 >128 >128 
ATCC 43300 
2 






8 >128 4 0.5 >128 >128 8 1 
NRS70 
1 






8 >128 2 0.5 >128 >128 >128 4 
NRS100 
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8 >128 2 8 >128 >128 16 2 
NRS19 
1 
8 >128 2 4 >128 >128 >128 >128 
NRS37 
1 
8 >128 2 8 >128 >128 32 2 




a     (MSSA) : methicillin sensitive Staphylococcus aureus; (MRSA): methicillin 
resistant Staphylococcus aureus; (VISA):vancomycin intermediate Staphylococcus 




















Table 5.5. Minimum inhibitory concentration (MIC) of peptides and antibiotics 
against clinical vancomycin resistant Staphylococcus aureus (VRSA) isolates 


















































VRS4 4 8 >128 32 64 >128 16 
VRS5 8 16 >128 32 4 >128  8 
VRS10 8 16 >128 >128 >128 >128 >128 
VRS11a 4 16 >128 >128 >128 >128 >128 
VRS11b 4 16 >128 >128 >128 >128 >128 
VRS12 8 16 >128 >128 >128 >128 >128 
VRS13 4 16 >128 >128 >128 >128 >128 
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Table 5.6. Minimum inhibitory concentration (MIC) of peptides against Methicillin 
resistant Staphylococcus aureus (MRSA) USA300 in different media conditions 










WR12 4 4 4 8 > 64 
D-IK8 16 32 64 64 16 
Pexiganan 16 32 64 16 nd 
nd: not determined 
 
Table 5.7. The fractional inhibitory concentration index range of peptides in 




























































































WR12 - 0.27 0.31 0.28 0.31   nd 0.26 0.28 0.50 0.28 0.27 
D-IK8  0.31 - 0.31 0.50 0.31 0.31 0.75 1.25 1.25 0.50 0.38 
MRSA 
USA300 
WR12 - 0.31 0.38 0.27 
0.31 
0.28 0.27 0.27 0.31 0.26 0.31 
D-IK8 0.38 - 0.50 0.75 
0.31 
0.75 0.75 0.75 1.25 1.25 1.25 
MRSE 
NRS101 
WR-12 - 0.38 0.38 0.38 0.26 0.31 0.38 0.50 0.75 0.75 0.28 
D-IK8 0.31 - 0.38 0.75 0.26 0.50 1.25 0.50 0.75 1.25 0.75 
VRSA 
(VRS10) 
WR12 - 1.25 0.50 0.75 0.26 0.50 0.27 1.25 0.75 0.38 0.75 
D-IK8 0.75 - 0.50 0.75 0.26 0.75 0.27 1.25 1.25 1.25 1.25 
a ∑FICI, fractional inhibitory concentration index. FIC index was interpreted as follows: 
An FIC index of ≤ 0.5 is considered to demonstrate synergy. Additive was defined as an 
FIC index of 1. Antagonism was defined as an FIC index of > 4. nd, not determined. 
(MSSA): methicillin sensitive Staphylococcus aureus; (MRSA): methicillin resistant 
Staphylococcus aureus; (VRSA): vancomycin resistant Staphylococcus aureus and 










Table 5.8. Resensitization of vancomycin resistant S. aureus (VRSA) to 
vancomycin, teicoplanin and oxacillin using a sub-inhibitory concentration 
(½×MIC) of WR12 or D-IK8 
a Fold of re-sensitization: it is the ratio of the MIC of antibiotic alone divided by the MIC 
of antibiotic after re-sensitization with (½×MIC) of peptides (WR12 or D-IK8). 
 
 
 Fold of re-sensitizationa 
strain 
 
Vancomycin Teicoplanin Oxacillin 
 
VRS4 
WR12 8 32 128 




WR12 256 256 256 
D-IK8 256 256 256 
VRS12 






WR12 64 16 256 




Figure 5.1. Permeabilization of the cytoplasmic membrane of MRSA USA300 as a 
function of peptide concentration. 
Permeabilization is indicated by percent of calcein leakage for 60 min exposure. The 
results are given as means ± SD (n = 3; data without error bars indicate that the SD is too 
small to be seen). Permeabilization of the cytoplasmic membrane of MRSA USA300 as a 




Figure 5.2. The kinetics of killing of peptides and antibiotics against logarithmic, 
persister cells and stationary phase of MRSA USA300. 
 
(a) Logarithmic phase of MRSA USA300 exposed to peptides (WR12, D-IK8) at 5X and 
10X MIC or (b) antibiotics at 10X MIC. (c) The kinetics of killing of persister cells and 
(d) stationary phase of MRSA USA300 exposed to peptides (WR12, D-IK8) and 
antibiotics at 10X MIC. In figure 1c, CIP means treatment of MRSA with ciprofloxacin 
at 10X MIC for 6 hr then the surviving persisters were exposed to peptides or antibiotics 
at 10X MIC as the arrow pointed. Untreated samples served as a control. Abbreviations, 
Van, vancomycin; Lin, linezolid; Cip, ciprofloxacin. The results are given as means ± SD 
(no=3); data without error bars indicate that the SD is too small to be seen. 
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Figure 5.3. The effect of peptides on staphylococcal biofilms Peptides (WR12, D-
IK8 and LL-37) and antibiotics (vancomycin & linezolid) investigated against 24 hr 
(a&c) and 48 hr (b&d) old biofilms of S. aureus (a&b) and S. epidermidis (c&d). 
The adherent biofilm stained by crystal violet, then the dye was extracted with ethanol, 
measured at 595 or 490 nm absorbance and presented as percentage of biofilm reduction 
compared to untreated wells “control”. All experiments were done in triplicate for 
statistical significance. The two tailed Student t test, was used to determine statistical 
significance between two groups. One asterisk (*) indicates statistically different than 
control (p < 0.05). Symbol (#) indicates statistically different than the antibiotic treated 
wells (p < 0.05).  



















































































































































































































































































































Figure 5.4. Survival and permeabilization of the cytoplasmic membrane of VRS10 
after treatment with 0.5 X MIC of WR12 and D-IK8. 
 
Membrane permeabilization is indicated by percent of calcein leakage after 60 min 
exposure to peptides. Bacterial count of VRS10 is presented as columns. The results are 
given as means ± SD (n = 3; data without error bars indicate that the SD is too small to be 
seen). 
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Figure 5.5. Sub-inhibitory concentration of WR12 and D-IK8 increase the uptake 
and binding of fluorescently labeled vancomycin (bodipy vancomycin). 
 
VRSA (VRS10) was incubated with sub-inhibitory concentration of WR12 and D-IK8 for 
one hour or left untreated. Then treated with bodipy vancomycin for 30 minutes. Bacterial 
pellets were fixed with 4% paraformaldehyde, and visualized under 40X oil objective of 






Figure 5.6. Toxicity (a) and intracellular anti-staphylococcal activity (b) of peptides 
in human keratinocyte (HaCaT). 
 
 Cytotoxicity assay showing the percent mean absorbance at 490 nm after incubating 
human keratinocyte (HaCaT) with peptides (WR12 and D-IK8) at different concentrations. 
Sterile water (peptide diluent) served as negative control. Cell viability was measured by 
MTS assay. EC50 is the half maximal effective concentration which equal 128 µM for 
WR12 and >256 µM for D-IK8. Results are expressed as means from three measurements 
± standard deviation. (b) The effect of (WR12 and D-IK8) and antibiotics (vancomycin & 
linezolid) to kill MRSA USA300 (left panel) and MSSA ATCC 6538 (right panel) inside 
HaCaT cells after treatment with 4 X MIC for 24 hr in DMEM +10 % FBS. Statistical 
analysis was calculated using one-way ANOVA, with post hoc Tukey’s multiple 
comparisons test. P values of ˂ 0.05 were considered significant. One asterisk (*) 
indicates significance from control negative.  Two asterisk (**) indicates significance 
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Figure 5.7. Internalization studies of WR12 inside macrophage cells. 
 
 Confocal images demonstrate cell penetration of WR12-FITC (10 µM) inside 







Figure 5.8. Efficacy of peptides and control antibiotics in bacterial load (a) and 
level of pro-inflammatory cytokines (b&d) in a murine model of MRSA skin 
infection. 
Mouse was injected with the highly virulent MRSA USA300. After injection, mouse 
developed an abscess at the local site of injection over the back which further developed 
into an open wound within 48 hr from infection. Two days after the start of infection, mice 
were treated twice daily for 3 days either topically with fusidic acid (2%), D-IK8 (2%), 
WR12 (2%) formulated in petroleum jelly; or orally with linezolid (25 mg/kg). Petroleum 
jelly alone served as negative control. Figure (a) show the average log count of MRSA 
after treatment. Figure (b&c) show the effect of peptides on production of anti-
inflammatory cytokines (TNF-α and IL-6) in MRSA skin lesions. Tissue homogenate 
supernatants were examined for cytokine production using ELISA. Cytokine levels were 
expressed as percent change relative to negative control. The two tailed Student t test, was 
used to determine statistical significance between two groups (a P value of < 0.05 was 
considered significant). One asterisk (*) indicates significance from control negative. 
Symbol (#) indicates statistically different than the antibiotic treated mice (p < 0.05).  
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CHAPTER 6. A SHORT D-ENANTIOMERIC ANTIMICROBIAL 
PEPTIDE WITH POTENT IMMUNOMODULATORY AND 
ANTIBIOFILM ACTIVITY AGAINST MULTIDRUG-
RESISTANT PSEUDOMONAS AERUGINOSA AND 
ACINETOBACTER BAUMANNII 
(Mohamed, M.F., Brezden A. Mohammed H, Chmielewski J, and Seleem, M.N (2016). 
A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and 
antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and 
Acinetobacter baumannii. Submitted to Antimicrobial agents and chemotherapy, under 
review) 
6.1 Abstract 
The emergence of resistance of Pseudomonas aeruginosa and Acinetobacter baumannii 
to critical antibiotics, including colistin and carbapenems, represents a serious medical 
threat. Antimicrobial peptides (AMPs) represent a promising therapeutic alternative for 
treatment of bacterial infections. Herein, the antimicrobial activity of a short α-helical 
peptide, RR, was markedly improved through systematic modifications made to this 
peptide’s primary structure. From the peptides designed in this study, RR4 and its D-
enantiomer, D-RR4, were the most potent analogues with at least 32-fold improvement in 
antimicrobial activity observed. The MIC50 of D-RR4 was 2 and 4 µM against multidrug-
resistant strains of A. baumannii and P. aeruginosa, respectively. Interestingly, D-RR4 
demonstrated potent activity against colistin-resistant, cystic fibrosis strains of P. 
aeruginosa indicating a potential therapeutic advantage of this peptide over several 
AMPs. In contrast to many natural AMPs, D-RR4 retained its antimicrobial activity under 
challenging physiological conditions (high salts, serum, and acidic pH). Furthermore, D-
RR4 was superior in disrupting adherent biofilms of A. baumannii and P. aeruginosa 
when compared to conventional antibiotics. Remarkably, D-RR4 demonstrated strong 
synergy with colistin, meropenem and cefotaxime, even in the case of meropenem and 
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cefotaxime-resistant isolates. Of note, D-RR4 was able to bind to LPS to reduce the 
endotoxin-induced proinflammatory cytokine response in macrophages. Finally, D-RR4 
protected Caenorhabditis elegans from lethal infections of P. aeruginosa and A. 
baumannii and enhanced the activity of colistin in vivo against colistin-resistant P. 
aeruginosa. The present study confirms D-RR4 possesses potent antimicrobial, 
antibiofilm and immunomodulatory activity that warrants further investigation. 
6.2 Introduction 
The emergence and spread of Pseudomonas aeruginosa and Acinetobacter baumannii 
strains exhibiting resistance to numerous antibiotics represents a serious global medical 
threat (1-3). P. aeruginosa has been linked to serious human illnesses including 
postoperative and burn wound infections, urinary tract infections, chronic leg ulcers, otitis 
and keratitis (4). Cystic fibrosis (CF) patients are particularly susceptible to pseudomonas 
infections that lead to progressive loss of lung function and premature death (5, 6). A. 
baumannii, like P. aeruginosa, has been associated with burn wound infections in addition 
to invasive syndromes such as ventilator-associated pneumonia and urinary tract 
infections (7, 8). Compounding the situation further, extensively drug-resistant and 
pandrug-resistant isolates of P. aeruginosa and A. baumannii have been increasingly 
reported worldwide (9-11). The ability of these resistant pathogens to form biofilms that 
are highly tolerant to antibiotics further aggravates the situation ultimately leading to 
persistent, recurring infections (5, 6). Furthermore, the emergence of resistance of P. 
aeruginosa and A. baumannii strains to antibacterials deemed agents of last resort, 
including colistin and carbapenems, presents an alarming challenge; this necessitates the 
development of novel therapeutic alternatives to traditional antibiotics in order to address 
this scourge (12-14).  
Currently, there is significant interest in antimicrobial peptides (AMPs) as novel 
therapeutic alternatives to conventional antibiotics. AMPs are major constituents of the 
host innate defense system for most organisms. AMPs possess several unique features that 
support their utility as antibacterial agents including possessing rapid bactericidal activity 
against a wide spectrum of pathogenic bacteria. Additionally, AMPs are typically not 
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susceptible to the same mechanisms that confer resistance to traditional antibiotics (15). 
However, naturally-derived AMPs do possess limitations that have hindered their 
translation as clinically useful agents including, moderate antimicrobial activity, toxicity 
to host tissues, intolerance to physiological conditions, sensitivity to enzymatic 
degradation, and high manufacturing costs due to their complex design and long length of 
amino acids (16-18). Furthermore, recent studies have reported that high salt and 
abnormally reduced pH in the airway surface liquid of CF patients inhibits the 
antimicrobial activity of host defense peptides including LL-37 and β-defensins leading 
to P. aeruginosa associated pulmonary infections in CF patients (18-20). Thus, successful 
translation of AMPs into the clinic requires that limitations due to inactivation by 
proteases and physiological conditions be overcome. 
We have recently identified a small synthetic peptide, RR (12 amino acids), with 
potent efficacy against methicillin-resistant Staphylococcus aureus both in vitro and in a 
murine staphylococcal skin infection model (21, 22). However, the antimicrobial activity 
of RR against Gram-negative pathogens is very weak. In the present study, we designed 
modified derivatives of RR to enhance the peptide’s potency and spectrum of 
antimicrobial activity while also reducing toxicity to eukaryotic cells.  The analogues of 
RR were subsequently examined against a collection of important multidrug-resistant 
strains of P. aeruginosa and A. baumannii. The stability of the newly constructed 
derivatives to proteolytic degradation and inactivation by salts and serum was confirmed. 
Additionally, the mechanism of action and immune-modulatory activity of the new 
peptides was explored. Furthermore, the peptides’ ability to eradicate preformed biofilm 
and to clear an intracellular infection was examined. Finally, the antibacterial activity of 
the most promising analogue, D-RR4, was investigated in vivo in a Caenorhabditis 
elegans model of bacterial infection. Taken altogether, our findings indicate that D-RR4 
is a promising AMP that warrants further investigation as an alternative therapeutic agent 




6.3 Materials and methods 
Bacterial isolates, peptides and reagents 
Clinical isolates of P. aeruginosa and A. baumannii are presented in Tables 1 and 2. 
Peptides were synthesized using solid-phase 9-fluorenylmethoxy carbonyl (Fmoc) 
chemistry (GenScript, Piscataway, NJ). Peptides were purified to a purity of 95% using 
reverse-phase high-performance liquid chromatography (HPLC). The correct peptide 
mass was confirmed via mass spectrometry. Melittin was purchased from Sigma-Aldrich 
(St. Louis, MO). Antibiotics were purchased from commercial vendors; proteinase K and 
Mueller-Hinton broth (MHB) were purchased from Sigma-Aldrich (St. Louis, MO). 
Trypsin was purchased from VWR (Arlington Heights, IL). The ENLITEN™ ATP Assay 
System and MTS reagent were purchased from Promega (Madison, WI, USA). Enzyme-
linked immunosorbent assay (ELISA) development kits for cytokines detection were 
purchased from R&D Systems, Inc. (Minneapolis, MN). 
 Determination of minimum inhibitory concentration (MIC) values 
The broth microdilution technique was utilized to assess the minimum inhibitory 
concentrations of designed peptides according to the guidelines of the Clinical and 
Laboratory Standards Institute (CLSI) (23). P. aeruginosa and A. baumannii isolates were 
diluted to 5×105 colony forming unit (CFU/ml) in MHB. The designed peptides were 
added to 96-well plates at specified concentrations and subsequently serially diluted. The 
MIC was defined as the smallest concentration of peptide that prevented visual bacterial 
growth. MIC was done in triplicate and was repeated twice independently. 
Circular dichroism spectroscopy (CD) 
Data were recorded on a Jasco circular dichroism spectropolarimeter (Model J810) at 
25 °C using a 1 mm path length quartz cell. The spectra were averaged over three scans 
taken from 250 to 190 nm, with a data pitch and bandwidth of 1 nm, at a scan rate of 20 
nm/min. All peptides were analyzed at 50 µM concentration in deionized water, 30 mM 
sodium dodecyl sulfate (SDS), or 30% trifluoroethanol (TFE) in water (mimicking a 




Resistance to proteolytic digestion by mammalian and bacterial proteases 
To examine the ability of peptides to resist proteolytic digestion by mammalian and 
bacterial proteases, RR4 and D-RR4 were incubated with trypsin or proteinase K at a 
molar ratio of 500: 1 (peptide: enzyme), respectively, in digestion buffer (50 mM Tris–
HCl, pH 7.4) at 37 °C for 4 hours. After incubation, the digestion mixture was heated at 
80°C for 10 minutes to halt the enzymatic reaction. After treatment, the MIC of the 
peptides was examined using the broth microdilution assay described above. Experiments 
were performed using triplicate samples for each peptide tested. Next, the stability of 
peptides to protease degradation was examined using HPLC as described previously (26). 
Resistance to salts, plasma and serum  
The activity of the designed peptides in different environmental conditions including salts, 
serum and plasma, was evaluated using the broth microdilution assay explained above. P. 
aeruginosa PAO1 was treated with peptides under specific physiological conditions as 
noted here: 100 mM NaCl, 150 mM NaCl, 2% human serum, 5% human serum, 2% FBS, 
5% FBS, 10% FBS, 2% human plasma, and 5% human plasma. The MIC was also 
determined at pH 5.5 and pH 6.5.  
Time-kill assay against logarithmic and stationary phase bacteria  
P. aeruginosa PAO1 and A. baumannii ATCC BAA-1605 were grown in MHB with 
aeration at 250 rpm at 37 ºC overnight. Bacteria were subsequently diluted in fresh MHB 
and incubated aerobically at 37 ºC until the suspension reached logarithmic phase of 
growth (OD600 = 0.2). Next, bacteria were diluted to 5×10
5 CFU/ml in MHB. Peptides (at 
5 × and 10 × MIC) and antibiotics (at 5 × MIC) were added to diluted bacteria, and 
incubated aerobically at 37 ºC in a shaking incubator at 250 rpm. Aliquots at specified 
time points were taken, serially diluted in phosphate-buffered saline (PBS) and plated in 
triplicate on tryptic soy agar (TSA). CFUs were counted after incubation of plates for 24 
hours at 37 ºC. In order to determine the kinetics of killing against stationary phase 
bacteria, P. aeruginosa PAO1 and A. baumannii ATCC BAA-1605 were grown in MHB 
with aeration at 250 rpm at 37 ºC overnight. Bacteria were subsequently exposed to 
peptides and antibiotics at 10 × MIC. Aliquots were taken and plated as described above. 
149 
 
Mechanism of action studies 
a) Outer membrane permeabilization assay 
Permeation of the bacterial outer membrane by peptides was assessed using the non-polar 
fluorescent dye 1-N-phenylnaphthylamine (NPN) as described elsewhere (27). P. 
aeruginosa PAO1 in logarithmic growth phase was centrifuged for 10 minutes at 4000 × 
g, washed, and adjusted to OD600 of 0.5. A small aliquot (100 µl) of bacteria was added 
to black wall 96-well plates. NPN was mixed with bacteria at a final concentration of 10 
μM. Peptides were added, in triplicates, at specified concentrations. Plates were monitored 
using a microplate reader (Molecular Devices, Sunnyvale, CA) at excitation and emission 
wavelengths of 350 nm and 420 nm, respectively. Data was corrected for background 
fluorescence and plotted as percentage ± standard deviation. This experiment was done in 
triplicate and was repeated twice independently. 
b) Inner (cytoplasmic) membrane permeabilization assay 
Damage of the bacterial inner (cytoplasmic) membrane after exposure to peptides was 
evaluated using the fluorescent propidium iodide dye, as described elsewhere (28). P. 
aeruginosa PAO1, in logarithmic growth phase, was centrifuged for 10 min at 4000 × g, 
washed, and adjusted to OD600 of 0.2. An aliquot (100 µl) of bacterial suspension was 
added to black 96-well plates. Propidium iodide dye was added at a final concentration of 
10 μM. Peptides were added, in triplicates, at specific concentrations. Bacteria treated 
with peptide diluent (distilled water) served as a negative control. Plates were read using 
a microplate reader at excitation and emission wavelengths of 585 nm and 620 nm, 
respectively. Data was corrected for background fluorescence and plotted as percentage ± 
standard deviation. This experiment was done in triplicate and was repeated twice 
independently. 
c) ATP leakage assay. 
ATP leakage from bacteria treated with peptides was detected using a luminescence assay 
according to the manufacturer’s instructions. P. aeruginosa PAO1 was grown to 
logarithmic growth phase, centrifuged for 10 minutes at 4000 × g, washed, and adjusted 
to an OD600 of 0.2. An aliquot (100 µl) of bacterial suspension was added to white 96-well 
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plates. Peptides were added, in duplicate, at specific concentrations and incubated for 5 
minutes at room temperature. Luciferase buffer (100 μl) was added to each well after 
incubation and luminescence was measured using a microplate reader  
d) Transmission electron microscopy 
P. aeruginosa PAO1 was grown in MHB with aeration at 250 rpm at 37 ºC overnight. 
Bacteria were subsequently diluted in fresh MHB and incubated aerobically at 37 ºC until 
the suspension reached logarithmic phase of growth. Next, bacteria were harvested by 
centrifugation, resuspended in PBS and adjusted to an OD600 ~0.2. The bacterial 
suspension was exposed to peptides, at 1 × and 10 × MIC, for 60 minutes. After treatment, 
bacteria were centrifuged and the supernatant was discarded. Bacterial pellets were fixed 
and examined with a Philips CM-100 microscope as described previously (29). 
Multi-step resistance selection 
To evaluate the ability of P. aeruginosa PAO1 to acquire resistance to the D-RR4 peptide 
and control antibiotics, a multi-step resistance selection experiment was employed. P. 
aeruginosa PAO1 was serially passaged in the presence of a sub-inhibitory concentrations 
of D-RR4 and three different classes of antibiotics, tobramycin, rifampicin, and 
ciprofloxacin for ten serial passages. The MIC was monitored daily using the broth 
microdilution assay. Results were presented as the change in MIC measurement observed 
after each passage in comparison to the initial MIC value. 
Combination studies with antibiotics 
The synergistic effect between peptides and antibiotics was performed as described 
previously with the following modification; we tested a fixed concentration of peptide, 
0.25 X MIC, which did not inhibit the growth of bacteria alone (21, 29-31). Synergism 
was done in triplicate and was repeated twice independently. 
Toxicity of peptides  
a) Toxicity of peptides against mammalian cell lines 
Peptides were assayed for potential in vitro toxicity against human keratinocytes (HaCaT) 
and murine macrophages (J774A.1) as described before (29) with the following 
modifications.  Cells were treated with peptides at various concentrations for 24 hours. 
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The therapeutic index of the peptides was calculated as the ratio of mammalian EC50 (the 
concentration of peptide which inhibits growth of 50% of mammalian cells) to the MIC50 
of peptides against bacteria. When there was no detectable cytotoxicity at 256 µM, we 
used the higher value (512 µM) to calculate the therapeutic index. Larger values of the 
therapeutic index indicate greater cell selectivity of peptides (32) . 
b) Hemolysis assay  
Peptides were assayed for hemolytic activity against human red blood cells as described 
previously (21). 
Efficacy of peptides on bacterial biofilms 
To examine the peptides’ ability to disrupt bacterial biofilms, the microtiter dish biofilm 
formation assay was employed (33). Briefly, overnight cultures of P. aeruginosa PAO1 
and A. baumannii ATCC BAA-1605 were diluted 1:100 in M63 minimal medium 
supplemented with magnesium sulfate, glucose and casamino acids. Bacterial suspensions 
were incubated in 96-well plates at 37 °C for 24 hours. After removing media, wells were 
rinsed with PBS and fresh MHB was added. D-RR4 peptide and selected antibiotics were 
added at concentrations range from 1X to 32X their respective MICs and plates were 
incubated at 37 °C for 24 hours. After incubation, wells were washed and stained with 
0.5% (w/v) crystal violet for 30 min. The dye was solubilized with ethanol (95%) and the 
biofilm mass was quantified at OD595. This experiment was done in triplicate and was 
repeated three times independently. 
Intracellular antibacterial efficacy of peptides in murine macrophages 
In order to assess the peptides’ ability to kill intracellular bacteria, murine macrophages 
(J774A.1) were infected, as described in previous studies (34-37). Briefly, J774A.1 was 
seeded and incubated as described above for the toxicity assessment. Following 
incubation, cells were infected with either P. aeruginosa PAO1 or A. baumannii ATCC 
19606 (multiplicity of infection 100:1) in DMEM + 10% FBS for two hours. After 
infection, the wells were washed with 200 µl media containing gentamicin (50 µg/ml) and 
further incubated for 30 minutes with gentamicin to kill any remaining extracellular 
bacteria. Drugs were diluted in DMEM + 10% FBS (to a concentration equal to 8 × MIC) 
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and added to appropriate wells. Medium alone was used as a negative control. After 
incubation, the media was aspirated and washed twice with PBS to remove any residual 
test agent. Next, 100 µl of PBS containing 0.01% triton X-100 was added to lyse J774 
cells. Subsequently, bacteria were diluted and plated on TSA plates. Plates were incubated 
at 37ºC for 16 hours. After incubation, bacteria were enumerated and analyzed. 
Experiments done in triplicate and were repeated twice independently and the average 
percent reduction of bacterial growth for each treatment regimen has been reported.  
LPS studies 
a) Binding of peptides to lipopolysaccharide, LPS (LAL assay) 
To determine if the peptides could bind to LPS, a Limulus amoebocyte lysate (LAL) kit 
(GenScript, USA Inc.) was utilized as described in previous studies (38). Peptides were 
dissolved in pyrogen-free water and serially diluted in the same solvent. The peptides were 
then incubated with one endotoxin unit (EU) of LPS at 37 °C for 30 minutes in order to 
permit the peptides to bind LPS. The reaction mixture (50 μl) was added to 50 μl of LAL 
reagent, and further incubated for 10 min. Next, 100 μl of LAL chromogenic substrate 
was added. The mixture was incubated at 37 °C for 6 minutes.  Samples were measured 
at OD545 using a microplate reader. Colistin was used as a positive control. The binding 
of peptides with LPS was expressed as percent change relative to the untreated control. 
b) Anti-inflammatory effect of peptides on LPS-stimulated macrophages  
To assess the anti-inflammatory effect of our peptides on LPS stimulated macrophages, 
J774A.1 cells were seeded and incubated as described above (for toxicity assessment). 
Next, the cells were stimulated with LPS (150 ng/ml final concentration) in the presence 
of different concentration of peptides (RR and D-RR4). Cells that were stimulated with 
LPS alone and untreated cells served as controls. Cells were incubated for six h at 37°C 
and supernatants from each treatment were collected and stored at -20°C until use. 
Cytokine detection of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in 
supernatants was performed using ELISA as described previously, per the manufacturer’s 
instructions (22). Cytokine levels were expressed as percent change relative to LPS 




 In vivo efficacy of peptides in a Caenorhabditis elegans infection model  
Infection and treatment of C. elegans was done as described previously with some 
modifications (39, 40). C. elegans AU37 [sek-1(km4); glp-4(bn2) I] was used to test the 
efficacy of peptides in vivo. This strain has a mutation in the sek-1 gene of the p38 
mitogen-activated protein kinase pathway (p38 MAPK pathway) that makes this 
particular strain more susceptible to bacterial infection (39, 40). Briefly, synchronized 
adult worms were transferred to modified NGM (0.35% peptone) agar plates seeded with 
a lawn of P. aeruginosa PAO1, colistin-resistant P. aeruginosa PAO1, or A. baumannii 
ATCC BAA-1605, for infection. After infection, worms were collected and washed with 
PBS three times. Worms (~30 per sample) were transferred either to microcentrifuge tubes 
or 96-well plates. D-RR4 and colistin (at 8 × MIC) were added, in triplicate, to all wells 
with one exception; worms treated with colistin (at 1 × MIC, equal to 128 µM) in colistin-
resistant P. aeruginosa 1109. Untreated worms served as a negative control. To assess the 
survival of infected C. elegans, worms were assessed for viability (live worms are 
sinusoidal with movement, whereas dead worms are rigid rods). In order to assess the 
bacterial load in worms, worms were washed three times with PBS and subsequently lysed 
by addition of 200 mg of 1.0-mm silicon carbide particles (Biospec Products, Bartlesville, 
OK) to each tube and vortexing for one minute. Bacteria were plated onto TSA plates 
containing 100 µg/ml ampicillin to permit the selective growth of P. aeruginosa and A. 
baumannii over Escherichia coli. Plates were incubated for 16 hours at 37°C and bacterial 
colonies were counted.  
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad 
Software, La Jolla, CA, USA). Comparison between two groups was analyzed using a 
two-tailed unpaired Student’s t-test. Comparison between three or more groups was 
analyzed using one-way ANOVA, with post hoc Tukey’s multiple comparisons test. P-




6.4 Results and discussion 
 Peptide design and antimicrobial activity  
Herein, we aimed to explore the antibacterial activity of RR against important Gram-
negative pathogens and to design modified derivatives of RR focusing on key structural 
elements that are essential for potent antimicrobial activity and reduced toxicity to 
eukaryotic cells. To address the latter aim, the following design features were considered, 
(i) peptides were designed to maintain the amphipathic helices by converging the 
hydrophobic residues on one side and the hydrophilic residues on the other side of the 
helical axis as shown in the helical wheel diagram (figure 6.1); (ii) the hydrophobic face 
of certain peptides was disrupted via inclusion of a single hydrophilic residue (lysine or 
arginine) in order to decrease toxicity and improve the selectivity toward bacteria (41, 42); 
(iii) the length of amino acids was kept short (12-14 residues) in order to reduce cost of 
production and minimize host toxicity; (iv) amino acids known to play a crucial role in 
the antimicrobial activity of RR were maintained in all modified derivatives. For example, 
tryptophan and arginine residues can improve antimicrobial activity under physiological 
conditions (e.g., salts, plasma, and serum) without negatively impacting host toxicity (24, 
43, 44); (v) the cationic net charge of the designed analogues was increased by adding one 
or more polar amino acids, particularly lysine residues, to enhance antibacterial activity 
(25, 45). The peptides were synthesized as described above, and mass spectrometry 
confirmed the expected molecular weight (Table 6.1).  
The antibacterial activity of RR and its modified derivatives was investigated against a 
collection of important multidrug-resistant strains of P. aeruginosa and A. baumannii. In 
the current study, RR displayed weak antibacterial activity against both P. aeruginosa and 
A. baumannii with MIC50 values equal to 64 µM and MIC90 values equal to 128 µM (Table 
6.2). All modified derivatives, except RR1, demonstrated improved antibacterial activity 
over RR, as discussed below.  
Modification of peptide RR, by replacing hydrophobic residues (leucine) with cationic 
residues (lysine) to generate RR1, increased the cationic charge from +5 to +7 and 
decreased the hydrophobicity from 0.45 to 0.24. As a result, RR1 was found to be inactive 
against all tested bacterial strains (MIC > 256 µM). This may be due to the inability of 
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RR1 to form an alpha helix, as was observed in the presence of membrane mimicking 
environments (figure 6. 2) due to disruption of amphipathicity when in a helical 
conformation (figure 6.1). These findings highlight that hydrophobicity is more critical 
for the antibacterial activity of helical AMPs than increasing the cationic charges. Indeed, 
the peptide with the highest helical content that maintained amphipathicity was found to 
have the most potent antibacterial activity. RR4, which also had an increased cationic 
charge, hydrophobicity and amphipathicity as compared to RR, exhibited very potent 
activity against both P. aeruginosa and A. baumannii strains with MIC50 and MIC90 values 
equal to 4 and 8 µM. This represents a 16-fold improvement in the MIC over RR. 
Replacing a lysine residue of RR4 with histidine and two leucine residues with isoleucine 
resulted in RR2, which demonstrated more potent antibacterial activity compared to RR 
(MIC50 value was equal to 4 µM and its MIC90 value was equal to 8 µM). The placement 
of two additional cationic amino acids within RR4, one within the hydrophobic face of 
the peptide, resulted in RR3. This modification increased the net charge (+8) of this 
peptide and reduced its hydrophobicity to 0.14. RR3 was found to be more potent than 
RR but less potent than RR4 and RR2, again emphasizing the importance of 
hydrophobicity in antibacterial activity of helical AMPs.  
Susceptibility of peptides to digestion by proteases serves as a major impediment to the 
clinical application of peptides (15). In order to overcome this limitation, we designed a 
D-enantiomer of the most active peptide, RR4. D-RR4 was amidated at the C-terminus in 
order to increase its cationic net charge. The MIC of D-RR4 ranged from 2 to 8 µM with 
MIC50 and MIC90 values equal to 2 and 4 µM, respectively. The antimicrobial activity of 
D-RR4 was one-fold more potent than RR4 against most P. aeruginosa strains. However, 
D-RR4 was similar to RR4 against most A. baumannii strains and one-fold less potent 
against two strains (NR-13382 and NR-17777) (Table 6.2). The reason for this minor 
discrepancy in antimicrobial activity between RR4 and D-RR4 against different bacterial 
isolates is not clear. Previously it was reported that membrane-targeting antimicrobial 
peptides work without the need for receptors and therefore D isomers have similar 
antimicrobial activity to L isomers (46). However, there are several studies that have 
reported that D isomers demonstrated different antimicrobial responses than their L 
isomer counterparts against different bacterial isolates. This may be due to the fact that 
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the backbone of D and L isomers of helical AMPs, in three-dimensional space, have 
opposite rotations and therefore their side chains would appear in different topology (47). 
For example, Papo et al reported that the antimicrobial peptide diastereomer 
(Amphipathic-1D) demonstrated improved activity (4-7 fold) over its L isomer 
(Amphipathic-1L) against all bacterial isolates (including P. aeruginosa). However, 
Amphipathic-1D demonstrated less activity (13 fold) than the L isomer against A. 
baumannii (48). Conversely, in another study, a D isoform peptide (IK8-all D) 
demonstrated improved activity (4 fold) than the L isomer (IK8-all L) against A. 
baumannii. However, IK8-all D demonstrated less activity (two- fold) than the L isomer 
against P. aeruginosa (25). 
As highlighted above, D-RR4 demonstrated the most potent antibacterial activity with a 
MIC50 value of 2 µM (3.73 µg/mL) against A. baumannii and a MIC50 value of 4 µM (7.5 
µg/mL) against P. aeruginosa. This is superior to the MIC values obtained for the natural 
derived human cathelicidin, LL-37, whose MIC50 value was found to be 4 and 32 µM (18 
and 144 µg/mL) against A. baumannii and P. aeruginosa, respectively. Bovine indolicidin 
demonstrated moderate antibacterial activity with MIC50 values of 32 and 64 µM (61 and 
122 µg/mL) against A. baumannii and P. aeruginosa, respectively.  
Circular dichroism spectroscopy (CD) 
The secondary structure of designed peptides in aqueous and membrane mimicking 
solvents (24, 25), such as TFE and SDS, was investigated using CD spectroscopy. In all, 
the peptides demonstrated a mostly random coil conformation in the aqueous solvent as 
demonstrated by a broad minimum peak at 200 nm. The starting peptide, RR, was found 
to have an increase in helical content in the presence of the membrane-mimicking solvents 
(TFE and SDS) to 20% and 12%, respectively, as determined by the mean residue 
ellipticity at 222 nm (figure 6.2). 1b). All of the modified peptides, with the exception of 
the non-amphipathic RR1, changed their conformation to some extent in the presence of 
the membrane-mimicking solvents (figure 6.2). Peptide RR2, which contained no leucine 
residues in the hydrophobic face as compared to the original RR peptide, displayed very 
modest changes in the CD spectra in the presence of the membrane-mimicking solvents. 
The pronounced maximum at 190 nm and strong minima at 208 and 222 nm displayed by 
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RR3 and RR4, however, are highly indicative of alpha helicity. RR4 was found to be 
somewhat more helical than RR with the addition of SDS and TFE, with helical contents 
of about 30%. In this study, an all D-amino acid version of the RR4 peptide (D-RR4) was 
prepared with an amidated C-terminus. As expected, the CD spectra of D-RR4 was the 
mirror image of the RR4 peptide, with mean residue ellipticities that were opposite in sign, 
but somewhat higher than RR4 with the addition of SDS and TFE (about 40% helical 
content) due to the addition of the C-terminal amide (figure 6.2). 
Antimicrobial activity against colistin-resistant P. aeruginosa  
After confirming the potent antibacterial activity of the designed peptides against relevant 
colistin-sensitive P. aeruginosa isolates, we moved to examine if the peptides’ activity 
could be retained against a panel of clinical isolates of colistin-resistant P. aeruginosa 
isolated from cystic fibrosis patients (13). Although these isolates showed high resistance 
to colistin and several natural peptides, our designed peptides retained their potent 
antibacterial activity (Table 6.3). The most potent peptide was D-RR4 with an MIC50 
value of 4 µM. This represents a 32-fold enhancement in the antimicrobial activity of this 
peptide compared to RR (MIC50 =128 µM). RR2 demonstrated improved activity over RR 
with a MIC50 value equal to 32 µM. RR3 and RR4 were found to be more potent than RR2 
with MIC50 values equal to 16 and 8 µM, respectively. However, the antimicrobial activity 
of indolicidin was abolished against all tested isolates. LL-37 showed weak to moderate 
activity against some strains (MIC50 of 64 µM), while no activity was observed against 
five colistin-resistant strains (Table 6.3). Colistin is an antibiotic of last resort for 
multidrug-resistant P. aeruginosa infections (49). The emergence of resistant isolates to 
colistin, particularly via plasmid-mediated resistance in Enterobacteriaceae (50), 
highlights the urgent need to discover new antimicrobial agents to address this issue. The 
discovery that RR4 and D-RR4 have potent activity against colistin-resistant P. 
aeruginosa isolates indicates a potential advantage of these peptides over several 
antimicrobial peptides that are ineffective against colistin-resistant P. aeruginosa (13). 
Resistance to proteolytic digestion  
To confirm the stability of D-RR4 to proteolytic digestion, we evaluated its antimicrobial 
activity after treatment with mammalian (trypsin) and bacterial (proteinase K) proteases 
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for 4 hours. As presented in Table 6.4, the antibacterial activity of the L isoform of RR4 
was completely abolished in the presence of both trypsin and proteinase K. However, the 
MIC of the D isoform of RR4 (D-RR4) was not sensitive to proteolytic degradation when 
tested against P. aeruginosa. 
We confirmed the stability of D-RR4 to proteases utilizing HPLC. As demonstrated in 
figure 6.3, incubation of the L isoform of RR4 with proteases for 4 hours led to the 
degradation of the intact peptide, resulting in multiple lower molecular weight peaks, 
hence explaining the loss of antimicrobial activity observed earlier (Table 6.4). However, 
D-RR4 remained intact after protease treatment, even after 24 hours of incubation with 
proteases (figure 6.3).  
Antimicrobial activity of designed peptides in the presence of salts, serum and acidic 
pH. 
A significant drawback of many antimicrobial peptides is their antibacterial activity is 
impaired in the presence of biological fluids (serum, plasma, high concentration of salts 
and acidic pH); this severely limits their clinical utility (16, 17). With this point in mind, 
we assessed the antibacterial activity of our peptides against P. aeruginosa PAO1 in 
several biologically relevant conditions. Overall, all designed peptides demonstrated low 
salt sensitivity (Table 6.4). All peptides showed a two-fold increase in the presence of 150 
mM NaCl. In the epithelial cell secretions of a CF patients, the NaCl concentration is 
approximately 120 mM (18); at this concentration all RR derivatives, particularly RR2, 
RR4 and D-RR4, maintained good antibacterial activity.  
Recently, several studies reported that abnormally reduced pH in the airway surface liquid 
of CF patients (pH 6.8) inhibits the antimicrobial activity of host defense peptides and 
may impair the host’s defense against pathogens (19, 20). Therefore, we assessed the 
effect of acidity on the antibacterial activity of our designed peptides by determining the 
MIC at pH 5.5 and pH 6.5. There was no significant difference in the MICs of most 
peptides at acidic pH (a one-fold decrease in MIC was observed at pH 5.5, except for RR3 
where a four-fold decrease was observed). A one-fold decrease in MIC was observed for 
RR and RR3 at pH 6.5 while no change in MIC for RR2 was observed. Interestingly, RR4 
and D-RR4 demonstrated a one-fold improvement in activity at pH 6.5 (Table 6.4).  
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In addition to salts and acidity, serum and plasma can also impair the antibacterial activity 
of conventional antibiotics and peptides either via proteolytic digestion or binding to 
protein or lipid fractions (51). We thus moved to examine whether our peptides would 
exhibit diminished activity. As presented in Table 6.4, the antimicrobial activity of most 
peptides was diminished or completely abolished in the presence of fetal bovine serum, 
human serum, and human plasma. Interestingly, D-RR4, retained its potent anti-
Pseudomonas activity under the same test conditions. We suspect D-RR4’s decreased 
susceptibility to the presence of serum is due to the resistance of the D isoform to 
enzymatic degradation, as discussed above. Given the designed peptides’, particularly D-
RR4, antibacterial activity is not significantly diminished in the presence of high salts, 
acidic pH, and serum, this indicates a selective advantage for our peptides over many 
natural and synthetic antimicrobial peptides, particularly in cystic fibrosis conditions (16, 
17). The stability of our peptide constructs in physiologically relevant test conditions, may 
be attributed to the high percentage of tryptophan and arginine residues in the peptides 
which can improve their antibacterial activity under physiologically relevant conditions 
(e.g., salts, plasma, and serum) (24, 43, 44). 
Time-kill assay against logarithmic and stationary phase bacteria 
After confirming that the AMPs possessed excellent antimicrobial activity against 
multidrug-resistant clinical isolates of P. aeruginosa and A. baumannii, we next assessed 
the killing kinetics of RR and the most promising analogue, D-RR4 against logarithmic 
phase P. aeruginosa PAO1 and A. baumannii ATCC BAA-1605. D-RR4 demonstrated 
fast and concentration-dependent killing of both bacteria (figure 6.4). At 5 × MIC, D-RR4 
reduced P. aeruginosa and A. baumannii starting inoculum by 2.1 and 2.58 log10, 
respectively, after one hour and completely eliminated both bacteria within two hours. 
Treatment with 10 × MIC of RR and D-RR4 completely eliminated both bacteria within 
one hour (figure 6.4). Similar to RR and D-RR4, colistin demonstrated rapid bactericidal 
activity. At 5 × and 10 × MIC, colistin completely eliminated P. aeruginosa PAO1 within 
one hour. However, colistin required three and two hours to eradicate A. baumannii ATCC 
BAA-1605 culture both at 5 × and 10 × MIC, respectively. Tobramycin and gentamicin, 
at 10 × MIC, demonstrated rapid bactericidal activity, eliminating P. aeruginosa PAO1 
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within three and two hours, respectively. Tobramycin, at 10 × MIC, eliminated A. 
baumannii ATCC BAA-1605 after three hours. AMPs with fast bactericidal activity have 
several advantages including limiting spread of infection, improving treatment prognosis, 
limiting the emergence of resistance, and reducing duration of treatment (52). 
Next, we examined the impact of RR and D-RR4 and select antibiotics against stationary-
phase P. aeruginosa and A. baumannii. This population of cells is known to contain a high 
percentage of persisters that are tolerant to many antimicrobial agents which can 
contribute to recurring infections (5, 53). Treatment of stationary-phase P. aeruginosa 
PAO1 with 10 × MIC D-RR4 resulted in rapid bactericidal activity (3-log10 reduction) of 
a high starting inoculum (3 × 109 CFU/ml) after three hours (figure 6.4). However, RR 
had no effect. This most likely is due to its weak antimicrobial activity against a high 
inoculum of P. aeruginosa. Conventional antibiotics had minimal impact on stationary-
phase P. aeruginosa PAO1. Tobramycin reduced the number of stationary-phase P. 
aeruginosa PAO1 by only 1.87 log10, after 24 hours of exposure, while colistin and 
gentamicin had no effect. Complete eradication of stationary-phase A. baumannii ATCC 
BAA-1605 was achieved after treatment with D-RR4 for three hours (figure 6.4). RR 
reduced the number of stationary-phase A. baumannii ATCC BAA-1605 by three-log10 
after three hours; however, regrowth of bacteria occurred after this, most likely due to 
degradation of the RR peptide. Tobramycin failed to demonstrate bactericidal activity 
(reduced the number of stationary-phase A. baumannii ATCC BAA-1605 by only 2.39 
log10). Colistin did not have any effect, which is in agreement with previous findings (54). 
The superior activity of D-RR4, when compared to conventional antibiotics, against 
stationary phase bacteria can be explained by its unique antimicrobial mechanism of 
action. Many antibiotics require bacteria to be growing and metabolically active in order 
to inhibit their molecular targets, including protein synthesis (tobramycin and gentamicin) 
(55). In contrast, as elaborated further below, the positive charge present in D-RR4 serves 
as a point of attraction with negatively-charged bacterial cell membranes and 
consequently leads to targeted disruption of the bacterial membrane and leakage of 
intracellular contents (24, 25). This unique mechanism of action of AMPs does not require 
cells to be metabolically active and is not impaired by the dormant and quiescent state of 
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bacteria (55). The results obtained provide valuable insight into using D-RR4 as a 
potential future therapeutic option for treatment of persistent bacterial infections. 
Mechanism of action of designed peptides 
In order to gain insight into the mode of bacterial killing of D-RR4, we performed a series 
of experiments to explore its antibacterial mode of action. First, damage to the bacterial 
outer membrane by D-RR4 was monitored by measuring the fluorescent intensity of P. 
aeruginosa PAO1 mixed with 1-N-phenylnaphthylamine (NPN) and incubated with 
varying peptide concentrations. As demonstrated in figure 6.5A, similar to the known 
membrane-targeting antimicrobial peptide LL-37, there was a significant and dose-
dependent increase of fluorescence intensity of P. aeruginosa cultures treated with D-RR4. 
These findings indicate that D-RR4 likely targets the bacterial outer membrane leading to 
partitioning of NPN into the outer membrane and increased fluorescence. Damage of the 
bacterial inner (cytoplasmic) membrane by peptides was monitored by measuring the 
fluorescence intensity of P. aeruginosa PAO1 mixed with propidium iodide and treated 
with D-RR4. As demonstrated in figure 6.5B, the fluorescence intensity didn’t change in 
untreated bacteria confirming cytoplasmic membrane integrity. However, when D-RR4 
and LL-37 were added to bacterial cultures, a rapid and significant increase in 
fluorescence due to access of propidium iodide inside bacteria was evident. At 10 × MIC, 
D-RR4 was faster and more potent at producing membrane perturbation in comparison to 
D-RR4 tested at 5 × MIC. To confirm our results of membrane permeabilization, we 
assayed the ATP level of bacterial cultures after exposure to D-RR4 compared to untreated 
bacteria. Physiologically, ATP is maintained inside bacterial cells with intact cell 
membranes. Leakage of ATP into the extracellular environment is indicative of membrane 
damage. As demonstrated in figure 6.5C, similar to LL-37, there was a significant increase 
in luminescence intensity of P. aeruginosa PAO1 treated with D-RR4 compared to the 
untreated control.  
To confirm the membrane-damaging effect of D-RR4 on bacteria, transmission electron 
microscopy was conducted on thin sections of P. aeruginosa PAO1 treated with two 
different concentrations of D-RR4 (figure 6.6). TEM micrographs of untreated bacteria 
revealed cell membranes that were intact and a distinct cell wall (figure 6.6 A and B). The 
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cytoplasmic region displayed a homogenous electron density. However, after exposure to 
D-RR4, severity of membrane damage was observed in a concentration-dependent manner. 
Bacteria treated with a low concentration of D-RR4 (1 × MIC) exhibited disintegrated 
membranes with blebs and an increase in the periplasmic space (figure 6.6C and D). 
Mesosomes, invaginations and condensed materials with similar electron density to that 
of the cell wall murein layer were also observed under membranes (figure 6.6C and D). 
Bacteria treated with a higher concentration of D-RR4 (10 × MIC) exhibited a more severe 
damaging effect on membranes as complete loss of membrane integrity and the cell wall 
were clearly observed (figure 6.6E, F and G). Leakage of cytoplasmic contents, which 
result in heterogeneous cytoplasmic densities, were also seen (figure 6.6E and G). Ghost 
cells due to complete loss of cytoplasmic contents were also evident at higher peptide 
concentrations (figure 6.6H). Collectively, these data confirm the membrane-destructive 
effect of D-RR4 against Gram-negative bacteria. 
Multi-step resistance selection 
To examine if the bacterial membrane-damaging effect of peptides can overcome 
traditional mechanisms of antibiotic resistance, we serially passaged P. aeruginosa PAO1 
with sub-inhibitory concentrations of D-RR4 and three different classes of antibiotics, 
tobramycin (protein synthesis inhibitor), rifampicin (RNA synthesis inhibitor) and 
ciprofloxacin (DNA synthesis inhibitor) for ten days. The MIC was determined daily 
using the broth microdilution assay. As presented in figure 6.7, P. aeruginosa PAO1 was 
not able to develop resistance to D-RR4 for ten passages. However, treatment of P. 
aeruginosa PAO1 with rifampicin induced a rapid shift in the MIC within the second 
passage and resulted in a 32-fold increase in rifampicin’s MIC by the sixth passage. The 
MIC of ciprofloxacin and tobramycin increased to 8 and 16-fold, respectively by the ninth 
passage (figure 6.7). The inability of bacteria to develop peptide resistance under 
laboratory conditions is attributed to the rapid action of peptides and their unique 
mechanism of action. Peptides disrupt bacterial membranes without the need for a specific 
receptor, so for bacteria to acquire resistance, significant changes to the membrane lipid 
composition would need to occur (56). These alterations are extremely difficult for 
bacteria to produce compared to point mutations in specific genes (15). The results of this 
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experiment, which was limited in terms of the number of passages, indicates that in vitro 
resistance emerged rapidly to several commercial antibiotics compared to D-RR4. Further 
investigation is required to validate these data in suitable animal models.  
Combination studies with conventional antibiotics 
We next investigated if peptide D-RR4 possesses a synergistic relationship with 
antibiotics, utilizing the checkerboard assay. As presented in Table 6.5, D-RR4 displayed 
potent synergistic activity when combined with colistin or polymyxin B against all tested 
bacterial isolates with FIC indices ranging from 0.38 to 0.5. Colistin is considered to have 
high nephrotoxicity rates of ∼45 to 55% under the currently recommended dosing regimen 
(57, 58). Nephrotoxicity is linked to both the total dose of colistin administered and 
duration of therapy. Decreasing the therapeutic dose of colistin required to treat bacterial 
infection (by combining it with our peptide) is beneficial as it will potentially reduce 
adverse side effects in patients receiving colistin treatment. 
Combining D-RR4 with aminoglycoside antibiotics (tobramycin, gentamicin and 
amikacin) resulted in no beneficial effect observed against P. aeruginosa strains. However, 
a synergistic relationship was evident against A. baumannii ATCC BAA-1605 with 
tobramycin and amikacin (FIC index, 0.38) but not with gentamicin (FIC index, 1.25). 
Remarkably, D-RR4 improved the activity of meropenem and cefotaxime, even in the 
case of meropenem-resistant and cefotaxime-resistant isolates of A. baumannii and P. 
aeruginosa which resulted in an 8 to 128-fold reduction in their MIC values (FIC indices 
0.26-0.38). Thus, this peptide holds promise for potentially prolonging the clinical use of 
these antibiotics against both antibiotic-sensitive and resistant strains. 
Toxicity of designed peptides 
A significant limitation for translating AMPs into clinical applications is their toxicity to 
host cells (59). Herein, we evaluated the cytotoxic effects of our peptide constructs against 
murine macrophages (J774.1A) and human keratinocytes (HaCaT cells) via the MTS 
assay. The half maximal effective concentration (EC50) of RR, RR1, RR2, RR3, RR4 and 
D-RR4 was 128/256, >256/>256, 128/64, 128/128, 64/128 and 64/64 µM, respectively, 
in the case of J774.1A / HaCaT cells (Table 6.6). Pexiganan had an EC50 equal to 64 µM 
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when tested against J774.1A cells. Melittin, however, had an EC50 equal to 2/4 µM, 
respectively, when tested against J774.1A / HaCaT cells. 
Table 6.6 also presents the therapeutic index (TI) of the peptide constructs. All modified 
derivatives displayed a higher safety window than the parent peptide, RR. The therapeutic 
index of RR is 2/4 respectively, in the case of J774.1A / HaCaT cells. RR2, RR3, RR4 
and D-RR4 have TI values equal to 32/16, 16/16, 16/32 and 32/32, respectively, in the 
case of J774.1A / HaCaT cells. These data demonstrate a 2-16 fold improvement in the 
safety window of the modified derivatives compared to RR. Pexiganan demonstrated a 
similar therapeutic index to D-RR4 (TI = 32).  On the other hand, melittin exhibited a very 
low therapeutic index of 0.25/0.5 in the case of J774.1A / HaCaT cells, respectively. This 
indicates the superior safety profile of our peptide constructs over this naturally-produced 
AMP. 
Next, we assessed the hemolytic activity of the peptides on human red blood cells (RBCs). 
As demonstrated in Table 6.6, The HC50 (the peptide concentration that causes 50% 
hemolysis of RBCs) for all peptides is equal to or more than 256 µM. Peptide D-RR4 
demonstrated the highest selective index (TI = 128) compared to RR (TI = 8). This 
translates to a 16-fold improvement in selectivity towards prokaryotic versus eukaryotic 
cell membranes. Previous reports indicate that pexiganan has a HC50 value in the range of 
120-208 µM (60, 61).  In contrast, melittin possessed a very low HC50 (4 µM) equal to ½ 
× MIC of melittin against P. aeruginosa (TI = 0.5). The low toxicity of designed peptides 
against mammalian cells in relation to their potent antimicrobial activity suggests the 
peptide constructs exhibit selectivity towards the negatively-charged bacterial membranes 
compared to the zwitterionic mammalian membranes.   
Efficacy of peptides on established biofilms 
Biofilms are aggregated bacterial communities covered by a polysaccharide matrix that 
protects bacteria from host immune defenses and hinders antibiotics from targeting deep-
seated bacteria encased within the biofilm (62). Biofilm development has been linked to 
serious biofilm-related infections including pneumonia in cystic fibrosis patients and 
colonization of medical devices (63). Biofilms of A. baumannii permit this pathogen to 
survive on abiotic equipment in hospital settings. This facilitates contact with susceptible 
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patients and has led to outbreaks of ventilator-associated pneumonia (7). Biofilms pose a 
serious medical challenge, that is difficult to control and there is a critical need to find 
novel approaches to address this problem. We examined the capability of the most 
promising peptide analogues, RR4 and D-RR4, and control antibiotics to disrupt 
established biofilms of P. aeruginosa PAO1 and A. baumannii ATCC BAA-1605. As 
shown in figure 6.8, RR4 and D-RR4 disrupted mature (24 hour) biofilms more potently 
than several antibiotics of choice. RR4 and D-RR4 demonstrated a concentration-
dependent biofilm-disrupting activity. RR4, at 4, 8, 16 and 32 × MIC, disrupted more than 
31, 39, 41 and 61% of biofilm mass, respectively (p < 0.05). D-RR4 disrupted more than 
30%, 40%, 60% and 75% of biofilm mass, respectively (p < 0.05), at the same 
concentrations. Colistin reduced more than 10%, 25%, 28%, and 75% of biofilm mass, 
respectively (p < 0.05), at the same concentrations. Gentamicin and tobramycin required 
a concentration equal to 32 × MIC to disrupt 50% of biofilm mass (p < 0.05). 
Remarkably, RR4 and D-RR4 were capable of reducing 20-35% of P. aeruginosa biofilm 
mass at very low concentrations equivalent to 0.5 - 1 × MIC, respectively. In contrast, low 
concentrations of gentamicin and tobramycin enhanced biofilm production (100 - 240% 
increase compared to untreated samples), which is in agreement with previous findings 
(64). 
When examining RR4 and D-RR4 against A. baumannii biofilm, a concentration-
dependent activity was observed (figure 6.8). At 8, 16 and 32 × MIC, RR4 disrupted more 
than 45%, 57% and 66% of biofilm mass, respectively (p < 0.05). D-RR4 reduced 40%, 
58% and 76% of biofilm mass, respectively (p < 0.05) at the same tested concentrations. 
Colistin reduced the biofilm mass by 10%, 36% and 51%, respectively (p < 0.05), at the 
same tested concentrations. Tobramycin, at 32 × MIC, disrupted only 20% of the biofilm 
mass (p < 0.05) while gentamicin was not effective as this strain is resistant to gentamicin 
(figure 5).  Collectively, the data demonstrates that peptides RR4 and D-RR4 are superior 
to conventional antibiotics in penetrating and disrupting adherent P. aeruginosa and A. 
baumannii biofilms.  
Recently, multiple AMPs have been reported that demonstrated potent antibiofilm 
activities compared to conventional antibiotics. For example, de la Fuente-Nunez et al. 
reported a potent broad-spectrum antibiofilm peptide (peptide 1018), despite its weak 
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antimicrobial activity against planktonic bacteria (65). The antibiofilm mechanism of 
peptide 1018 was through binding and degradation of the stress-related second messenger, 
guanosine pentaphosphate (pppGpp) (65). The same group designed a series of more 
potent antibiofilm peptides that work by the same mechanism. The most potent antibiofilm 
peptides in the series were two D enantiomeric peptides (DJK-5 and DJK-6). They were 
proteolysis-resistant and protected invertebrates from lethal P. aeruginosa infections (47). 
Another group of researchers reported a de novo engineered cationic antimicrobial peptide 
(WLBU2) that reduced P. aeruginosa biofilm growth on CF airway epithelial cells and 
protected mice from lethal P. aeruginosa infections (66, 67). 
Intracellular antibacterial activity of peptides in murine macrophages 
P. aeruginosa and A. baumannii were considered to be primarily extracellular pathogens 
for many years. However, recent studies have revealed that these pathogens can gain entry 
and persist inside both phagocytic and non-phagocytic eukaryotic cells such as alveolar 
macrophages and lung epithelial cells (35-37). The intracellular persistence of pathogens 
constitutes a significant challenge as they are able to avoid host immune defenses. 
Additionally, intracellular pathogens evade the action of many antibiotics that exhibit low 
intracellular penetration ability such as aminoglycosides and colistin (35). Eradication of 
these challenging bacterial pathogens is critical to ensure successful treatment of 
persistent intracellular bacterial infections. Here, we investigated if our designed peptides 
have the ability to kill intracellular P. aeruginosa and A. baumannii residing in murine 
macrophages. As demonstrated in figure 6.9, the D isoform of RR4, but not the L form, 
showed significant reduction of intracellular P. aeruginosa and A. baumannii at nontoxic 
concentrations. D-RR4 showed the maximum efficacy as it killed 96.00% ± 1.15 and 
100.00% ± 0.00 of intracellular P. aeruginosa PAO1 and A. baumannii ATCC 19606, 
respectively, at 8 × MIC. In contrast, the L isoform of RR4 produced a 14.60 % ± 5.50 
and 25.00% ± 8.90 reduction of intracellular P. aeruginosa PAO1 and A. baumannii 
ATCC 19606, at 8 × MIC. The enhanced efficacy of D-RR4 compared to RR4 may be 
related to its resistance to proteolysis by serum and other cellular enzymes, as described 
earlier. The potent intracellular activity of D-RR4 may be useful in treating certain chronic 
diseases such as cystic fibrosis where P. aeruginosa persists inside eukaryotic cells as 
pods leading to failures to antibiotic therapy (36). 
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Lipopolysaccharide (LPS) studies 
A) Binding of peptides to LPS (LAL assay) 
A key virulence factor unique to Gram-negative bacterial pathogens is the presence of 
lipopolysaccharide (LPS). LPS is a principal structure of the outer membrane of Gram-
negative bacteria. During bacterial death, cell replication or exposure to certain antibiotics, 
LPS is released from bacteria leading to stimulation of proinflammatory cytokine release 
such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) from mononuclear 
phagocytes. Excessive LPS exposure leads to overproduction of these cytokines which 
can result in septic shock and death. Annually there are 18 million cases of septic shock 
globally with a mortality rate of ~30% (68, 69). Therefore, identifying agents that are 
capable of neutralizing LPS is critical.  
We investigated if our peptides could bind to and neutralize the effect of LPS. As 
presented in figure 6.10A, RR and its analog, D-RR4 were able to bind to LPS in vitro as 
evident by inhibition of the LPS-induced activation of the LAL enzyme 
(Limulus amoebocyte lysate). RR produced a 21.3%, 43.2%, 59.6% and 82.4% inhibition 
of the LAL enzyme at 5, 10, 15 and 20 µM, respectively. D-RR4 demonstrated a more 
significant inhibition than RR, producing a 42.0%, 67.3%, and 85.6% reduction at 5, 10 
and 15 µM, respectively. Complete inhibition was achieved at 20 µM. We suspect the 
high cationic charge of D-RR4, in relation to RR, is responsible for the enhanced binding 
affinity of this peptide to LPS. Colistin, a known LPS binding agent, showed significant 
inhibition generating a 51.2% and 83.0% reduction at 5 and 10 µM. Complete inhibition 
of LPS-induced activation of the LAL enzyme was achieved at both 15 and 20 µM (figure 
6.10A).  
B) Anti-inflammatory effect of peptides on LPS stimulated macrophages 
(neutralizing the effect of LPS on macrophages) 
Next, we examined if RR and D-RR4 could reduce the endotoxin-induced 
proinflammatory cytokine response in murine macrophages by measuring cytokine levels 
using ELISA. As depicted in figure 6.10B, RR and its analog, D-RR4 were able to inhibit 
LPS-induced proinflammatory cytokines in macrophages in a manner similar to colistin. 
The inhibition of cytokine production was found to be concentration-dependent. RR, at 
10 µM, decreased TNF-α and IL-6 levels by 24.4% and 75.4%, respectively. At 20 µM, 
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RR inhibited 84.0% and 96.5 % of TNF-α and IL-6 production, respectively. At 10 µM, 
D-RR4 was superior to RR as it decreased TNF-α and IL-6 production by 64.7% and 96.4% 
of TNF-α and IL-6 production, respectively. At 20 µM, D-RR4 inhibited 85.6% and 96.5% 
of TNF-α and IL-6 production, respectively. Colistin, as expected, produced a >95% 
inhibition of both cytokines at the tested concentration (10 and 20 µM) (figure 6.10B). 
The capability of the designed peptides to reduce endotoxin-mediated proinflammatory 
cytokine production provides a potential avenue for their development as antibacterial 
agents to treat sepsis and also as an adjunctive with antibiotics to overcome sepsis.  
In vivo efficacy of peptides in a C. elegans infection model.  
To test the efficacy of the synthetic peptides to protect against infections in vivo, we 
utilized a C. elegans model of bacterial infection. This model has been used extensively 
for early-stage evaluation of promising antimicrobials (47, 70, 71). Initially, the lethal 
dose of D-RR4 against uninfected nematodes was determined. D-RR4 and colistin were 
not toxic to worms at 8 × MIC (figure 6.11A). D-RR4 and pexiganan at 32 × MIC killed 
approximately 50% of worms after 4 days (figure 6.11A). However, melittin completely 
killed C. elegans after 3 days which is in agreement with its known toxicity to mammalian 
cells. Therefore, a nontoxic concentration of D-RR4 (8 × MIC) was selected for worm 
efficacy studies.   
 
 
We next evaluated the ability of D-RR4 to reduce the bacterial burden inside the gut of 
infected worms. As demonstrated in figure 6.11B, D-RR4 produced a significant 
reduction of P. aeruginosa PAO1 at 8 × MIC (85%). Similarly, colistin (8 × MIC) 
produced an 89% reduction in bacterial load. Potent synergism was evident when D-RR4 
was combined with colistin as complete clearance of bacteria from worms was achieved. 
Next, we evaluated their activity against a colistin-resistant P. aeruginosa 1109 strain 
isolated from a CF patient. Colistin was unable to significantly decrease bacterial burden, 
in contrast to D-RR4, which produced a 75% reduction. Interestingly, the combination of 
D-RR4 and colistin showed enhanced killing as the combination reduced 98% of colistin-
resistant P. aeruginosa in infected worms (figure 6.11B). When the same test agents were 
evaluated against A. baumannii, a similar pattern was observed. D-RR4 and colistin, 
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independently decreased bacterial burden by 95% and 96%. When the two agents were 
tested in combination, a complete eradication of bacterial load was observed (figure 
6.11B). 
Bolstered by these results, we next examined whether D-RR4 could protect infected 
worms from the cidal activity of bacteria. Interestingly, P. aeruginosa PAO1 killed 80% 
of untreated worms after 24 hours and 100% mortality was observed after 36 hours (figure 
6.11C). D-RR4 and colistin significantly increased the rate of survival for Pseudomonas-
infected C. elegans in contrast to untreated worms, giving nearly complete protection for 
24 and 36 hours. A 65% to 72% protection was observed up to 48 hours. A combination 
of D-RR4 and colistin showed complete protection of worms even up to 48 hours (figure 
6.11C). 
The survival experiment with C. elegans was next utilized to examine the impact of 
colistin-resistant P. aeruginosa 1109. As expected, this strain demonstrated higher 
virulence than PAO1 as it completely killed C. elegans after 24 hours. While colistin failed 
to protect worms from killing, D-RR4 significantly increased the survival rate of C. 
elegans giving nearly complete protection after 24 hours and 85% and 47% protection 
after 36 and 48 hours, respectively. Interestingly, a combination of D-RR4 and colistin 
showed enhanced protection as they showed complete protection of worms after 24 and 
36 hours and 75% protection after 48 hours (figure 6.11C). 
A. baumannii killed worms more slowly than P. aeruginosa, killing 75% and 95% of 
worms after 48 and 72 hours, respectively. A notable protective effect was provided by 
D-RR4 and colistin as they showed complete protection of worms after 36 hours and 80-
85% protection after 72 hours. Consistent with in vitro data, the combination of D-RR4 
and colistin showed complete protection up to 72 hours (figure 6.11C). 
6.5 Conclusion 
The worldwide increase of antibiotic resistance and limited supply of new antibiotics 
necessitates the discovery and development of novel alternatives to address this 
burgeoning challenge. In the present study, we designed modified derivatives of a short 
synthetic peptide, RR, to enhance its potency and spectrum of activity against Gram-
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negative pathogens. RR4 and its D-enantiomer, D-RR4, were the most potent analogues 
of RR, highlighting the significance of hydrophobicity and amphipathicity in the 
antimicrobial activity of AMPs against Gram-negative bacteria. These modifications 
successfully improved the antibacterial activity of D-RR4 against both multidrug-resistant 
P. aeruginosa and A. baumannii and also stabilized D-RR4 to the effect of high salts, 
acidic pH, human serum, and both bacterial and mammalian proteases. This indicates a 
selective advantage of our peptides over many natural and synthetic antimicrobial peptides. 
D-RR4 was found to exert its antibacterial activity via disruption of both the outer and 
inner membranes of the cell envelope. However, no adverse toxic effect was observed to 
mammalian cells at concentrations 16 times higher than the MIC, indicating D-RR4 
possesses an enhanced safety profile compared to RR. Moreover, D-RR4 displayed a 
lower propensity to select for resistant bacteria compared to conventional antibiotics. In 
addition to its potent antibacterial activity, D-RR4 demonstrated significant disruption of 
established bacterial biofilms more than conventional antibiotics, even at subinhibitory 
concentrations. Furthermore, D-RR4 was capable of binding strongly to LPS and 
subsequently reduced the endotoxin-mediated proinflammatory cytokine production in 
murine macrophage cells. This discovery highlights a potential avenue for development 
of D-RR4 to treat sepsis. D-RR4 also significantly reduced the burden of intracellular P. 
aeruginosa and A. baumannii highlighting the potential application of D-RR4 for 
treatment of certain chronic diseases, such as cystic fibrosis, where P. aeruginosa persists 
inside eukaryotic cells. Finally, D-RR4’s potent antibacterial activity, alone and in 
combination with colistin, was confirmed in vivo as it significantly reduced the bacterial 
burden inside the gut of infected C. elegans and increased the rate of survival for 
nematodes infected with either P. aeruginosa or A. baumannii. Collectively, the unique 
antibacterial, antibiofilm, and anti-inflammatory properties of D-RR4 warrant further 
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RR WLRRIKAWLRR 11 1553.92 1553.91 +5 54 % 0.453 0.831 
RR1 WKRRIKIWKKIR 12 1711.17 1711.16 +7 41 % 0.242 0.659 
RR2 WIRRIKKWIRRVHK 14 1975.46 1975.45 +7 42 % 0.303 0.901 
RR3 WLRRIKAWLRRKRK 14 1966.45 1966.44 +8 42 % 0.142 0.652 
RR4 WLRRIKAWLRRIKA 14 1866.33 1866.32 +6 57 % 0.436 0.759 
D-
RR4 
wlrrikawlrrika-NH2 a 14 1866.33 1866.32 +7 57 % 0.436 0.759 











Table 6.2. Minimum inhibitory concentration (MIC) (µM) of peptides against 



























































PAO1 64 >256 4 8 4 2 16 64 0.5 
ATCC 9721 64 >256 8 16 8 4 32 >256 0.5 
ATCC BAA-
1744 
128 >256 16 16 8 8 32 64 0.5 
ATCC 27853 64 256 8 8 8 4 16 64 0.25 
ATCC 35032 64 >256 16 16 8 4 128 >256 0.5 
ATCC 25619 64 >256 8 4 8 4 16 >256 0.25 
ATCC 9027 64 >256 4 4 4 2 16 32 0.25 
ATCC 15442 128 >256 16 16 8 4 32 64 0.25 





32 >256 4 16 2 2 4 32 0.25 
ATCC 19606 16 >256 2 16 2 2 2 8 0.125 
ATCC BAA-
747 
64 >256 4 8 2 2 8 32 0.25 
NR-9667 32 >256 4 32 4 4 4 32 0.0625 
NR-13374 32 128 4 8 4 4 4 8 0.125 
NR-13375 32 >256 2 8 2 2 4 32 0.125 
NR-13382 32 >256 4 16 4 8 4 32 0.5 
NR-17777 16 >256 4 8 2 4 4 32 0.5 
NR-17778 16 >256 4 8 2 2 4 32 0.0625 
NR-17780 32 >256 4 8 2 2 4 32 0.25 
NR-17783 32 >256 4 8 4 4 4 16 0.0625 
NR-17784 64 >256 4 4 2 2 4 64 0.0625 
NR-17785 32 >256 4 8 2 2 4 32 0.25 
NR-17786 16 >256 4 4 2 2 4 16 0.0625 
NR-19298 32 >256 2 4 2 2 2 8 0.25 
NR-19299 64 >256 4 32 4 4 8 64 0.25 
MIC50  64 >256 4 8 4 2 4 32 0.25 




Table 6.3. Minimum inhibitory concentration (MIC) (µM) of peptides against 
clinical isolates of colistin resistant P. aeruginosa isolated from cystic fibrosis 
patients. 
 
strain RR RR1 RR2 RR3 RR4 D-RR4 LL-37 Indolicidin Colistin 
1109 128 >128 16 8 4 2 64 >128 128 
1125 128 >128 32 32 8 4 128 >128 32 
1571 128 >128 32 8 4 2 16 >128 256 
1603 128 >128 16 8 8 4 32 >128 64 
16011 >128 >128 32 32 16 4 >128 >128 128 
1017 >128 >128 16 64 32 16 >128 >128 >256 
1020 128 >128 16 8 4 2 32 >128 256 
1133 64 >128 32 32 16 8 32 >128 32 
1015 >128 >128 16 8 32 4 >128 >128 >256 
1016 >128 >128 32 32 32 16 >128 >128 >256 
1131 128 >128 32 16 8 4 16 >128 64 
MIC50 128 >128 32 16 8 4 64 >128 128 









Table 6.4. MIC values of designed peptides in the presence of salts, pH 5.5 or pH 
6.5, fetal bovine serum (FBS, 2%, 5% or 10%), human serum (2% or 5%), plasma 












































































































RR 64 64 128 128 128 64 64 128 256 256 128 256 nd nd 
RR2 4 4 8 8 4 8 32 128 128 128 8 16 nd nd 
RR3 8 16 16 32 16 16 32 64 32 128 16 16 nd nd 
RR4 4 4 8 8 2 4 4 16 16 32 16 32 >64 >64 
D-RR4 2 2 4 4 1 2 2 4 2 4 2 2 2 2 

















Table 6.5. The fractional inhibitory concentration index range of peptide, D-RR4 in 

















at the FIC 
 
P. aeruginosa PAO1 
Colistin 0.5 0.125 0.5 Synergism 4 
Polymyxin 
B 
0.5 0.07 0.39 Synergism 8 
Tobramycin 1 1 1.25 Indifference 0 
Gentamicin 2 2 1.25 Indifference 0 
Amikacin 2 2 1.25 Indifference 0 
Cefotaxime 32 4 0.38 Synergism 8 
P. aeruginosa ATCC 
BAA 1744 
Colistin 0.5 0.06 0.38 Synergism 8 
Polymyxin 
B 
0.5 0.06 0.38 Synergism 8 
Tobramycin 0.5 1 2.25 Indifference 0 
Gentamicin 2 4 2.25 Indifference 0 
Amikacin 1 2 2.25 Indifference 0 
Meropenem 256 16 0.31 Synergism 16 
Cefotaxime 64 4 0.31 Synergism 16 
A. baumannii ATCC 
AB 1605 
Colistin 0.25 0.06 0.49 Synergism 4 
Polymyxin 
B 
0.25 0.03 0.38 Synergism 8 
Tobramycin 2 0.25 0.38 Synergism 8 
Gentamicin 256 256 1.25 Indifference 0 
Amikacin 4 0.5 0.38 Synergism 8 
Meropenem 256 2 0.26 Synergism 128 
Cefotaxime 256 4 0.27 Synergism 64 
181 
 













RR 64 128/256 2/4 >256 8 
RR1 >256 >256/>256 NA >256 NA 
RR2 4 128/64 32/16 256 64 
RR3 8 128/128 16/16 >256 64 
RR4 4 64/128 16/32 256 64 
D-RR4 2 64/64 32/32 256 128 
Melittin 8 2/4 0.25/0.5 4 0.5 




a MIC50 (µM) of peptide against P. aeruginosa and A. baumannii isolates (Table 6.2). 
b EC50 is the peptide concentration that inhibited 50 % of macrophage cell line (J774.1) or 
human keratinocyte (HaCaT). 
 c Therapeutic index is the ratio of the EC50 or HC50 value over the MIC50 value. 
d HC50
 is 
the peptide concentration that cause 50 % hemolysis of RBCs. 
e from reference (60).f from reference (61).  
ND. not determined. 





Figure 6.1. Helical wheel projections of the designed peptides 
 
Yellow and blue circles represent hydrophobic and hydrophilic residues, respectively.  
Grey and bright blue circles represent alanine and histidine residues, respectively. The 
arrows indicate the directions and magnitudes of the hydrophobic moments (µH) 






Figure 6.2. CD analyses of the designed peptides 
 
Peptides at 50 µM concentration were dissolved in deionized water, 30 mM sodium 




Figure 6.3. Analytical HPLC spectra demonstrating proteolytic activity of trypsin 












Figure 6.4. The killing kinectics of peptides. Time-kill of peptides and antibiotics 
against logarithmic (A&B) and stationary phase (C&D) cultures of P. aeruginosa 
PAO1 (A&C) and A. baumannii ATCC BAA-1605 (B&D). 
 
(A&B) Logarithmic phase of bacteria were exposed to D-RR4 and colistin at 5 × and 10 
× MIC or RR, tobramycin and gentamicin at 10 × MIC. (C&D) The killing kinectics of 
stationary phase of bacteria exposed to peptides and antibiotics at 10 × MIC. Untreated 
samples served as a control. The killing curves were identical (overlapping in the figure 
A) for RR, D-RR4 and colistin at 10 × MIC and identical for RR, D-RR4 at 10 × MIC in 
B. The results are given as means ± SD (n = 3); data without error bars indicate that the 
SD is too small to be seen. 
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Figure 6.5. Permeabilization of bacterial membrane by peptides 
 
A) Permeabilization of the outer membrane of P. aeruginosa PAO1 by antimicrobial 
peptides as indicated by the enhanced uptake of 1-Nphenylnaphthylamine (NPN). 
Fluorescence intensity caused by the partitioning of NPN into the outer membrane was 
monitored after addition of antimicrobial peptides. Data are presented as means ± standard 
error of the means (n = 3). B) Permeabilization of the inner (cytoplasmic) membrane by 
antimicrobial peptides is indicated by propidium iodide fluorescence. C) Release of ATP 
from bacteria treated with peptides was detected using a luminescence assay after mixing 
with luciferase reagent. Each experiment was performed in duplicate, and the values 
represent means ± standard deviation. 
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Figure 6.6. TEM micrographs of untreated and peptide-treated P. aeruginosa 
PAO1 
 
The cells of untreated bacteria are intact, with a well-defined cell membrane (A&B). 
Bacteria treated with low concentration of D-RR4 peptide (1 × MIC) showed disintegrated 
membranes with blebs and increases in periplasmic space (black arrow heads), 
mesosomes and invaginations (dashed lines) and condensed materials under membranes 
(white arrows) (C&D). Bacteria treated with a higher concentration of D-RR4 peptide (10 
× MIC) (E-H) showed complete loss of membranes (black arrows) and leakage of 
cytoplasmic contents (dashed arrow). Ghost cells due to loss of most cytoplasmic contents 
were also evident at higher peptide concentrations (H). Lower panel is a higher 







Figure 6.7. Drug-resistance development profile of P. aeruginosa PAO1 exposed to 
peptides 
 
 P. aeruginosa PAO1 exposed to 10 passages in the presence of sub-inhibitory 
concentrations of D-RR4 peptide and three classes of antibiotics including the protein 
synthesis inhibitor, tobramycin, the RNA synthesis inhibitor, rifampicin and the DNA 
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Figure 6.8. Efficacy of peptides on established biofilms of P. aeruginosa PAO1 and 
A. baumannii ATCC BAA-1605 
 
Twenty four hour old biofilms were treated with different concentrations of RR4, D-RR4, 
colistin, tobramycin and gentamicin and plates were incubated at 37°C for 24 hours. After 
incubation, wells were washed and biofilms were stained with 0.5% (w/v) crystal violet 
for 30 minutes. The dye was solubilized with ethanol (95%) and the optical density (OD) 
of biofilms was measured. Experiments were repeated twice independently and the 
average values are reported.  
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Figure 6.9. Intracellular antibacterial activity of peptides in murine macrophage. 
 
 The effect of RR4 and D-RR4, at 8 × MIC, to kill intracellular P. aeruginosa PAO1 and 
A. baumannii ATCC 19606 inside infected J774A.1 cells after treatment for 24 hours. 
Statistical analysis was calculated using one-way ANOVA, with post hoc Tukey’s 
multiple comparisons test. P values of ˂  0.05 were considered significant. One asterisk (*) 
indicates significance from the negative control. Results are expressed as means from 











































































Figure 6.10. Anti-inflammatory effect and LPS binding activity of peptides 
 
A) LPS binding activity of peptides. Peptides at different concentrations were incubated 
with one endotoxin unit (EU) of LPS at 37°C for 30 minutes. Colistin was used as positive 
control due to its high binding affinity for LPS. The binding of peptides with LPS is 
expressed as percent change relative to untreated samples. B) Anti-inflammatory effect of 
peptides on LPS stimulated macrophage. J774A.1 cells were stimulated with LPS (150 
ng/mL final concentration) in the presence of different concentrations of peptides. Cells 
stimulated with LPS alone and untreated cells served as controls. Cells were incubated for 
six hours at 37 °C after which the supernatants of the medium from each treatment were 
collected. Cytokine detection of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) 
in supernatants was analyzed using ELISA. Cytokine levels are expressed as percent 
change relative to the LPS stimulated control. Statistical analysis was calculated using 
one-way ANOVA, with post hoc Tukey’s multiple comparisons test. P values of ˂ 0.05 
were considered significant. One asterisk (*) indicates significance from the negative 
control.  
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Figure 6.11. Evaluation of toxicity and efficacy of peptides in Caenorhabditis 
elegans. 
 
 A). Evaluation of toxicity of peptides in Caenorhabditis elegans. C. elegans strain glp-
4;sek 1 was grown for four days in the presence of peptides at different concentrations. 
Worms were monitored daily and the live worms were counted. Results are expressed as 
a Kaplan-Meier survival-curve. B) Evaluation of antimicrobial activity of peptides on 
reducing the bacterial count inside infected Caenorhabditis elegans. C. elegans strain glp-
4; sek 1 were infected with P. aeruginosa PAO1, colistin-resistant P. aeruginosa 1109 or 
A. baumannii ATCC BAA-1605. After infection, worms were treated with D-RR4, 
colistin, or a combination of both agents. After treatment, worms were lysed and bacteria 
were counted. One asterisk (*) indicates significance from the negative control. Two 
asterisks (**) indicate significance from the monotherapy treatment (P < 0.05). Results 
are expressed as means from three biological replicates ± standard deviation. C) Efficacy 
of peptides in a Caenorhabditis elegans model of bacterial infection. C. elegans strain 
glp-4;sek 1 were infected with P. aeruginosa PAO1, colistin resistant P. aeruginosa 1109 
or A. baumannii ATCC BAA-1605. After infection, worms were treated with D-RR4, 
colistin, or a combination of both. Worms were monitored daily and the live worms were 
counted. Results are expressed as a Kaplan-Meier survival-curve. C. elegans receiving no 






































CHAPTER 7. TARGETING BIOFILMS AND PERSISTERS OF 
ESKAPE PATHOGENS WITH P14KANS, A KANAMYCIN 
PEPTIDE CONJUGATE 
(Mohamed, M.F., Brezden A., Mohammed H, Chmielewski J, and Seleem, M.N. 
Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin 
peptide conjugate. BBA General Subjects, under review) 
7.1 Abstract 
The worldwide emergence of antibiotic resistance represents a serious medical threat. The 
ability of these resistant pathogens to form biofilms that are highly tolerant to antibiotics 
further aggravates the situation leading to recurring infections. Thus, new therapeutic 
approaches with novel mechanisms of action are urgently needed. To address this 
significant problem, we conjugated the antibiotic kanamycin with a novel antimicrobial 
peptide (P14LRR) to develop a kanamycin peptide conjugate (P14KanS). P14KanS 
showed enhanced and potent antimicrobial activity against ESKAPE pathogens. P14KanS 
demonstrated at least 128 fold improvement in the MIC over kanamycin against 
kanamycin resistant strains. Mechanistic studies confirmed that P14KanS exerts its 
antibacterial effect by selectively disrupting the bacterial cell membrane. P14KanS was 
not toxic or hemolytic at concentrations much higher than required for antibacterial 
activity. In contrast to many antibiotics, P14KanS demonstrated rapid bactericidal activity 
against stationary phases of Gram-positive and Gram-negative pathogens, Furthermore, 
P14KanS was superior in disrupting adherent bacterial biofilms and killing intracellular 
pathogens when compared to conventional antibiotics. Of note, P14KanS demonstrated 
potential anti-inflammatory activity by suppression of LPS-induced proinflammatory 
cytokines. Finally, P14KanS protected C. elegans from lethal infections of Gram-positive 
and Gram-negative pathogens. In conclusions, this study show that equipping kanamycin 
with selective membrane activity is a promising way for tackling biofilms and bacterial 




The emergence of antibiotic resistance is a notorious problem worldwide [1]. In the United 
States alone, antibiotic-resistant bacteria infect at least two million people, killing  23,000 
patients annually [2]. Currently, members of the ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species) represent one of the most significant 
threats to human health as strains exhibit resistance to multiple antibiotic classes[3]. 
Compounding the situation further, global reports of extensively drug-resistant (XDR) 
and pandrug-resistant (PDR) isolates of P. aeruginosa and A. baumannii have been 
increasing [4-6]. The ability of these resistant pathogens to form biofilms that are highly 
tolerant to antibiotics further aggravates the situation, ultimately leading to persistent and  
recurring infections [7, 8]. Hence, the development of therapeutic alternatives that have 
novel mechanisms of action are urgently needed in order to effectively address this 
problem.  
Aminoglycosides are a class of valuable antibiotics that are used in the treatment of several 
microbial infections [9-11]. They bind to the 16S rRNA component of the bacterial 
ribosome, leading to mistranslation and bacterial death. However, the worldwide epidemic 
of resistance to aminoglycosides, to kanamycin in particular, has diminished their 
widespread clinical use [9-12].  
We recently conjugated kanamycin with the antibacterial peptide P14LRR to achieve a 
dual agent (P14KanS) (Figure 7.1). P14LRR is a small de novo proline rich antimicrobial 
peptide that forms a cationic amphiphilic polyproline helix and demonstrates broad-
spectrum efficacy against pathogenic bacteria [13, 14]. P14LRR is non-hemolytic and 
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highly stable to proteases. These characteristics contributed to the selection of P14LRR 
for conjugation to kanamycin.  However, much remains to be examined with P14KanS 
including its spectrum of activity against Gram-positive and Gram-negative pathogens, its 
mechanism of action, its ability to disrupt bacterial biofilms, its efficacy against stationary 
phase bacteria, and confirming its potent antibacterial activity in a suitable animal model 
of infection. 
In the present study, we investigated the activity of the P14KanS conjugate against 
important multidrug-resistant strains of the ESKAPE family. Additionally, we explored 
the conjugate’s mechanism of action against kanamycin-resistant isolates. Moreover, the 
conjugate’s ability to eradicate preformed biofilms and to kill stationary phases of 
pathogens was examined. Furthermore, the immune-modulatory activity of the conjugate 
was explored. Finally, the antibacterial activity of the conjugate was validated in vivo 
using a Caenorhabditis elegans model of bacterial infection. Taken altogether, our 
findings indicate that the conjugate is a promising candidate that warrants further 
investigation as a therapeutic agent for multidrug-resistant bacterial pathogens. 
7.3 Materials and methods 
Bacterial isolates, drugs and reagents 
Clinical isolates used in the study are presented in Table 1. P14LRR peptide and the 
peptide kanamycin conjugate (P14KanS) (figure 7.1) were synthesized as described 
previously (13, 14). Melittin was purchased from Sigma-Aldrich (St. Louis, MO). 
Antibiotics were purchased from commercial vendors. Mueller-Hinton broth (MHB), 
Dulbecco’s phosphate buffered saline (PBS), fetal bovine serum (FBS), and Dulbecco's 
Modified Eagle's medium (DMEM) were purchased from Sigma-Aldrich (St. Louis, MO). 
MTS reagent were purchased from Promega (Madison, WI, USA). Brain heart infusion 
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broth (BHIB), trypticase soy broth (TSB) and trypticase soy agar (TSA) were purchased 
from Becton-Dickinson (Cockeysville, MD). Enzyme-linked immunosorbent 
assay (ELISA) development kits for cytokine detection were purchased from R&D 
Systems, Inc. (Minneapolis, MN). 
Determination of minimum inhibitory concentration (MIC) values 
The broth microdilution technique was utilized to assess the minimum inhibitory 
concentrations of compounds according to the guidelines of the Clinical and Laboratory 
Standards Institute (CLSI) (15). Bacterial isolates were diluted to 5×105 colony forming 
unit (CFU/ml) in MHB (except E. faecium, diluted in BHIB). Compounds were added to 
96-well plates at specified concentrations and subsequently serially diluted. The MIC was 
defined as the lowest concentration of compound that prevented visual bacterial growth. 
Mechanism of action studies 
A) Outer membrane permeabilization assay 
Permeation of the bacterial outer membrane by compounds was assessed using the non-
polar fluorescent dye 1-N-phenylnaphthylamine (NPN) as described elsewhere (16). P. 
aeruginosa PAO1, in logarithmic growth phase was centrifuged for 10 minutes at 4000 × 
g, washed, and adjusted to OD600 of 0.5. A small aliquot (100 µl) of bacteria was added 
to black wall 96-well plates. NPN was mixed with bacteria at a final concentration of 10 
μM. Compounds were added, in triplicates, at specified concentrations. Plates were 
monitored using a microplate reader (Molecular Devices, Sunnyvale, CA) at excitation 
and emission wavelengths of 350 nm and 420 nm, respectively. Data was corrected for 
background fluorescence and plotted as percentage ± standard deviation. Experiments was 
done in triplicate and was repeated twice independently. 
B) Inner (cytoplasmic) membrane permeabilization assay 
Damage of the bacterial inner (cytoplasmic) membrane after exposure to compounds was 
evaluated using the fluorescent propidium iodide dye, as described elsewhere (17). P. 
aeruginosa PAO1 in logarithmic growth phase, was centrifuged for 10 min at 4000 × g, 
washed, and adjusted to OD600 of 0.2. An aliquot (100 µl) of bacterial suspension was 
added to black 96-well plates. Propidium iodide dye was added at a final concentration of 
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10 μM. Compounds were added, in triplicates, at specific concentrations. Bacteria treated 
with compounds diluent (distilled water) served as a negative control. Plates were read 
using a microplate reader at excitation and emission wavelengths of 585 nm and 620 nm, 
respectively. Data was corrected for background fluorescence and plotted as percentage ± 
standard deviation. Experiments was done in triplicate and was repeated twice 
independently. 
C) Calcein leakage assay 
Membrane permeabilization of S. epidermidis (ATCC 35984) by the peptide kanamycin 
conjugate was monitored and quantified by the leakage of the preloaded fluorescent dye, 
calcein, as described before(18, 19). 
Time-kill assay against logarithmic and stationary phase bacteria  
S. aureus ATCC 6538, S. epidermidis ATCC 35984, P. aeruginosa PAO1 and A. 
baumannii ATCC BAA-1605 were grown in MHB with aeration at 250 rpm at 37 ºC 
overnight, then diluted in fresh MHB and incubated aerobically at 37 ºC until the 
suspension reached a logarithmic phase of growth (OD600 = 0.2). Next, bacteria were 
diluted to 5×105 CFU/ml in MHB. Compounds were added at desired concentrations (10 
µM for S. aureus and S. epidermidis and 20 µM for P. aeruginosa and A. baumannii), in 
triplicate. Bacteria were incubated aerobically at 37 ºC in a shaking incubator at 250 rpm. 
Aliquots at specified time points were taken, serially diluted in phosphate-buffered saline 
(PBS) and plated in triplicate on TSA. CFUs were counted after incubation of plates for 
24 hours at 37 ºC. In order to determine the kinetics of killing against stationary phase 
bacteria S. aureus ATCC 6538, S. epidermidis ATCC 35984, P. aeruginosa PAO1 and A. 
baumannii ATCC BAA-1605 were grown in MHB with aeration at 250 rpm at 37 ºC 
overnight. Bacteria were subsequently exposed to compounds at similar concentrations 
used in logarithmic phase. Aliquots were taken and plated as described above. 
Toxicity of compounds against mammalian cell lines 
Compounds were assayed for potential in vitro toxicity against human keratinocytes 
(HaCaT) and HeLa cells as described before (20) with the following modifications. Cells 
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were treated with compounds at various concentrations for 24 hours. Compounds were 
assayed for hemolytic activity against human red blood cells as described previously (18). 
Efficacy of compounds on bacterial biofilms 
To examine the compounds’ ability to disrupt bacterial biofilms, the microtiter dish 
biofilm formation assay was employed (21). Briefly, overnight cultures of S. aureus 
(ATCC 6538) and S. epidermidis (ATCC 35984) were diluted 1:100 in TSB supplemented 
with 1% glucose. Overnight cultures of P. aeruginosa PAO1 and A. baumannii ATCC 
BAA-1605 were diluted 1:100 in M63 minimal medium supplemented with magnesium 
sulfate, glucose and casamino acids. Bacterial suspensions were incubated in 96-well 
plates at 37°C for 24 hours. After removing media, wells were rinsed with PBS to remove 
planktonic bacteria before re-filling wells with fresh media. Compounds were added at 
specific concentrations and plates were incubated at 37°C for 24 hours. After incubation, 
wells were washed and biofilms were stained with 0.5% (w/v) crystal violet for 30 min. 
The dye was solubilized with ethanol (95%) and the biofilm mass was quantified at OD595. 
Experiments was done in triplicate and was repeated twice independently. 
Intracellular antibacterial efficacy of compounds in human keratinocytes 
In order to assess the compounds’ ability to kill intracellular staphylococci, human 
keratinocytes were infected, as described in previous studies (14, 22). Briefly, HaCaT 
cells was seeded and incubated in DMEM + 10% FBS. Following incubation, cells were 
infected with S. aureus (multiplicity of infection 100:1) in DMEM + 10% FBS for two 
hours. After infection, the wells were washed with 200 µl media containing gentamicin 
(50 µg/ml) and further incubated for 30 minutes with gentamicin to kill any remaining 
extracellular bacteria. Compounds were diluted in DMEM + 10% FBS to the desired 
concentrations and wells were treated with 100 µl of DMEM +10 FBS containing 
compounds for 24 hours. Medium alone was used as a negative control. After incubation, 
the media was aspirated and washed twice with PBS to remove any residual test agent. 
Next, 100 µl of PBS containing 0.01% triton X-100 was added to lyse cells. Subsequently, 
bacteria were diluted and plated on TSA plates. Plates were incubated at 37ºC for 16 hours. 
After incubation, bacteria were enumerated and analyzed. Experiments were repeated 
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twice independently and the average percent reduction of bacterial growth for each 
treatment regimen was determined. 
Lipopolysaccharides (LPS) studies 
A) Binding of compounds to LPS (LAL assay) 
To determine if the compounds could bind to LPS, a Limulus amoebocyte lysate (LAL) 
kit (Genscript, USA Inc.) was utilized as described in previous studies (23). Compounds 
were dissolved in pyrogen-free water and serially diluted in the same solvent. The 
compounds were then incubated with one endotoxin unit (EU) of LPS at 37 °C for 30 
minutes in order to permit the compounds to bind LPS. The reaction mixture (50 μl) was 
added to 50 μl of LAL reagent, and further incubated for 10 min. Next, 100 μl of LAL 
chromogenic substrate was added. The mixture was incubated at 37 °C for 6 minutes. 
Samples were measured at OD545 using a microplate reader. Colistin was used as a positive 
control. The binding of compounds with LPS was expressed as percent change relative to 
the untreated control. 
B) Anti-inflammatory effect of compounds on LPS stimulated macrophages 
(Neutralizing the effect of LPS on macrophage) 
To investigate the anti-inflammatory effect of compounds on LPS stimulated 
macrophages, J774A.1 cells were seeded and incubated as described above. Next, the cells 
were stimulated with LPS (150 ng/ml final concentration) in the presence of 10 µM of 
compounds. Cells that were stimulated with LPS alone and untreated cells served as 
controls. Cells were incubated for six hours at 37°C and supernatants from each treatment 
were collected and stored at -20°C until use. Cytokine detection of tumor necrosis factor-
α (TNF-α) and interleukin-6 (IL-6) in supernatants was done using ELISA as described 
before following the manufacturer’s instructions (24, 25). Cytokine levels were expressed 
as percent change relative to LPS stimulated control using triplicate samples for each 
treatment condition.  
Multi-step resistance selection 
To evaluate the ability of S. aureus to acquire resistance to the peptide kanamycin 
conjugate and control antibiotics, a multi-step resistance selection experiment was 
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employed. S. aureus ATCC 6538 was serially passaged in the presence of a sub-inhibitory 
concentrations of kanamycin, P14LRR, P14KanS and three different classes of antibiotics, 
ampicillin, rifampicin, and ciprofloxacin for eight serial passages. The MIC was 
monitored daily using the broth microdilution assay. Results were presented as the change 
in MIC measurement observed after each passage in comparison to the initial MIC value. 
In vivo efficacy of compounds in a C. elegans infection model  
Infection and treatment of C. elegans was done as described previously with some 
modifications (26, 27). C. elegans AU37 [sek-1(km4); glp-4(bn2) I] was used to test the 
efficacy of peptides in vivo. This strain has a mutation in the sek-1 gene of the p38 
mitogen-activated protein kinase pathway (p38 MAPK pathway) that makes this 
particular strain more susceptible to bacterial infection (26, 27). Briefly, synchronized 
adult worms were transferred to modified NGM (0.35% peptone) agar plates seeded with 
a lawn of P. aeruginosa PAO1, A. baumannii ATCC BAA-1605, S. aureus ATCC 6538 
or S. epidermidis ATCC 35984 for infection. After infection, worms were collected and 
washed with PBS three times. Worms (~30 per sample) were transferred to 96-well plates. 
Compounds were added at desired concentrations (10 µM for S. aureus and S. epidermidis 
and 50 µM for P. aeruginosa and A. baumannii), in triplicate. Untreated worms served as 
a negative control. To assess the survival of infected C. elegans, worms were assessed for 
viability (live worms are sinusoidal with movement, whereas dead worms are rigid rods). 
Statistical analyses  
Statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad 
Software, La Jolla, CA, USA). Comparison between two groups were analyzed using two-
tailed unpaired Student t-tests. Comparison between three or more groups was analyzed 
using one-way ANOVA, with post hoc Tukey’s multiple comparisons test. P-values of ˂ 





7.4 Results and discussion 
Antimicrobial activity 
The antibacterial activity of kanamycin and the conjugate was investigated against 
ESKAPE pathogens. Herein, P14LRR displayed moderate to weak antibacterial activity 
against ESKAPE pathogens with MIC range from 8-64 µM (Table 1). Kanamycin 
demonstrated activity only against two strains (S. aureus ATCC 6538 and MRSA 
USA400). However, other bacteria were resistant to kanamycin (MIC, 128 to >256 µM). 
P14KanS demonstrated a very potent broad spectrum antibacterial activity over 
kanamycin and the peptide (P14LRR). The MIC of P14KanS was 1 to 2 µM against all 
strains tested. This represents a 2-4 fold improvement in the MIC over kanamycin against 
kanamycin sensitive strains and 128 to >256 fold improvement in the MIC over 
kanamycin against kanamycin resistant strains. Interestingly, P14KanS demonstrated 
potent activity against several clinical multidrug-resistant isolates including methicillin 
resistant S. aureus (MRSA USA400), methicillin resistant S. epidermidis (MRSE) and 
vancomycin resistant E. faecium (VRE) (Table 1). Of particular note, P14KanS 
demonstrated potent activity against A. baumannii ATCC BAA-1605 which is a 
multidrug-resistant isolate obtained from the sputum of a Canadian soldier serving in 
Afghanistan. This strain is resistance to numerous antibiotics including kanamycin, 
meropenem, imipenem, ceftazidime, ciprofloxacin, piperacillin, ticarcillin, cefepime, 
aztreonam and gentamicin (Table 1). Moreover, P14KanS demonstrated potent activity 
against colistin-resistant P. aeruginosa (1109) isolated from cystic fibrosis patients (28). 
This isolate showed high resistance to colistin (MIC = 128 µM), kanamycin and several 
antimicrobial peptides (28). Colistin is an antibiotic of last resort for multidrug-resistant 
P. aeruginosa infections (29). The emergence of resistant isolates to colistin, particularly 
via plasmid-mediated resistance in Enterobacteriaceae (30), highlights the urgent need to 
discover new antimicrobial agents to address this issue. The discovery that P14KanS have 
potent activity against colistin-resistant P. aeruginosa indicates a potential therapeutic 
advantage of P14KanS over several antimicrobials that are ineffective against colistin-




Mechanism of action of P14KanS 
In order to gain insight into the mode of action of P14KanS and its activity against 
kanamycin resistant strains, we performed a series of experiments on a kanamycin 
resistant bacteria to explore its antibacterial mode of action. First, damage to the bacterial 
outer membrane by P14KanS was monitored by measuring the fluorescent intensity of P. 
aeruginosa PAO1 mixed with 1-N-phenylnaphthylamine (NPN) and incubated with 
varying concentrations. As demonstrated in figure 7.2a, similar to the known membrane 
targeting antibiotic, colistin, there was a significant and dose-dependent increase of 
fluorescence intensity of P. aeruginosa cultures treated with P14KanS but not kanamycin 
nor the P14LRR peptide. Remarkably, P14KanS demonstrated more potent activity than 
colistin. These findings indicate that P14KanS likely targets the bacterial outer membrane 
leading to partitioning of NPN into the outer membrane and increased fluorescence. 
Damage of the bacterial inner (cytoplasmic) membrane by P14KanS was monitored by 
measuring the fluorescence intensity of P. aeruginosa PAO1 mixed with propidium iodide 
and treated with P14KanS. As demonstrated in figure 7.2b, the fluorescence intensity 
didn’t change in untreated bacteria and with kanamycin and P14LRR treated bacteria, 
confirming the cytoplasmic membrane integrity. However, when P14KanS and colistin 
were added to bacterial cultures, a rapid and significant increase in fluorescence due to 
access of propidium iodide inside the bacteria was evident. The membrane damaging 
effect was both concentration-and time-dependent. At 10 × MIC, P14KanS demonstrated 
more potent membrane perturbation than at 5 × MIC.  
To confirm our results of membrane permeabilization against a Gram-positive pathogen, 
we studied the effect of P14KanS on S. epidermidis (kanamycin resistant) membranes 
using a calcein leakage assay. Calcein AM is a non-fluorescent derivative that is able to 
penetrate cell membranes; once inside the cells it is hydrolyzed by intracytoplasmic 
esterases to a fluorescent calcein, which is non-permeable to membranes (19, 31). Damage 
of membrane integrity is indicated by calcein leakage from bacterial cells, which is in turn 
proportional to a reduction of fluorescence intensity. In a similar way like the well-known 
membrane damaging peptide, nisin (figure 7.2c); P14KanS damage the S. epidermidis cell 
membrane led to fast leakage of preloaded calcein within seconds (figure 7.2c). However, 
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P14LRR demonstrated no leakage implying a non-lytic mechanism of action. Collectively, 
these data confirm the membrane-destructive effect of P14KanS against Gram-negative 
and Gram-positive bacteria and clarify why P14KanS demonstrated efficacy against 
kanamycin resistant isolates. 
Time kill assay against logarithmic and stationary phase bacteria 
After confirming that P14KanS possessed excellent antimicrobial activity against a broad 
spectrum of multidrug-resistant clinical isolates, we next assessed its killing kinetics 
against logarithmic phase of selected Gram-positive (S. aureus ATCC 6538 and S. 
epidermidis ATCC 35984) and Gram-negative pathogens (P. aeruginosa PAO1 and A. 
baumannii ATCC BAA-1605). As demonstrated in figure 7.3, P14KanS demonstrated 
fast killing of Gram-positive bacteria. At 10 µM, P14KanS completely eradicated 
logarithmic cultures of S. aureus ATCC 6538 and S. epidermidis ATCC 35984 starting 
inoculum after 0.5 and 2 hours, respectively. However, kanamycin required 6 hours to 
eradicate S. aureus and was not effective against S. epidermidis. P14LRR was not 
effective at the same tested concentrations. In contrast, vancomycin demonstrated slower 
killing kinetics. As shown in figure 7.3, vancomycin caused more than 2.5 log reduction 
after 6 hours. Linezolid showed a bacteriostatic effect. 
Similar to Gram-positive pathogens, P14KanS demonstrated fast killing of Gram-negative 
bacteria. At 20 µM, P14KanS completely eradicated logarithmic cultures of P. aeruginosa 
and A. baumannii starting inoculum after one hour. However, kanamycin and P14LRR 
were not effective. Tobramycin and gentamicin eliminated P. aeruginosa PAO1 within 2-
3 hours. Tobramycin eliminated A. baumannii ATCC BAA-1605 after three hours. 
Antimicrobials with fast bactericidal activity have several advantages including limiting 
spread of infection, improving treatment prognosis, limiting the emergence of resistance, 
and reducing duration of treatment (32). 
Next, we examined the impact of P14KanS and select antibiotics against the stationary-
phase of bacteria. This population of cells is known to contain a high percentage of 
persisters that are tolerant to many antimicrobial agents and contributes to recurring 
infections (7, 33-35). As shown in figure 7.3, P14KanS completely eradicated bacterial 
cultures of S. aureus after 4 hours and demonstrated rapid bactericidal activity (3-log10 
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reduction) against S. epidermidis.  On the other hand, antibiotics were not able to show 
bactericidal effect on stationary phases, despite their bactericidal activity against 
logarithmic bacteria. Kanamycin demonstrated only1.3 log10 reduction of S. aureus after 
6 hr.  Vancomycin and linezolid were not effective against stationary bacteria in same 
time frame (figure 7.3). Treatment of stationary-phase P. aeruginosa and A. baumannii 
with 20 µM of P14KanS resulted in rapid bactericidal activity (3-log10 reduction) and 
complete eradication of a high starting inoculum (109 CFU/ml) after three hours and six 
hours, respectively. (figure 7.4). Conventional antibiotics had minimal impact on 
stationary-phase bacteria which is in agreement with previous findings (7, 33-35).  
The superior activity of P14KanS when compared to conventional antibiotics, against 
stationary phase bacteria may be explained by its unique antimicrobial mechanism of 
action. Many antibiotics require bacteria to be growing and metabolically active in order 
to inhibit their molecular targets, including protein synthesis (linezolid, tobramycin and 
gentamicin) and cell wall synthesis (vancomycin) (36). In contrast, as mentioned above, 
the positive charge present in P14KanS serves as a point of attraction with negatively-
charged bacterial cell membranes and consequently leads to targeted disruption of the 
bacterial membrane and leakage of intracellular contents (37, 38). This unique mechanism 
of action of P14KanS would not require cells to be metabolically active and would not be 
impaired by the dormant and quiescent state of bacteria (36). The results obtained above 
provide valuable insight into using P14KanS as a potential future therapeutic option for 
persistent and chronic bacterial infections. 
Efficacy of P14KanS on established biofilms 
Biofilms are aggregated bacterial communities covered by polysaccharide matrix that 
protects bacteria from host immune defenses and hinders antibiotics from targeting deep-
seated bacteria encased within the biofilm (39). Furthermore, biofilms act as an infectious 
niche with sustained release of bacteria inside the host which leads to disease relapses and 
therapy failure(40). Biofilm development has been linked to serious biofilm-related 
infections including pneumonia in cystic fibrosis patients and colonization of medical 
devices and urinary tract infections (41). Biofilms pose a serious medical challenge, that 
is difficult to control and there is a critical need to find novel approaches to address this 
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problem. We examined the capability of P14KanS and control antibiotics to disrupt 
established biofilms of four different bacterial isolates responsible for major biofilm 
infections; S. aureus, S. epidermidis, P. aeruginosa and A. baumannii. As shown in figure 
7.5, P14KanS disrupted the 24 hour old biofilms more potently than several antibiotics of 
choice. P14KanS was superior to kanamycin and the peptide P14LRR against the 
kanamycin sensitive isolate (S. aureus). P14KanS demonstrated a concentration-
dependent biofilm-disrupting activity. P14KanS, at low concentration (1 µM) disrupted 
more than 65 % of biofilm mass of S. aureus (p < 0.05); whereas kanamycin and P14LRR 
were not effective at the same concentrations (figure 7.5A). At higher concentrations, 
P14KanS disrupted more than 75 and 82% of biofilm mass of S. aureus at 4 and 8 µM, 
respectively, (p < 0.05). Kanamycin, vancomycin and linezolid, at 8 µM, reduced 
approximately 50% of biofilm mass (p < 0.05); whereas, P14LRR was not effective 
(figure 7.5A).  
We further assessed the efficacy of P14KanS against biofilms of a clinical multi-drug 
resistant S. epidermidis ATCC 35984, a high slime producing strain that was isolated from 
septicemic patients with colonized intravascular catheters in Tennessee, US (42) This 
strain is a multi-drug resistant as it shows resistance to methicillin, erythromycin, 
kanamycin, gentamicin, clindamycin and trimethoprim. The great thickness of the 
exopolysaccharide matrix of S. epidermidis biofilms cause it to become extremely 
resilient to antibiotics penetration (39, 43-45). Indeed, the 24 hr old biofilms of S. 
epidermidis were less susceptible to vancomycin and linezolid even at 64 µM (64-128 X 
MIC) showing 25-30% biofilm reduction (figure 7.5B). However, P14KanS disrupted 
more than 30, 50, 70, 80% of biofilm mass at 8, 16, 32 and 64 µM, respectively, (p < 0.05). 
P14LRR was not effective except at 64 µM, disrupting approximately 50% of biofilm 
mass. Kanamycin didn’t disrupt biofilms (figure 7.5B). 
Remarkably, P14KanS was capable of eradicating P. aeruginosa and A. baumannii 
biofilms at 32 µM, however, kanamycin was not effective (figure 7.5C). P14LRR (32 µM) 
was not effective against P. aeruginosa biofilms and demonstrated only 30% reduction of 
A. baumannii biofilms (figure 7.5C). Collectively, the data demonstrate that P14KanS is 




Toxicity of P14KanS against mammalian cells 
A significant limitation for translating novel membrane targeting antimicrobials into 
clinical applications is their toxicity to host cells (46). Herein, we assessed the hemolytic 
activity of P14KanS on human red blood cells (RBCs). As demonstrated in figure 7.6a, 
P14KanS and P14LRR displayed no hemolysis even at very high concentrations (256 µM) 
(Therapeutic index “TI” >256). In contrast, melittin completely lysed RBCs at very low 
concentrations (8 µM) equal to ½ × MIC of melittin against P. aeruginosa (TI = 0.5). 
Failure of P14KanS to lyse human RBCs confirms the selectivity of P14KanS toward 
negatively charged bacterial membrane. 
Next, we evaluated the cytotoxic effects of P14KanS against human keratinocytes (HaCaT 
cells) and HeLa cells via the MTS assay. The half maximal effective concentration (EC50) 
was 128/256 µM, respectively, in the case of HeLa / HaCaT cells (figure 7.6B). This 
confirms that P14KanS displayed a higher safety window. The therapeutic index of 
P14KanS is 128/256 respectively, in the case of HeLa / HaCaT cells. The data indicate 
the superior safety profile of P14KanS and its selectivity toward bacterial cells. 
Intracellular antibacterial activity of P14KanS  
S. aureus was considered to be primarily an extracellular pathogen for many years. 
However, extensive studies have revealed that these pathogens can gain entry and persist 
inside both phagocytic and non-phagocytic eukaryotic cells, such as alveolar macrophages 
and keratinocytes (47-49). The intracellular persistence of pathogens constitutes a 
significant challenge as they are able to avoid host immune defenses. Additionally, 
intracellular pathogens evade the action of many antibiotics that exhibit low intracellular 
penetration ability such as aminoglycosides and vancomycin (50). Eradication of these 
challenging bacterial pathogens is critical to ensure successful treatment of persistent 
intracellular bacterial infections. Here, we investigated if P14KanS had the ability to kill 
intracellular S. aureus residing in human keratinocytes. As demonstrated in figure 7.7, 
P14KanS showed significant reduction of intracellular S. aureus and MRSA USA400 at 
nontoxic concentrations. P14KanS showed the maximum efficacy as it reduced 
intracellular S. aureus and MRSA USA400 by 2.52±0.37 and 1.24±0.26 log, respectively 
at 15 µM. In contrast, peptide P14LRR was not effective. Kanamycin and vancomycin 
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produced approximately 0.4-0.6 log reduction of intracellular S. aureus and MRSA 
USA400. The potent intracellular activity of P14KanS may be useful in treating certain 
chronic exacerbating skin diseases such as Darier’s disease (keratosis follicularis) where 
S aureus persists inside keratinocytes leading to failures to antibiotic therapy and recurrent 
infections in affected patients (51).   
3.7. Anti-inflammatory effect of P14KanS 
A key virulence factor unique to Gram-negative bacterial pathogens is the presence of 
lipopolysaccharide (LPS). LPS is a principal structure of the outer membrane of Gram-
negative bacteria. During bacterial death, cell replication or exposure to certain antibiotics, 
LPS is released from bacteria leading to stimulation of proinflammatory cytokine release 
such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) from mononuclear 
phagocytes. Excessive LPS exposure leads to overproduction of these cytokines which 
can result in septic shock and death. Annually there are 18 million cases of septic shock 
globally with a mortality rate of ~30% (52, 53). Therefore, identifying agents that are 
capable of neutralizing LPS is critical.  
We investigated if P14KanS could bind to and neutralize the effect of LPS. As presented 
in figure 7.8A, P14KanS and the peptide P14LRR were able to bind to LPS in vitro as 
evident by inhibition of the LPS-induced activation of the LAL enzyme 
(Limulus amoebocyte lysate). P14KanS, P14LRR and colistin (a known LPS binding 
agent) produced 60.8 ± 6.5, 71.2 ± 5 and 79.76 ± 4.6 % inhibition of the LAL enzyme at 
10 µM, respectively. However, kanamycin demonstrated only minimal inhibition (6.9% 
± 3.5) at the same concentration.  
Next, we examined if P14KanS and the peptide, P14LRR could reduce the endotoxin-
induced proinflammatory cytokine response in murine macrophages by measuring 
cytokine levels using ELISA. As depicted in figure 7.8B, P14KanS and P14LRR were 
able to inhibit LPS-induced proinflammatory cytokines in macrophages in a manner 
similar to colistin. P14KanS, P14LRR and colistin, at 10 µM, decreased TNF-α levels by 
65.53% ± 2.45, 68.4% ± 5.43, 97.53% ± 0.32, respectively; and IL-6 levels by 74.71% ± 
9.10, 81.92% ± 0.78 and 95.04% ± 0.56%, respectively. However, kanamycin 
demonstrated 11.41% ± 4.5 and 10% ± 3.30 inhibition of TNF-α and IL-6 levels, 
respectively. The capability of P14KanS to reduce endotoxin-mediated proinflammatory 
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cytokine production provides a potential avenue for their development as antibacterial 
agents to treat sepsis and also as an adjunctive with antibiotics to overcome sepsis.  
Multi-step resistance selection 
To examine if the dual mechanism of action of P14KanS can overcome traditional 
mechanisms of antibiotic resistance, we serially passaged a kanamycin sensitive S. aureus 
isolate (ATCC 6538) with sub-inhibitory concentrations of P14KanS, kanamycin, 
P14LRR and three different classes of antibiotics, ampicillin (cell wall synthesis inhibitor), 
rifampicin (RNA synthesis inhibitor) and ciprofloxacin (DNA synthesis inhibitor) for 
eight days. The MIC was determined daily using the broth microdilution assay. As 
presented in figure 7.9, S. aureus did not develop resistance to P14KanS for six passages 
and only a fourfold change in MIC was observed after eight passages. However, treatment 
of S. aureus with kanamycin induced a rapid shift in the MIC within the fourth passage 
and resulted in 64-fold increase in kanamycin’s MIC by passage seven. The MIC of 
P14LRR increased by 4 and 16 fold by passage 6 and 8, respectively. The MIC of 
rifampicin and ampicillin increased to 64-fold and ciprofloxacin increased to 16 fold by 
the sixth passage (figure 7.9). Thus, the conjugation of kanamycin with P14LRR proved 
to decrease the emergence of resistance. This is attributed to the unique mechanism of 
action of P14KanS. P14KanS disrupted bacterial membranes, so for bacteria to acquire 
resistance, significant changes to the membrane lipid composition would need to occur 
(54). These alterations are extremely difficult for bacteria to produce compared to point 
mutations in specific genes (36, 55). This result thus provides strong evidence that the 
selective membrane-disrupting activity of P14KanS can effectively overcome 
conventional mechanisms of antibiotic resistance.  
In vivo efficacy of P14KanS in a C. elegans infection model.  
To test the efficacy of the synthetic peptides to protect against infections in vivo, we 
utilized a C. elegans model of bacterial infection. This model has been used extensively 
for early-stage evaluation of promising antimicrobials (56-58). Moreover, this model 




Bolstered by in vitro results, we examined whether P14KanS could protect infected worms 
from the cidal activity of bacteria. Interestingly, P14KanS significantly increased the rate 
of survival for P. aeruginosa and A. baumannii infected C. elegans in contrast to 
monotherapy, giving complete protection for 72 hours (figure 7.10). However, kanamycin 
and P14LRR failed to protect the worms. (P. aeruginosa PAO1 and A. baumannii 
completely killed untreated worms after 36 and 72 hours, respectively) (figure 7.10). 
The survival experiment with C. elegans was next utilized to examine the impact of 
biofilm forming S. aureus. While kanamycin and P14LRR failed to protect worms from 
killing by a kanamycin sensitive isolate (S. aureus ATCC 6538), P14KanS at 10 µM, 
significantly increased the survival rate of C. elegans, giving nearly complete protection 
for 72 hours (figure 7.10).  
Next, we evaluated the activity of P14KanS to rescue C. elegans from infection by the 
multi-drug resistant clinical isolate, S. epidermidis ATCC 35984 (NRS 101). Indeed, this 
strain demonstrated higher virulence than S. aureus as it completely killed C. elegans after 
72 hours. A notable protective effect was provided by P14KanS, but not with kanamycin 
and P14LRR. P14KanS rescued 80% of infected worms after 72 hours. Interestingly, 
P14KanS was superior to drugs of choice (vancomycin and linezolid) as they protected 
approximately 70% and 60% of S. aureus and S. epidermidis infected worms, respectively 
at the same tested concentrations (10 µM) (figure 7.10). Collectively, these data confirm 
the potent therapeutic efficacy of P14KanS in vivo against notorious biofilm infections of 
Gram-positive and Gram-negative pathogens. 
7.5 Conclusion 
The worldwide increase of antibiotic resistance and limited supply of new antibiotics 
necessitates the discovery and development of novel approaches to address this 
burgeoning challenge. In the present study, we conjugated the aminoglycoside antibiotic, 
kanamycin with the antibacterial peptide P14LRR to enhance the antibiotic’s potency and 
spectrum of activity against resistant bacterial strains. This conjugation successfully 
improved the antibacterial activity of kanamycin against both kanamycin-sensitive and 
kanamycin-resistant strains of key ESKAPE pathogens. P14KanS was found to exert its 
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antibacterial activity via disruption of both the outer and inner membranes of the cell 
envelope. However, no adverse toxic effect was observed to mammalian cells at 
concentrations 128 times higher than the MIC, indicating P14KanS possesses a selective 
membrane-active effect to bacterial cells. The rapid, membrane-disruptive nature of 
P14KanS against bacteria shows low propensity for resistance development in comparison 
to kanamycin and conventional antibiotics. In addition to its potent antibacterial activity, 
P14KanS significantly disrupted established bacterial biofilms more so than conventional 
antibiotics. Furthermore, P14KanS was capable of binding strongly to LPS and 
subsequently reduced the endotoxin-mediated proinflammatory cytokine production in 
murine macrophage cells. This discovery highlights a potential avenue for development 
of P14KanS to treat sepsis. P14KanS also significantly reduced the burden of intracellular 
MRSA potentially opening an avenue for exploring P14KanS for treatment of certain 
chronic skin diseases, such as Darier’s disease. Furthermore, P14KanS’s potent 
antibacterial activity was confirmed in vivo as it significantly increased the rate of survival 
for nematodes infected with both Gram-positive and Gram-negative pathogens. The 
conjugation of kanamycin with a cell-penetrating peptide has great potential to facilitate 
delivery of drugs directly to the site of infection (lungs) via intrapulmonary delivery [62]. 
Clearly, further investigation of potential clinical applications is necessary in more 
advanced animal models of infection. The success of this approach will open the door for 
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Table 7.1. Minimum inhibitory concentration (MIC) (µM) of compounds against 
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Figure 7.1. The designed dual agents (P14KanS) composed of the antibiotic, 





Figure 7.2. Mechanism of action of P14KanS. 
A) Permeabilization of the outer membrane of P. aeruginosa PAO1 by compounds as 
indicated by the enhanced uptake of 1-Nphenylnaphthylamine (NPN). Fluorescence 
intensity caused by the partitioning of NPN into the outer membrane was monitored after 
addition of compounds. Data are presented as means ± standard error of the means (n = 
3). B) Permeabilization of the inner (cytoplasmic) membrane by compounds is indicated 
by propidium iodide fluorescence. C) Permeabilization of the cytoplasmic membrane of 
kanamycin resistant S. epidermidis ATCC 35984 as a function of compounds 
concentration, indicated by percent of calcein leakage for 60 min exposure. Each 
experiment was performed in triplicate, and the values represent means ± standard 
deviation. 
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Figure 7.3. The killing kinectics of P14KanS and control antibiotics against 
logarithmic (A&B) and stationary phase (C&D) cultures of S. aureus ATCC 6538 
(A&C) and S. epidermidis ATCC 35984 (B&D). 
(A&B) Logarithmic phase of bacteria were exposed to compounds at 10 µM. (C&D) The 
killing kinectics of stationary phase of bacteria exposed to compounds at 10 µM. 
Untreated samples served as a control. The results are given as means ± SD (n = 3); data 
without error bars indicate that the SD is too small to be seen. 
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Figure 7.4. The killing kinectics of P14KanS and control antibiotics against 
logarithmic (A&B) and stationary phase (C&D) cultures of P. aeruginosa PAO1 
(A&C) and A. baumannii ATCC BAA-1605 (B&D). 
(A&B) Logarithmic phase of bacteria were exposed to compounds at 20 µM. (C&D) The 
killing kinectics of stationary phase of bacteria exposed to compounds at 20 µM. 
Untreated samples served as a control. The results are given as means ± SD (n = 3); data 
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Figure 7.5. Efficacy of P14KanS on established biofilms of A) S. aureus ATCC 
6538; B) S. epidermidis ATCC 35984; C) P. aeruginosa PAO1 and A. baumannii 
ATCC BAA-1605. 
Twenty-four hour old biofilms were treated with different concentrations of P14KanS, 
P14LRR, kanamycin and control antibiotics and plates were incubated at 37°C for 24 
hours. After incubation, wells were washed and biofilms were stained with 0.5% (w/v) 
crystal violet for 30 minutes. The dye was solubilized with ethanol (95%) and the optical 
density (OD) of biofilms was measured. Experiments were repeated twice independently 
and the average values are reported. Statistical analysis was calculated using one-way 
ANOVA, with post hoc Tukey’s multiple comparisons test. P values of ˂ 0.05 were 
considered significant. One asterisk (*) indicates significance from the negative control. 
Two asterisks (**) indicate significance of P14KanS compared to P14LRR and 
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Figure 7.6. Toxicity of P14KanS against mammalian cells.  
(A) The release of hemoglobin in the supernatant of human erythrocytes after treatment 
with increasing amounts of P14KanS, P14LRR, and melittin was measured at 415 nm. 
Triton X-100 served as positive control. (B) Cytotoxicity assay showing the percent mean 
absorbance at 490 nm after incubating human keratinocyte (HaCaT) or HeLa cells with 
compounds at different concentrations. Sterile water (compounds diluent) served as 
negative control. Cell viability was measured by MTS assay. Results are expressed as 
means from three measurements ± standard deviation. 
 
Figure 7.7. Intracellular antibacterial activity of P14KanS in human keratinocytes 
(HaCaT). 
The effect of kanamycin, P14LRR, P14KanS and vancomycin, at 15 µM, to kill 
intracellular S. aureus ATCC 6538 and MRSA USA400 inside infected HaCaT cells after 
treatment for 24 hours. Statistical analysis was calculated using one-way ANOVA, with 
post hoc Tukey’s multiple comparisons test. P values of ˂ 0.05 were considered 
significant. One asterisk (*) indicates significance from the negative control. Two 
asterisks (**) indicate significance of P14KanS compared to P14LRR and kanamycin. 
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Figure 7.8. Anti-inflammatory effect and LPS binding activity of P14KanS. 
A) LPS binding activity of compounds. Compounds at 10 µM were incubated with one 
endotoxin unit (EU) of LPS at 37°C for 30 minutes. Colistin was used as positive control 
due to its high binding affinity for LPS. The binding of compounds with LPS is expressed 
as percent change relative to untreated samples. B) Anti-inflammatory effect of 
compounds on LPS stimulated macrophage. J774A.1 cells were stimulated with LPS (150 
ng/mL final concentration) in the presence of 10 µM of compounds. Cells stimulated with 
LPS alone and untreated cells served as controls. Cells were incubated for six hours at 
37 °C after which the supernatants of the medium from each treatment were collected. 
Cytokine detection of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in 
supernatants was analyzed using ELISA. Cytokine levels are expressed as percent change 
relative to the LPS stimulated control.  
















































































































































































































Figure 7.9. Drug-resistance development profile of S. aureus. 
S. aureus ATCC 6538 exposed to eight passages in the presence of sub-inhibitory 
concentrations of kanamycin, P14LRR, P14KanS and three classes of antibiotics 
including the cell wall synthesis inhibitor, ampicillin, the RNA synthesis inhibitor, 
rifampicin and the DNA synthesis inhibitor, ciprofloxacin. 
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Figure 7.10. Efficacy of P14KanS in a Caenorhabditis elegans model of bacterial 
infection. 
C. elegans strains glp-4;sek 1 were infected with P. aeruginosa PAO1, A. baumannii 
ATCC BAA-1605, S. aureus ATCC 6538 and S. epidermidis ATCC 35984. After 
infection, worms were treated with P14KanS, P14LRR, kanamycin and control antibiotics. 
Worms were monitored daily and the live worms were counted. Results are expressed as 
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